U.S. patent application number 15/565897 was filed with the patent office on 2018-04-26 for n2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient.
This patent application is currently assigned to KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY. The applicant listed for this patent is KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY. Invention is credited to Sunjoo Ahn, Chong Hak Chae, Sung Yun Cho, Jae Du Ha, Jong Yeon Hwang, Hee Jung Jung, Hyoung Rae Kim, Pilho Kim, Chong Ock Lee, Chi Hoon Park, Chang Soo Yun.
Application Number | 20180111905 15/565897 |
Document ID | / |
Family ID | 57446602 |
Filed Date | 2018-04-26 |
United States Patent
Application |
20180111905 |
Kind Code |
A1 |
Kim; Pilho ; et al. |
April 26, 2018 |
N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING
SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR
TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT
Abstract
The present invention relates to a
N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method
thereof, and a pharmaceutical composition for the prevention or
treatment of cancer comprising the same as an active ingredient.
The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer
thereof, or the pharmaceutically acceptable salt thereof of the
present invention is very effective in suppressing anaplastic
lymphoma kinase (ALK) activity and as a result it can improve the
effectiveness of treatment on cancer cells having anaplastic
lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK,
so that it can be effectively used as a pharmaceutical composition
for preventing or treating cancer.
Inventors: |
Kim; Pilho; (Daejeon,
KR) ; Kim; Hyoung Rae; (Daejeon, KR) ; Cho;
Sung Yun; (Daejeon, KR) ; Ha; Jae Du;
(Daejeong, KR) ; Jung; Hee Jung; (Daejeon, KR)
; Yun; Chang Soo; (Daejeon, KR) ; Hwang; Jong
Yeon; (Jeollabuk-do, KR) ; Park; Chi Hoon;
(Daejeon, KR) ; Lee; Chong Ock; (Seoul, KR)
; Ahn; Sunjoo; (Daejoen, KR) ; Chae; Chong
Hak; (Daejeon, KR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
Daejeon |
|
KR |
|
|
Assignee: |
KOREA RESEARCH INSTITUTE OF
CHEMICAL TECHNOLOGY
Daejoen
KR
|
Family ID: |
57446602 |
Appl. No.: |
15/565897 |
Filed: |
April 6, 2016 |
PCT Filed: |
April 6, 2016 |
PCT NO: |
PCT/KR2016/003597 |
371 Date: |
October 11, 2017 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A23L 33/10 20160801;
A23L 33/30 20160801; A61K 31/505 20130101; A23L 33/40 20160801;
C07D 403/12 20130101; A61P 35/00 20180101; A23V 2002/00 20130101;
C07D 401/12 20130101; C07D 239/48 20130101 |
International
Class: |
C07D 239/48 20060101
C07D239/48; A61P 35/00 20060101 A61P035/00; C07D 401/12 20060101
C07D401/12; C07D 403/12 20060101 C07D403/12; A23L 33/00 20060101
A23L033/00; A23L 33/10 20060101 A23L033/10 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 14, 2015 |
KR |
10-2015-0052572 |
Apr 5, 2016 |
KR |
10-2016-0041920 |
Claims
1. A compound represented by formula 1, an optical isomer thereof,
or a pharmaceutically acceptable salt of the same: ##STR00186##
wherein R.sup.1 is hydrogen, C.sub.1-5 straight or branched alkyl,
--(CR.sup.5R.sup.6).sub..alpha.--(CR.sup.7R.sup.8).sub..beta.--(CR.sup.9R-
.sup.10).sub..gamma.--NR.sup.11R.sup.12, or
--(CH.sub.2).sub.p--C(.dbd.O)--R.sup.13, R.sup.5, R.sup.6, R.sup.7,
R.sup.8, R.sup.9, and R.sup.10 are independently hydrogen or
C.sub.1-10 straight or branched alkyl, R.sup.5 and R.sup.6 can form
unsubstituted C.sub.3-8 cycloalkyl along with the carbon atoms
conjugated to the same, R.sup.7 and R.sup.8 can form unsubstituted
C.sub.3-10 cycloalkyl or oxo group (.dbd.O) along with the carbon
atoms conjugated to the same, R.sup.11 and R.sup.12 are
independently hydrogen, C.sub.1-10 straight or branched alkyl
wherein unsubstituted or one or more hydroxyl groups are
substituted, C.sub.1-10 straight or branched alkyl sulfonyl,
unsubstituted C.sub.6-10 aryl C.sub.1-5 straight or branched alkyl,
--(CH.sub.2).sub.n--C(.dbd.X)R.sup.14, unsubstituted C.sub.6-10
heteroaryl containing one or more hetero atoms selected from the
group consisting of N, O, and S, or unsubstituted C.sub.6-10 aryl,
wherein X is O or S, R.sup.14 is hydrogen, --OH, C.sub.1-10
straight or branched alkoxy, C.sub.1-10 straight or branched alkyl
wherein unsubstituted or one or more halogens are substituted,
unsubstituted C.sub.6-10 aryl C.sub.1-5 straight or branched alkyl,
or --NR.sup.15R.sup.16, R.sup.15 and R.sup.16 are independently
hydrogen, C.sub.1-5 straight or branched alkyl, unsubstituted
C.sub.5-10 cycloalkyl, unsubstituted C.sub.6-10 aryl, or
unsubstituted C.sub.6-10 aryl C.sub.1-5 alkyl, and n is an integer
of 0-5, R.sup.11 and R.sup.12 can form unsubstituted C.sub.5-10
heterocycloalkyl containing one or more hetero atoms selected from
the group consisting of N, O, and S along with the nitrogen atoms
conjugated to the same, .alpha., .beta., and .gamma. are
independently integers of 0-2, R.sup.13 is --OH or
--(OCH.sub.2CH.sub.2).sub.q--H, wherein q is an integer of 1-2, p
is an integer of 1-2; R.sup.2 is hydrogen, halogen, unsubstituted
or substituted C.sub.5-10 heteroaryl containing one or more hetero
atoms selected from the group consisting of N, O, and S, C.sub.1-10
straight or branched alkyl wherein unsubstituted or one or more
nitrile groups (--CN) are substituted, C.sub.1-10 straight or
branched alkyl wherein unsubstituted or one or more amine groups
(--NH.sub.2) are substituted, unsubstituted C.sub.6-10,
--(CR.sup.17R.sup.18).sub.k--(CR.sup.19R.sup.20).sub.j--NR.sup.21R.sup.22-
, --C(.dbd.CH.sub.2)--R.sup.3, or
--CH.sub.2--N.sup.+(CH.sub.3).sub.3I.sup.-, the substituted
C.sub.5-10 heteroaryl can be substituted with C.sub.1-5 straight or
branched alkyl, R.sup.17, R.sup.18, R.sup.19, and R.sup.20 are
independently hydrogen or C.sub.1-5 straight or branched alkyl, and
k and j are independently integers of 0-2, R.sup.21 and R.sup.22
are independently hydrogen, formyl group (--C(.dbd.O)H), or
C.sub.1-5 straight or branched alkyl, R.sup.23 is C.sub.1-5
straight or branched alkyl; R.sup.3 is hydrogen; R.sup.4 is
hydrogen or C.sub.1-5 straight or branched alkoxy; and Z is
hydrogen, F, Cl, or Br.
2. The compound represented by formula 1, the optical isomer
thereof, or the pharmaceutically acceptable salt of the same
according to claim 1, wherein: R.sup.1 is hydrogen, C.sub.1-5
straight or branched alkyl,
--(CR.sup.5R.sup.6).sub..alpha.--(CR.sup.7R.sup.8).sub..beta.--(CR.sup.9R-
.sup.10).sub..gamma.--NR.sup.11R.sup.12, or
--(CH.sub.2).sub.p--C(.dbd.O)--R.sup.13, R.sup.5, R.sup.6, R.sup.7,
R.sup.8, R.sup.9, and R.sup.10 are independently hydrogen or
C.sub.1-5 straight or branched alkyl, R.sup.5 and R.sup.6 can form
unsubstituted C.sub.3-8 cycloalkyl along with the carbon atoms
conjugated to the same, R.sup.7 and R.sup.8 can form unsubstituted
C.sub.3-8 cycloalkyl or oxo group (.dbd.O) along with the carbon
atoms conjugated to the same, R.sup.11 and R.sup.12 are
independently hydrogen, C.sub.1-5 straight or branched alkyl
wherein unsubstituted or one or more hydroxyl groups are
substituted, C.sub.1-5 straight or branched alkyl sulfonyl,
unsubstituted C.sub.6-8 aryl C.sub.1-3 straight or branched alkyl,
--(CH.sub.2).sub.n--C(.dbd.X)R.sup.14, unsubstituted C.sub.6-10
heteroaryl containing one or more hetero atoms selected from the
group consisting of N, O, and S, or unsubstituted C.sub.6-10 aryl,
wherein, X is O or S, R.sup.14 is hydrogen, --OH, C.sub.1-5
straight or branched alkoxy, C.sub.1-5 straight or branched alkyl
wherein unsubstituted or one or more halogens are substituted,
unsubstituted C.sub.6-8 aryl C.sub.1-3 straight or branched alkyl,
or --NR.sup.15R.sup.16, R.sup.15 and R.sup.16 are independently
hydrogen, C.sub.1-3 straight or branched alkyl, unsubstituted
C.sub.5-8 cycloalkyl, unsubstituted C.sub.6-8 aryl, or
unsubstituted C.sub.6-8 aryl C.sub.1-3 alkyl, and n is an integer
of 0-3, R.sup.11 and R.sup.12 can form unsubstituted C.sub.5-8
heterocycloalkyl containing one or more hetero atoms selected from
the group consisting of N, O, and S along with the nitrogen atoms
conjugated to the same, .alpha., .beta., and .gamma. are
independently integers of 0-1, R.sup.13 is --OH or
--(OCH.sub.2CH.sub.2).sub.q--H, wherein q is an integer of 1-2, p
is an integer of 1-2; R.sup.2 is hydrogen, halogen, unsubstituted
or substituted C.sub.5-8 heteroaryl containing one or more hetero
atoms selected from the group consisting of N, O, and S, C.sub.1-5
straight or branched alkyl wherein unsubstituted or one or more
nitrile groups (--CN) are substituted, C.sub.1-5 straight or
branched alkyl wherein unsubstituted or one or more amine groups
(--NH.sub.2) are substituted, unsubstituted C.sub.6-8 aryl,
--(CR.sup.17R.sup.18).sub.k--(CR.sup.19R.sup.20).sub.j--NR.sup.21R.sup.22-
, --C(.dbd.CH.sub.2)--R.sup.3, or
--CH.sub.2--N.sup.+(CH.sub.3).sub.3I.sup.-, the substituted
C.sub.5-8 heteroaryl can be substituted with C.sub.1-5 straight or
branched alkyl, R.sup.17, R.sup.18, R.sup.19, and R.sup.20 are
independently hydrogen or C.sub.1-3 straight or branched alkyl, and
k and j are independently integers of 0-2, R.sup.21 and R.sup.22
are independently hydrogen, formyl group (--C(.dbd.O)H), or
C.sub.1-3 straight or branched alkyl, R.sup.23 is C.sub.1-3
straight or branched alkyl; R.sup.3 is hydrogen; R.sup.4 is
hydrogen or C.sub.1-5 straight or branched alkoxy; and Z is
hydrogen, F, Cl, or Br.
3. The compound represented by formula 1, the optical isomer
thereof, or the pharmaceutically acceptable salt of the same
according to claim 1, wherein: R.sup.1 is methyl, ##STR00187##
##STR00188## ##STR00189## R.sup.2 is hydrogen, --Br, ##STR00190##
R.sup.3 is hydrogen; R.sup.4 is methoxy, ethoxy, or iso-propoxy; Z
is hydrogen or F.
4. The compound represented by formula 1, the optical isomer
thereof, or the pharmaceutically acceptable salt of the same
according to claim 1, wherein the compound represented by formula 1
is selected from the group consisting of the following compounds:
(1)
N2-(5-(1-(aminomethyl)cyclopentyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine; (2)
N2-(5-(1-(aminomethyl)cyclohexyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopro-
pylsulfonyl)phenyl)pyrimidine-2,4-diamine; (3)
N2-(5-((1-aminocyclopropyl)methyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine; (4)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)p-
henyl) pyrimidine-2,4-diamine; (5)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl-N2-(2-methoxy-5-(1-(piperidine-1-
-ylmethyl)cyclopentyl)phenyl)pyrimidine-2,4-diamine; (6)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(1-(morpholinom-
ethyl)cyclopentyl)phenyl)pyrimidine-2,4-diamine; (7)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)acetamide; (8)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)methanesulfonamide; (9)
5-chloro-N2-(5-(2-(dimethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyl-
sulfonyl)phenyl)pyrimidine-2,4-diamine; (10)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(methylamino-
)ethyl)phenyl)pyrimidine-2,4-diamine; (11)
N2-(5-(2-(benzylamino)ethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine; (12)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-2-phenylacetamide; (13)
5-chloro-N2-(5-(2-(ethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropylsul-
fonyl)phenyl)pyrimidine-2,4-diamine; (14)
5-chloro-N2-(5-(2-(diethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine; (15)
5-chloro-N2-(5-(2-(isopropylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropy-
lsulfonyl)phenyl)pyrimidine-2,4-diamine; (16)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylurea; (17)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-cyclohexylurea; (18)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-phenylurea; (19)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-methylthiourea; (20)
1-benzyl-3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2--
ylamino)-4-methoxyphenethyl)thiourea; (21)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperidine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine; (22)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-morpholinoet-
hyl)phenyl)pyrimidine-2,4-diamine; (23)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylthiourea; (24) methyl
3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)propanoate; (25)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(pyrimidine--
2-ylamino)ethyl)phenyl)pyrimidine-2,4-diamine; (26) methyl
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetate; (27)
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetic acid; (28)
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxybenzyl)-2,2,2-trifluoroacetamide; (29)
N2-(5-(aminomethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)ph-
enyl)pyrimidine-2,4-diamine; (30)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-2,2,2-trifluoroacetamide; (31)
N2-(5-(2-aminoethyl)-2-isopropoxyphenyl)-5-chloro-N4-(2-(isopropylsulfony-
l)phenyl)pyrimidine-2,4-diamine; (32)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(4-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine; (33)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(5-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride; (34)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-fluoro-6-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride; (35)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine; (36)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(4-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (37)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(5-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (38)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-fluo-
ro-6-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (39)
2,2'-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamin-
o)-4-methoxyphenethylazeindiyl)diethanol; (40)
N-(3-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide; (41)
N2-(5-(3-aminopropyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)-
phenyl)pyrimidine-2,4-diamine; (42)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetamide; (43) 2-ethoxyethyl
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetate; (44)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetic acid; (45)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-morpholinoethane-1-one; (46)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperidine-1-yl)ethane-1-one; (47)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(hydroxymethyl)acetamide; (48)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperazine-1-yl)ethane-1-one; (49)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(pyridine-4-yl)acetamide; (50)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-phenylacetamide; (51)
N2-(5-(2-aminoethyl)-4-bromo-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine; (52)
N2-(5-(2-aminoethyl)-2-methoxy-4-(1-methyl-1H-pyrazole-4-ylphenyl)-5-chlo-
ro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (53)
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)acetonitrile; (54)
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)-2-methylpropanenitrile; (55)
N2-(4-(2-aminoethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine; (56)
N2-(4-(1-amino-2-methylpropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N-
4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (57)
N2-(4-(2-aminopropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine; (58)
5-chloro-N2-(4-(2-(dimethylamino)ethyl)-2-methoxy-5-methylphenyl)-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (59)
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)-2-methylpropyl)formamide; (60)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-met-
hyl-1-(methylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine; (61)
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)propane-2-yl)formamide; (62)
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-ylamin-
o)-5-methoxy-2-methylphenethyl)formamide; (63)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)ethyl)phenyl)pyrimidine-2,4-diamine; (64)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine; (65)
5-chloro-N2-(4-(1-(dimethylamino)-2-methylpropane-2-yl)-2-methoxy-5-methy-
lphenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(66)
5-chloro-N2-(4-(2-(dimethylamino)propane-2-yl)-2-methoxy-5-methylphenyl)--
N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (67)
N2-(2-(2-aminoethyl)-5-methoxybiphenyl-4-yl)-5-chloro-N4-(2-isopropylsulf-
onyl)phenyl)pyrimidine-2,4-diamine; (68)
N2-(4-(aminomethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine; (69)
1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-ylamin-
o)-5-methoxy-2-methylphenyl)-N,N,N-trimethylmethanealuminum iodide;
(70)
5-chloro-N2-(4-((dimethylamino)methyl)-2-methoxy-5-methylphenyl)-N4-(2-(i-
sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (71)
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-ylamin-
o)-5-methoxy-2-methylbenzyl)formamide; (72)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-((meth-
ylamino)methyl)phenyl)pyrimidine-2,4-diamine; (73)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperazine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine; (74)
N2-(5-(2-aminoethyl)-2-ethoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; and (75)
N2-(5-(2-aminoethyl)-2-methoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2--
(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine.
5. A method for preparing the compound represented by formula 1
according to claim 1 comprising preparing the compound represented
by formula 1 by reacting the compound represented by formula 2 with
the compound represented by formula 3 (step 1) as shown in reaction
formula 1 below: ##STR00191## wherein R.sup.1, R.sup.2, R.sup.3,
R.sup.4, and Z are as defined in formula 1 according to claim
1.
6. A pharmaceutical composition comprising the compound represented
by formula 1 according to claim 1, the optical isomer thereof, or
the pharmaceutically acceptable salt of the same as an active
ingredient for the prevention or treatment of cancer.
7. The pharmaceutical composition according to claim 6, wherein the
pharmaceutical composition inhibits the activity of anaplastic
lymphoma kinase (ALK).
8. The pharmaceutical composition according to claim 6, wherein the
cancer is selected from the group consisting of non-small cell lung
cancer, neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomyosarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
9. A health functional food composition comprising the compound
represented by formula 1 according to claim 1, the optical isomer
thereof, or the pharmaceutically acceptable salt of the same as an
active ingredient for the prevention or improvement of cancer.
10. The health functional food composition according to claim 9,
wherein the cancer is selected from the group consisting of
non-small cell lung cancer, neuroblastoma, inflammatory myeloid
fibroblastic tumor, rhabdomyosarcoma, myofibroblastoma, breast
cancer, stomach cancer, lung cancer, and melanoma.
11. A method of treating cancer comprising administering a
pharmaceutically effective amount of the compound represented by
formula 1 of claim 1, the optical isomer thereof, or the
pharmaceutically acceptable salt thereof to a subject in need
thereof.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0001] The present invention relates to a
N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method
thereof, and a pharmaceutical composition for the prevention or
treatment of cancer comprising the same as an active
ingredient.
2. Description of the Related Art
[0002] Cells are the smallest units that make up a human body.
Cells are divided and grow by the regulatory function of the cells
themselves. When they reach their lifespan or become damaged, they
kill themselves and maintain an overall balance of numbers.
However, when the regulatory function of these cells is not
functioning normally due to various reasons, the cells to be killed
are abnormally proliferated and invade tissues around and other
organs to form a mass, leading to the formation of a tumor.
[0003] Unlike a normal cell that is proliferated or suppressed
according to a certain rule and a necessary manner, the cancer cell
is unlimitedly proliferated in a tissue in disregard of such
necessary rules and manners, and cancer is a cell mass made of such
unlimitedly proliferating undifferentiated cells. The unlimitedly
proliferating cancer cells invade into the tissues around and even
to the other organs with causing a serious pain and problems and
even death, so that cancer is regarded as an incurable disease.
[0004] According to the report by American Cancer Society, new
patients diagnosed with cancer in 2007 world-widely were at least
12 million people, among which 7.6 million people were dead,
indicating that approximately 20,000 patients were dead by cancer
every day. In Korea, death of cancer was the number 1 cause of
death in 2006, according to the report by Statistics Korea.
Therefore, it is urgently requested to develop an anticancer agent
which is excellent in cancer treating effect in order to reduce
emotional and physical pain caused by cancer outbreak and
experienced in the course of treating cancer and at the same time
to increase quality of life of a patient.
[0005] The mechanism of normal cells being cancer cells has not
been clearly understood. Cancer is developed by the combined
actions of external factors such as environmental factors,
chemicals, radiation, and virus and internal factors such as
genetic factors and immunological factors. Genes involved in the
cancer development are oncogenes and tumor suppressor genes. When
the balance between the two cancer-associated genes is broken by
any internal or external factors mentioned above, cancer is
developed.
[0006] Cancer is largely divided into blood cancer that show
abnormalities in the number of blood cells and solid cancer in the
form of cell masses with constant hardness and morphology in the
body. Cancer can be developed in almost every body parts, resulting
in lung cancer, stomach cancer, breast cancer, oral cavity cancer,
liver cancer, uterine cancer, esophageal cancer, and skin cancer,
etc. Surgical operation, radiotherapy, and chemotherapy to suppress
cell proliferation are the major anticancer treatment methods.
[0007] However, the chemotherapy is not the targeted therapy and
the biggest problem of the conventional chemotherapy is side effect
caused by cytotoxicity and drug resistance, which is the reason of
failure in the treatment using an anticancer agent even after the
successful early treatment with it. To overcome the limit of the
chemotherapy, it is constantly required to develop a targeted agent
based on the clear understanding on the anticancer mechanism of
it.
[0008] Thus, studies have been undergoing with specific molecular
biological factors involved in tumor formation, in order to develop
a targeted agent. In particular, the molecular biological factors
are used in the prediction of cancer prognosis or in making
decision of chemotherapy or radiotherapy.
[0009] Recently, drugs such as Gleevec or Herceptin have been used
as a targeted agent for bone marrow cancer or breast cancer.
Gleevec is the drug that can suppress tyrosine kinase receptor, one
of the molecular biological factors involved in cancer. Gleevec
displays an anticancer effect by suppressing Bcr-Abl fusion gene
formed by translocation in Philadelphia chromosome observed in
chronic myelocytic leukemia, which is one of tyrosine kinase
inhibitors and has been effective in treating chronic myelocytic
leukemia. Gleevec is a tyrosine kinase inhibitor that is used as a
targeted agent for chronic myelocytic leukemia. When Gleevec is
administered to patients with chronic myelocytic leukemia, it has
achieved satisfactory therapeutic results.
[0010] Other anticancer agents as a tyrosine kinase inhibitor are
Gefitinib and Erlotinib which are EGFR (epidermal growth factor
receptor) tyrosine kinase suppressors used in the treatment of
non-small cell lung cancer, and Sorafenib and Sunitinib which are
used in the treatment of renal cell carcinoma. However, these drugs
display such side effects as hemorrhage, heart attack, heart
failure, and liver failure, etc.
[0011] Recently, anaplastic lymphoma kinase (ALK) was identified in
various tumors, so that it has been a target of study.
[0012] In the ALK-mediated cancer development, the ALK-NPM
(Nucleophosmin) fusion gene found in anaplastic large cell lymphoma
is known to be a key factor. Once ALK is activated by gene fusion,
tyrosine kinase included in ALK starts abnormal action to cause
cancer. That is, the abnormally activated anaplastic lymphoma
kinase (ALK) induces cell proliferation, interrupts apoptosis in
order to prevent cell death, to rearrange cytoskeleton, and
accordingly to transform cell shape.
[0013] Oncogenic conversion of anaplastic lymphoma kinase (ALK) is
accomplished by the interaction between ALK and its downstream
molecule. The downstream molecule is a material to mediate the
intracellular signal transduction. ALK interacts with normal genes
or other oncogenic converted tyrosine kinase genes to activate
various other pathways.
[0014] In particular, ALK gene in the lung cancer cell is fused
with EML4 (Echinoderm Microtubule-Associated Protein-Like 4) gene
to produce EML4-ALK, the active tyrosine kinase. At this time, the
cancer inducing activity of EML4-ALK is dependent on the enzyme
activity. It has been also reported by Mosse, et al that about 26%
ALK gene amplification has been confirmed in 491 neuroblastoma
samples. In addition, the ALK gene is found in many
nonhematopoietic cell tumors including large B-cell lymphoma,
systemic histiocytosis, inflammatory myofibroblastoma, esophageal
squamous cell carcinoma, non-small cell lung cancer,
rhabdomysarcoma, myofibroblastic tumor, breast cancer, and melanoma
cell lines. In inflammatory myeloid blastoma, which is a rare
disease, different kinds of anaplastic lymphoma kinase (ALK) fusion
proteins are frequently observed, suggesting that such fusion
proteins are involved deeply in the tumor development.
[0015] An anticancer agent targeting ALK-NPM is under development
by using the method to block the ALK activation pathway. It has
been recently confirmed by Pfizer that Crizotinib (PF-02341066)
which is one of the small molecule tyrosine kinase inhibitors
developed as a tumorigenic mutation specific inhibitor is effective
in treating non-small cell lung cancer by inhibiting ATP
competitive c-Met/HGFR (hepatocyte growth factor receptor) and ALK
and accordingly it has been approved as a new drug by FDA in 2011.
It was also confirmed that LDK-378 (Ceritinib) developed by
Novartis. And clinical trials of multiple anaplastic lymphoma
kinase (ALK) inhibitors are in progress.
[0016] Patent references 1-3 describe that the therapeutic agent
candidates having various frames are under development in order to
suppress ALK activity and a pyrimidine derivative can selectively
inhibit ALK so that it can be developed as an anticancer agent.
[0017] Thus, the present inventors tried to develop a compound
which is effective in suppressing anaplastic lymphoma kinase (ALK)
activity. As a result, the inventors found out that a
N2-(2-methoxyphenyl)pyrimidine derivative in a specific structure
was excellent in inhibiting ALK activity so that it could be used
as a cancer preventive or cancer treating agent, leading to the
completion of this invention.
PRIOR ART REFERENCE
Patent Reference
[0018] WO 2009143389 A1
[0019] WO 2008051547 A1
[0020] WO 2004080980 A1
SUMMARY OF THE INVENTION
[0021] It is an object of the present invention to provide a
N2-(2-methoxyphenyl)pyrimidine derivative, an optical isomer
thereof, or a pharmaceutically acceptable salt of the same.
[0022] It is another object of the present invention to provide a
method for preparing the said N2-(2-methoxyphenyl)pyrimidine
derivative.
[0023] It is also an object of the present invention to provide a
pharmaceutical composition comprising the said
N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer
thereof, or the pharmaceutically acceptable salt of the same as an
active ingredient for the prevention or treatment of cancer.
[0024] It is further an object of the present invention to provide
a health functional food composition comprising the said
N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer
thereof, or the pharmaceutically acceptable salt of the same as an
active ingredient for the prevention or improvement of cancer.
[0025] To achieve the above objects, the present invention provides
a compound represented by formula 1, an optical isomer thereof, or
a pharmaceutically acceptable salt of the same.
[0026] Formula 1
##STR00001##
[0027] In the formula 1,
[0028] R.sup.1 is hydrogen, C.sub.1-5 straight or branched alkyl,
--(CR.sup.5R.sup.6).sub..alpha.--(CR.sup.7R.sup.8).sub..beta.--(CR.sup.9R-
.sup.10).sub..gamma.--NR.sup.11R.sup.12, or
--(CH.sub.2).sub.p--C(.dbd.O)--R.sup.13,
[0029] R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10
are independently hydrogen or C.sub.1-10 straight or branched
alkyl,
[0030] R.sup.5 and R.sup.6 can form unsubstituted C.sub.3-8
cycloalkyl along with the carbon atoms conjugated to the same,
[0031] R.sup.7 and R.sup.8 can form unsubstituted C.sub.3-10
cycloalkyl or oxo group (.dbd.O) along with the carbon atoms
conjugated to the same,
[0032] R.sup.11 and R.sup.12 are independently hydrogen, C.sub.1-10
straight or branched alkyl wherein unsubstituted or one or more
hydroxyl groups are substituted, C.sub.1-10 straight or branched
alkyl sulfonyl, unsubstituted C.sub.6-10 aryl C.sub.1-5 straight or
branched alkyl, --(CH.sub.2).sub.n--C(.dbd.X)R.sup.14,
unsubstituted C.sub.6-10 heteroaryl containing one or more hetero
atoms selected from the group consisting of N, O, and S, or
unsubstituted C.sub.6-10 aryl,
[0033] wherein, X is O or S, R.sup.14 is hydrogen, --OH, C.sub.1-10
straight or branched alkoxy, C.sub.1-10 straight or branched alkyl
wherein unsubstituted or one or more halogens are substituted,
unsubstituted C.sub.6-10 aryl C.sub.1-5 straight or branched alkyl,
or --NR.sup.15R.sup.16, R.sup.15 and R.sup.16 are independently
hydrogen, C.sub.1-5 straight or branched alkyl, unsubstituted
C.sub.5-10 cycloalkyl, unsubstituted C.sub.6-10 aryl, or
unsubstituted C.sub.6-10 aryl C.sub.1-5 alkyl, and n is an integer
of 0-5,
[0034] R.sup.11 and R.sup.12 can form unsubstituted C.sub.5-10
heterocycloalkyl containing one or more hetero atoms selected from
the group consisting of N, O, and S along with the nitrogen atoms
conjugated to the same,
[0035] .alpha., .beta., and .gamma. are independently integers of
0-2,
[0036] R.sup.13 is --OH or --(OCH.sub.2CH.sub.2).sub.q--H, wherein
q is an integer of 1-2,
[0037] p is an integer of 1-2;
[0038] R.sup.2 is hydrogen, halogen, unsubstituted or substituted
C.sub.5-10 heteroaryl containing one or more hetero atoms selected
from the group consisting of N, O, and S, C.sub.1-10 straight or
branched alkyl wherein unsubstituted or one or more nitrile groups
(--CN) are substituted, C.sub.1-10 straight or branched alkyl
wherein unsubstituted or one or more amine groups (--NH.sub.2) are
substituted, unsubstituted C.sub.6-10,
--(CR.sup.7R.sup.8).sub.k--(CR.sup.19R.sup.20).sub.j--NR.sup.21R.sup.22,
--C(.dbd.CH.sub.2)--R.sup.23, or
--CH.sub.2--N.sup.+(CH.sub.3).sub.3I.sup.-,
[0039] the substituted C.sub.5-10 heteroaryl can be substituted
with C.sub.1-5 straight or branched alkyl,
[0040] R.sup.17, R.sup.18, R.sup.19, and R.sup.20 are independently
hydrogen or C.sub.1-5 straight or branched alkyl, and k and j are
independently integers of 0-2,
[0041] R.sup.21 and R.sup.22 are independently hydrogen, formyl
group (--C(.dbd.O)H), or C.sub.1-5 straight or branched alkyl,
[0042] R.sup.23 is C.sub.1-5 straight or branched alkyl;
[0043] R.sup.3 is hydrogen;
[0044] R.sup.4 is hydrogen or C.sub.1-5 straight or branched
alkoxy; and
[0045] Z is hydrogen, F, Cl, or Br.
[0046] The present invention also provides a method for preparing
the compound represented by formula 1 containing the step of
preparing the compound represented by formula 1 by reacting the
compound represented by formula 2 with the compound represented by
formula 3 (step 1) as shown in reaction formula 1 below.
##STR00002##
[0047] In the reaction formula 1,
[0048] R.sup.1, R.sup.2, R.sup.3, R.sup.4, and Z are as defined in
formula 1.
[0049] The present invention also provides a pharmaceutical
composition comprising the compound represented by formula 1, the
optical isomer thereof, or the pharmaceutically acceptable salt of
the same as an active ingredient for the prevention or treatment of
cancer.
[0050] In addition, the present invention provides a health
functional food composition comprising the compound represented by
formula 1, the optical isomer thereof, or the pharmaceutically
acceptable salt of the same as an active ingredient for the
prevention or improvement of cancer.
Advantageous Effect
[0051] The N2-(2-methoxyphenyl)pyrimidine derivative, the optical
isomer thereof, or the pharmaceutically acceptable salt thereof of
the present invention is very effective in suppressing anaplastic
lymphoma kinase (ALK) activity and as a result it can improve the
effectiveness of treatment on cancer cells having anaplastic
lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK,
so that it can be effectively used as a pharmaceutical composition
for preventing or treating cancer.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0052] Hereinafter, the present invention is described in
detail.
[0053] The present invention provides a compound represented by
formula 1, an optical isomer thereof, or a pharmaceutically
acceptable salt of the same.
##STR00003##
[0054] In the formula 1,
[0055] R.sup.1 is hydrogen, C.sub.1-5 straight or branched alkyl,
--(CR.sup.5R.sup.6).sub..alpha.--(CR.sup.7R.sup.8).sub..beta.--(CR.sup.9R-
.sup.10).sub..gamma.--NR.sup.11R.sup.12, or
--(CH.sub.2).sub.p--C(.dbd.O)--R.sup.13,
[0056] R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10
are independently hydrogen or C.sub.1-10 straight or branched
alkyl,
[0057] R.sup.5 and R.sup.6 can form unsubstituted C.sub.3-8
cycloalkyl along with the carbon atoms conjugated to the same,
[0058] R.sup.7 and R.sup.8 can form unsubstituted C.sub.3-10
cycloalkyl or oxo group (.dbd.O) along with the carbon atoms
conjugated to the same,
[0059] R.sup.11 and R.sup.12 are independently hydrogen, C.sub.1-10
straight or branched alkyl wherein unsubstituted or one or more
hydroxyl groups are substituted, C.sub.1-10 straight or branched
alkyl sulfonyl, unsubstituted C.sub.6-10 aryl C.sub.1-5 straight or
branched alkyl, --(CH.sub.2).sub.n--C(.dbd.X)R.sup.14,
unsubstituted C.sub.6-10 heteroaryl containing one or more hetero
atoms selected from the group consisting of N, O, and S, or
unsubstituted C.sub.6-10 aryl,
[0060] wherein, X is O or S, R.sup.14 is hydrogen, --OH, C.sub.1-10
straight or branched alkoxy, C.sub.1-10 straight or branched alkyl
wherein unsubstituted or one or more halogens are substituted,
unsubstituted C.sub.6-10 aryl C.sub.1-5 straight or branched alkyl,
or --NR.sup.15R.sup.16, R.sup.15 and R.sup.16 are independently
hydrogen, C.sub.1-5 straight or branched alkyl, unsubstituted
C.sub.5-10 cycloalkyl, unsubstituted C.sub.6-10 aryl, or
unsubstituted C.sub.6-10 aryl C.sub.1-5 alkyl, and n is an integer
of 0-5,
[0061] R.sup.11 and R.sup.12 can form unsubstituted C.sub.5-10
heterocycloalkyl containing one or more hetero atoms selected from
the group consisting of N, O, and S along with the nitrogen atoms
conjugated to the same,
[0062] .alpha., .beta., and .gamma. are independently integers of
0-2,
[0063] R.sup.13 is --OH or --(OCH.sub.2CH.sub.2).sub.q--H, wherein
q is an integer of 1-2,
[0064] p is an integer of 1-2;
[0065] R.sup.2 is hydrogen, halogen, unsubstituted or substituted
C.sub.5-10 heteroaryl containing one or more hetero atoms selected
from the group consisting of N, O, and S, C.sub.1-10 straight or
branched alkyl wherein unsubstituted or one or more nitrile groups
(--CN) are substituted, C.sub.1-10 straight or branched alkyl
wherein unsubstituted or one or more amine groups (--NH.sub.2) are
substituted, unsubstituted C.sub.6-10,
--(CR.sup.7R.sup.8).sub.k--(CR.sup.19R.sup.20).sub.j--NR.sup.21R.sup.22,
--C(.dbd.CH.sub.2)--R.sup.23, or
--CH.sub.2--N.sup.+(CH.sub.3).sub.3I.sup.-,
[0066] the substituted C.sub.5-10 heteroaryl can be substituted
with C.sub.1-5 straight or branched alkyl,
[0067] R.sup.17, R.sup.18, R.sup.19, and R.sup.20 are independently
hydrogen or C.sub.1-5 straight or branched alkyl, and k and j are
independently integers of 0-2,
[0068] R.sup.21 and R.sup.22 are independently hydrogen, formyl
group (--C(.dbd.O)H), or C.sub.1-5 straight or branched alkyl,
[0069] R.sup.23 is C.sub.1-5 straight or branched alkyl;
[0070] R.sup.3 is hydrogen;
[0071] R.sup.4 is hydrogen or C.sub.1-5 straight or branched
alkoxy; and
[0072] Z is hydrogen, F, Cl, or Br.
[0073] Preferably,
[0074] R.sup.1 is hydrogen, C.sub.1-5 straight or branched alkyl,
--(CR.sup.5R.sup.6).sub..alpha.--(CR.sup.7R.sup.8).sub..beta.--(CR.sup.9R-
.sup.10).sub..gamma.--NR.sup.11R.sup.12, or
--(CH.sub.2).sub.p--C(.dbd.O)--R.sup.13,
[0075] R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10
are independently hydrogen or C.sub.1-10 straight or branched
alkyl,
[0076] R.sup.5 and R.sup.6 can form unsubstituted C.sub.3-8
cycloalkyl along with the carbon atoms conjugated to the same,
[0077] R.sup.7 and R.sup.8 can form unsubstituted C.sub.3-8
cycloalkyl or oxo group (.dbd.O) along with the carbon atoms
conjugated to the same,
[0078] R.sup.11 and R.sup.12 are independently hydrogen, C.sub.1-5
straight or branched alkyl wherein unsubstituted or one or more
hydroxyl groups are substituted, C.sub.1-5 straight or branched
alkyl sulfonyl, unsubstituted C.sub.6-8 aryl C.sub.1-3 straight or
branched alkyl, --(CH.sub.2).sub.n--C(.dbd.X)R.sup.14,
unsubstituted C.sub.6-10 heteroaryl containing one or more hetero
atoms selected from the group consisting of N, O, and S, or
unsubstituted C.sub.6-10 aryl,
[0079] wherein, X is O or S, R.sup.14 is hydrogen, --OH, C.sub.1-5
straight or branched alkoxy, C.sub.1-5 straight or branched alkyl
wherein unsubstituted or one or more halogens are substituted,
unsubstituted C.sub.6-8 aryl C.sub.1-3 straight or branched alkyl,
or --NR.sup.15R.sup.16, R.sup.15 and R.sup.16 are independently
hydrogen, C.sub.1-3 straight or branched alkyl, unsubstituted
C.sub.5-8 cycloalkyl, unsubstituted C.sub.6-8 aryl, or
unsubstituted C.sub.6-8 aryl C.sub.1-3 alkyl, and n is an integer
of 0-3,
[0080] R.sup.11 and R.sup.12 can form unsubstituted C.sub.5-8
heterocycloalkyl containing one or more hetero atoms selected from
the group consisting of N, O, and S along with the nitrogen atoms
conjugated to the same,
[0081] .alpha., .beta., and .gamma. are independently integers of
0-1,
[0082] R.sup.13 is --OH or --(OCH.sub.2CH.sub.2).sub.q--H, wherein
q is an integer of 1-2,
[0083] p is an integer of 1-2;
[0084] R.sup.2 is hydrogen, halogen, unsubstituted or substituted
C.sub.5-8 heteroaryl containing one or more hetero atoms selected
from the group consisting of N, O, and S, C.sub.1-5 straight or
branched alkyl wherein unsubstituted or one or more nitrile groups
(--CN) are substituted, C.sub.1-5 straight or branched alkyl
wherein unsubstituted or one or more amine groups (--NH.sub.2) are
substituted, unsubstituted C.sub.6-8,
--(CR.sup.17R.sup.18).sub.k--(CR.sup.19R.sup.20).sub.j--NR.sup.21R.sup.22-
, --C(.dbd.CH.sub.2)--R.sup.23, or
--CH.sub.2--N.sup.+(CH.sub.3).sub.3I.sup.-,
[0085] the substituted C.sub.5-8 heteroaryl can be substituted with
C.sub.1-5 straight or branched alkyl,
[0086] R.sup.17, R.sup.18, R.sup.19, and R.sup.20 are independently
hydrogen or C.sub.1-3 straight or branched alkyl, and k and j are
independently integers of 0-2,
[0087] R.sup.21 and R.sup.22 are independently hydrogen, formyl
group (--C(.dbd.O)H), or C.sub.1-3 straight or branched alkyl,
[0088] R.sup.23 is C.sub.1-3 straight or branched alkyl;
[0089] R.sup.3 is hydrogen;
[0090] R.sup.4 is hydrogen or C.sub.1-5 straight or branched
alkoxy; and
[0091] Z is hydrogen, F, Cl, or Br.
[0092] More preferably,
[0093] R.sup.1 is methyl,
##STR00004## ##STR00005## ##STR00006##
[0094] R.sup.2 is hydrogen, --Br,
##STR00007##
[0095] R.sup.3 is hydrogen;
[0096] R.sup.4 is methoxy, ethoxy, or iso-propoxy;
[0097] Z is hydrogen or F.
[0098] The compound represented by formula 1 of the present
invention can be exemplified by the following compounds: [0099] (1)
N2-(5-(1-(aminomethyl)cyclopentyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0100] (2)
N2-(5-(1-(aminomethyl)cyclohexyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopro-
pylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0101] (3)
N2-(5-((1-aminocyclopropyl)methyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0102] (4)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)p-
henyl)pyrimidine-2,4-diamine; [0103] (5)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl-N2-(2-methoxy-5-(1-(piperidine-1-
-ylmethyl)cyclopentyl) phenyl)pyrimidine-2,4-diamine; [0104] (6)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(1-(morpholinom-
ethyl)cyclopentyl)phenyl)pyrimidine-2,4-diamine; [0105] (7)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)acetamide; [0106] (8)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl) methanesulfonamide; [0107] (9)
5-chloro-N2-(5-(2-(dimethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyl-
sulfonyl)phenyl)pyrimidine-2,4-diamine; [0108] (10)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(methylamino-
)ethyl)phenyl)pyrimidine-2,4-diamine; [0109] (11)
N2-(5-(2-(benzylamino)ethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine; [0110] (12)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-2-phenylacetamide; [0111] (13)
5-chloro-N2-(5-(2-(ethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropylsul-
fonyl)phenyl)pyrimidine-2,4-diamine; [0112] (14)
5-chloro-N2-(5-(2-(diethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine; [0113] (15)
5-chloro-N2-(5-(2-(isopropylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropy-
lsulfonyl)phenyl)pyrimidine-2,4-diamine; [0114] (16)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylurea; [0115] (17)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-cyclohexylurea; [0116] (18)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-phenylurea; [0117] (19)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-methylthiourea; [0118] (20)
1-benzyl-3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2--
ylamino)-4-methoxyphenethyl)thiourea; [0119] (21)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperidine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine; [0120] (22)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-morpholinoet-
hyl)phenyl)pyrimidine-2,4-diamine; [0121] (23)
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylthiourea; [0122] (24) methyl
3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino) propanoate; [0123] (25)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(pyrimidine--
2-ylamino)ethyl)phenyl)pyrimidine-2,4-diamine; [0124] (26) methyl
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetate; [0125] (27)
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetic acid; [0126] (28)
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxybenzyl)-2,2,2-trifluoroacetamide; [0127] (29)
N2-(5-(aminomethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)ph-
enyl)pyrimidine-2,4-diamine; [0128] (30)
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-2,2,2-trifluoroacetamide; [0129] (31)
N2-(5-(2-aminoethyl)-2-isopropoxyphenyl)-5-chloro-N4-(2-(isopropylsulfony-
l)phenyl)pyrimidine-2,4-diamine; [0130] (32)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(4-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine; [0131] (33)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(5-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride; [0132] (34)
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-fluoro-6-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride; [0133] (35)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0134] (36)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(4-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0135] (37)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(5-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0136] (38)
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-fluo-
ro-6-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0137] (39)
2,2'-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamin-
o)-4-methoxyphenethylazeindiyl) diethanol; [0138] (40)
N-(3-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide; [0139]
(41)
N2-(5-(3-aminopropyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)-
phenyl)pyrimidine-2,4-diamine; [0140] (42)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetamide; [0141] (43) 2-ethoxyethyl
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetate; [0142] (44)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetic acid; [0143] (45)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-morpholinoethane-1-one; [0144] (46)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperidine-1-yl)ethane-1-one; [0145] (47)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(hydroxymethyl)acetamide; [0146] (48)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperazine-1-yl)ethane-1-one; [0147] (49)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(pyridine-4-yl)acetamide; [0148] (50)
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-phenylacetamide; [0149] (51)
N2-(5-(2-aminoethyl)-4-bromo-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine; [0150] (52)
N2-(5-(2-aminoethyl)-2-methoxy-4-(1-methyl-1H-pyrazole-4-yl)phenyl)-5-chl-
oro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0151]
(53)
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)acetonitrile; [0152] (54)
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)-2-methylpropanenitrile; [0153] (55)
N2-(4-(2-aminoethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine; [0154] (56)
N2-(4-(1-amino-2-methylpropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N-
4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0155] (57)
N2-(4-(2-aminopropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0156] (58)
5-chloro-N2-(4-(2-(dimethylamino)ethyl)-2-methoxy-5-methylphenyl)-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0157] (59)
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)-2-methylpropyl) formamide; [0158]
(60)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-met-
hyl-1-(methylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine;
[0159] (61)
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)propane-2-yl) formamide; [0160]
(62)
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenethyl)formamide; [0161] (63)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)ethyl)phenyl)pyrimidine-2,4-diamine; [0162] (64)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine; [0163] (65)
5-chloro-N2-(4-(1-(dimethylamino)-2-methylpropane-2-yl)-2-methoxy-5-methy-
lphenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
[0164] (66)
5-chloro-N2-(4-(2-(dimethylamino)propane-2-yl)-2-methoxy-5-methylphe-
nyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0165]
(67)
N2-(2-(2-aminoethyl)-5-methoxybiphenyl-4-yl)-5-chloro-N4-(2-isopropylsulf-
onyl)phenyl)pyrimidine-2,4-diamine; [0166] (68)
N2-(4-(aminomethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine; [0167] (69)
1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)-N,N,N-trimethylmethanealuminum
iodide; [0168] (70)
5-chloro-N2-(4-((dimethylamino)methyl)-2-methoxy-5-methylphenyl)-N4-(2-(i-
sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; [0169] (71)
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylbenzyl)formamide; [0170] (72)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-((meth-
ylamino)methyl)phenyl)pyrimidine-2,4-diamine; [0171] (73)
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperazine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine; [0172] (74)
N2-(5-(2-aminoethyl)-2-ethoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; and [0173] (75)
N2-(5-(2-aminoethyl)-2-methoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2--
(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine.
[0174] The compound represented by formula 1 of the present
invention can be used as a form of a pharmaceutically acceptable
salt, in which the salt is preferably acid addition salt formed by
pharmaceutically acceptable free acids.
[0175] The acid addition salt herein can be obtained from inorganic
acids such as hydrochloric acid, nitric acid, phosphoric acid,
sulfuric acid, hydrobromic acid, hydriodic acid, nitrous acid, and
phosphorous acid; non-toxic organic acids such as aliphatic
mono/dicarboxylate, phenyl-substituted alkanoate, hydroxy
alkanoate, alkandioate, aromatic acids, and aliphatic/aromatic
sulfonic acids; or organic acids such as acetic acid, benzoic acid,
citric acid, lactic acid, maleic acid, gluconic acid,
methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, and
fumaric acid. The pharmaceutically non-toxic salts are exemplified
by sulfate, pyrosulfate, bisulfate, sulphite, bisulphite, nitrate,
phosphate, monohydrogen phosphate, dihydrogen phosphate,
metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride,
acetate, propionate, decanoate, caprylate, acrylate, formate,
isobutylate, caprate, heptanoate, propiolate, oxalate, malonate,
succinate, suberate, cabacate, fumarate, maliate,
butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate,
methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate,
phthalate, terephthalate, benzenesulfonate, toluenesulfonate,
chlorobenzenesulfonate, xylenesulfonate, phenylacetate,
phenylpropionate, phenylbutylate, citrate, lactate,
hydroxybutylate, glycolate, malate, tartrate, methanesulfonate,
propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate,
and mandelate.
[0176] The acid addition salt in this invention can be prepared by
the conventional method known to those in the art. For example, the
derivative represented by formula 1 is dissolved in an organic
solvent such as methanol, ethanol, acetone, methylenechloride, or
acetonitrile, to which organic acid or inorganic acid is added to
induce precipitation. Then, the precipitate is filtered and dried
to give the salt.
[0177] Or the solvent and the excessive acid are distillated under
reduced pressure, and dried to give the salt.
[0178] Or the precipitate is crystallized in an organic solvent to
give the same.
[0179] The present invention includes not only the compound
represented by formula 1 but also a pharmaceutically acceptable
salt thereof, and a solvate, an optical isomer, or a hydrate
possibly produced from the same.
[0180] The present invention also provides a method for preparing
the compound represented by formula 1 containing the step of
preparing the compound represented by formula 1 by reacting the
compound represented by formula 2 with the compound represented by
formula 3 (step 1) as shown in reaction formula 1 below.
##STR00008##
[0181] In the reaction formula 1,
[0182] R.sup.1, R.sup.2, R.sup.3, R.sup.4, and Z are as defined in
formula 1.
[0183] Hereinafter, the method for preparing the compound
represented by formula 1 of the present invention is described in
more detail.
[0184] In the method for preparing the compound represented by
formula 1 of the present invention, the compound represented by
formula 1 was prepared by reacting the compound represented by
formula 2 with the compound represented by formula 3. Particularly,
the compound represented by formula 1 was prepared by reacting the
compound represented by formula 2 with the compound represented by
formula 3 in the presence of an organic solvent and an acid.
[0185] At this time, the organic solvent used herein was selected
from the group consisting of tetrahydrofuran (THF); dioxane; ether
solvents including ethylether and 1,2-dimethoxyethane; lower
alcohols including methanol, ethanol, propanol, and butanol;
dimethylformamide (DMF), dimethylsulfoxide (DMSO), dichloromethane
(DCM), dichloroethane, water, acetonagensulfonate,
toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate,
phenylacetate, phenylpropionate, phenylbutylate, citrate, lactate,
hydroxybutylate, glycolate, malate, tartrate, methanesulfonate,
propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate,
and mandelate, and dimethylformamide (DMF) was preferably
selected.
[0186] The acid used herein was selected from the group consisting
of acetic acid, trifluoroacetic acid, hydrochloric acid, sulfuric
acid, and toluene sulfonic acid, and hydrochloric acid was
preferably selected.
[0187] At this time, the reaction was preferably performed at a
temperature between 0.degree. C. and the boiling point of the
solvent, and the reaction time was not particularly limited, but it
was preferably 0.5-40 hours.
[0188] The present invention also provide a pharmaceutical
composition comprising the compound represented by formula 1, the
optical isomer thereof, or the pharmaceutically acceptable salt of
the same as an active ingredient for the prevention or treatment of
cancer. The pharmaceutical composition is characterized by the
inhibition of the expression and the growth of cancer cells by
suppressing the activation of anaplastic lymphoma kinase (ALK). The
cancer herein is exemplified by non-small cell lung cancer,
neuroblastoma, inflammatory myelofibroblastoma, rhabdomyosarcoma,
myofibroblastoma, breast cancer, stomach cancer, lung cancer, and
melanoma.
[0189] ALK is the gene inducing the proliferation of cancer cells,
which is activated by gene fusion. At this time, a tyrosine kinase
included in ALK starts acting abnormally to induce cell
proliferation, interrupt apoptosis, re-arrange cytoskeleton,
transform cell shape, and activates other pathways or interacts
with other tyrosine kinases which are either normal or
oncogenic.
[0190] Particularly, the compound of the present invention was
confirmed to reduce efficiently the activity of ALK WT containing
ALK enzyme (see Table 2 of Experimental Example 1); to inhibit ALK
L1196M also containing ALK enzyme (see Table 3 of Experimental
Example 2); and to inhibit the activity of IR protein containing
ALK (see Table 4 of Experimental Example 3).
[0191] The compound of the present invention also displayed
cytotoxic effect on H3122 and H2228 (non-small cell lung cancer
cells) (see Tables 5 and 6 of Experimental Examples 4 and 5) and
EML4 (Echiinoderm Microtubule-Associated Protein-like 4)-ALK and
L1196M mutant cells (see Tables 7 and 8 of Experimental Examples 6
and 7).
[0192] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
have an excellent activity to inhibit ALK activity and cancer cell
specific toxicity, so that it can be effectively used as a
composition for the prevention or treatment of such cancers as
non-small cell lung cancer, neuroblastoma, inflammatory
myelofibroblastoma, rhabdomyosarcoma, myofibroblastoma, breast
cancer, stomach cancer, lung cancer, and melanoma.
[0193] The compound represented by formula 1 of the present
invention can be administered orally or parenterally in various
formulations at the time of clinical administration. The
formulations can be prepared by mixing the compound of the
invention with generally used diluents or excipients such as
fillers, extenders, binders, wetting agents, disintegrants, and
surfactants.
[0194] The formulations for oral administration are exemplified by
tablets, pills, powders, granules, capsules, and troches (candy
type), etc. Such solid preparations are prepared by mixing one or
more compounds of the present invention with one or more excipients
such as starch, calcium carbonate, sucrose, lactose and gelatin.
Except for the simple excipients, lubricants, for example magnesium
stearate, talc, etc, can be used. Liquid formulations for oral
administrations are suspensions, solutions (medicines dissolved or
dispersed in water or organic solvents), emulsions or syrups, and
the above-mentioned formulations can contain various excipients
such as wetting agents, sweeteners, aromatics and preservatives in
addition to generally used simple diluents such as water and liquid
paraffin.
[0195] Formulations for parenteral administration are sterilized
aqueous solutions, water-insoluble excipients, suspensions,
emulsions, lyophilized preparations and suppositories. Water
insoluble excipients and suspensions can contain, in addition to
the active compound or compounds, propylene glycol, polyethylene
glycol, vegetable oil like olive oil, injectable ester like
ethylolate, etc.
[0196] Suppositories can contain, in addition to the active
compound or compounds, witepsol, macrogol, tween 61, cacao butter,
laurin butter, glycerol, gelatin, etc.
[0197] The effective dosage of the compound of the present
invention can be adjusted according to age, weight, and gender of
patient, administration pathway, health condition, severity of
disease, etc.
[0198] For example, the effective dosage is generally 0.001-100
mg/kg/day, and preferably 0.01-35 mg/kg/day.
[0199] Based on an adult patient weighing 70 kg, the effective
dosage is generally 0.07-7000 mg/day, and preferably 0.7-2500
mg/day, which can be administered 1--several times a day or the
dosage can be divided and administered several times a day at a
regular interval according to the judgment of a doctor or a
pharmacist.
[0200] In addition, the present invention provides a health
functional food composition comprising the
N2-(2-methoxyphenyl)pyrimidine derivative represented by formula 1,
the optical isomer thereof, or the pharmaceutically acceptable salt
of the same as an active ingredient for the prevention or
improvement of cancer.
[0201] Particularly, the food comprising the
N2-(2-methoxyphenyl)pyrimidine derivative represented by formula 1,
the optical isomer thereof, or the pharmaceutically acceptable salt
of the same as an active ingredient herein is not limited. For
example, the compound of the present invention can be added to
drinks, meats, sausages, breads, biscuits, rice cakes, chocolates,
candies, snacks, cookies, pizza, ramyuns, flour products, gums,
dairy products including ice cream, soups, beverages, vitamin
complex, milk products, and milk-processing products, and in a wide
sense, almost every food applicable in the production of health
food can be included. The compound of the present invention can be
added as it is or as mixed with other food components according to
the conventional method.
[0202] The N2-(2-methoxyphenyl)pyrimidine derivative represented by
formula 1 of the present invention was confirmed to have an
excellent activity to inhibit ALK activity, so that it can be
effectively used as a health functional food composition for the
prevention or improvement of such cancers as non-small cell lung
cancer, neuroblastoma, inflammatory myelofibroblastoma,
rhabdomyosarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
[0203] Practical and presently preferred embodiments of the present
invention are illustrative as shown in the following Examples.
[0204] However, it will be appreciated that those skilled in the
art, on consideration of this disclosure, may make modifications
and improvements within the spirit and scope of the present
invention.
Preparative Example 1: Preparation of
N-((1-(3-amino-4-methoxyphenyl)cyclopentyl)methyl)-2,2,2-trifluoroacetami-
de
##STR00009##
[0205] Step 1: Preparation of
1-(4-methoxyphenyl)cyclopentane-1-carbonitrile
[0206] Sodium hydride (2.85 g, 71.34 mmol) was dissolved in
dimethylformamide (50 ml), to which 2-(4-methoxyphenyl)acetonitrile
(5.0 g, 33.97 mmol) and 1,4-dibromobutane (8.80 g, 40.77 mmol) were
loaded at 0.degree. C. The reaction mixture was stirred at room
temperature for 2 hours. Water was added thereto to terminate the
reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 1/1) to give the
target compound 1-(4-methoxyphenyl)cyclopentane-1-carbonitrile as a
white solid (5.10 g, 25.3 mmol, yield: 75%).
[0207] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.36 (d, J=8.7 Hz,
2H), 7.36 (d, J=9.0 Hz, 2H), 3.81 (s, 3H), 2.44-2.46 (m, 2H),
1.91-2.04 (m, 6H); LC/MS 202.1[M+H.sup.+].
Step 2: Purification of
(1-(4-methoxyphenyl)cyclopentyl)methaneamine
[0208] 1-(4-methoxyphenyl)cyclopentane-1-carbonitrile prepared in
step 1 was dissolved in diethylether (5 ml). This mixed solution
was added to diethylether (50 ml) containing lithium aluminum
hydride (1.89 g, 49.97 mmol) dissolved therein at 0.degree. C. The
reaction mixture was stirred at room temperature for 4 hours. Water
and 2 N sodium hydroxide aqueous solution were added thereto at
0.degree. C. The reaction mixture was stirred for 20 minutes and
the produced solid was filtered. The filtrate was dried over sodium
sulfate, and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
(1-(4-methoxyphenyl)cyclopentyl)methaneamine as a yellow solid (4.3
g, 20.944 mmol, yield: 83%).
[0209] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.21 (d, J=7.8 Hz,
2H), 6.87 (d, J=7.8 Hz, 2H), 4.74 (br, 2H), 3.79 (s, 3H), 2.85 (s,
2H), 1.94 (br, 4H), 1.70-1.73 (m. 4H); LC/MS 206.10[M+H.sup.+].
Step 3: Preparation of
2,2,2-trifluoro-N-((1-(4-methoxyphenyl)cyclopentyl)methyl)acetamide
[0210] (1-(4-methoxyphenyl)cyclopentyl)methaneamine (4.5 g, 21.92
mmol) prepared in step 2 was dissolved in dichloromethane (50 ml),
to which anhydrous trifluoroacetic acid (5.5 g, 26.30 mmol) and
triethylamine (7.6 ml, 54.79 mmol) were loaded at 0.degree. C. The
reaction mixture was stirred at room temperature for 2 hours. Water
was added thereto to terminate the reaction, followed by extraction
twice with dichloromethane. The extracted organic layer was dried
over sodium sulfate and then filtered. The solvent was eliminated
by distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-((1-(4-methoxyphenyl)cyclopentyl)methyl)acetamide
as a white solid (5.1 g, 16.926 mmol, yield: 77%).
[0211] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.19 (d, J=9.0 Hz,
2H), 6.90 (d, J=8.7 Hz, 2H), 5.89 (br, 1H), 3.81 (s, 3H), 3.44 (d,
J=6.3 Hz, 2H), 1.60-1.89 (m, 8H); LC/MS 206.10[M+H.sup.+].
Step 4: Preparation of
2,2,2-trifluoro-N-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)acetami-
de
[0212]
2,2,2-trifluoro-N-((1-(4-methoxyphenyl)cyclopentyl)methyl)acetamide
(5.0 g, 16.59 mmol) prepared in step 3 was dissolved in
trifluoroacetic acid (50 ml), to which trifluoroacetic acid (12.5
ml) solution containing concentrated nitric acid (1.05 g, 16.59
mmol) dissolved therein was added at 0.degree. C. The reaction
mixture was stirred at 0.degree. C. for 2 hours. The reaction
mixture was distillated under reduced pressure, followed by
extraction twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)acetami-
de as a yellow solid (4.1 g, 11.839 mmol, yield: 72%).
[0213] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.75 (d, J=1.5 Hz,
1H), 7.46 (d, J=8.7 Hz, 1H), 7.09 (d, J=8.4 Hz, 1H), 6.09 (br, 1H),
3.96 (s, 3H), 3.50 (d, J=6.6 Hz, 2H), 1.68-2.04 (m, 8H); LC/MS
346.92 [M+H.sup.+].
Step 5: Preparation of
N-((1-(3-amino-4-methoxyphenyl)cyclopentyl)methyl)-2,2,2-trifluoroacetami-
de
[0214]
2,2,2-trifluoro-N-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)a-
cetamide (300 mg, 0.89 mmol) prepared in step 4 was dissolved in
methanol (5 ml), to which 10 weight % Pd/C (30 mg) was added. The
mixture was stirred for 4 hours under a hydrogen gas balloon. The
solid generated in the reaction mixture was filtered with celite,
which was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
N-((1-(3-amino-4-methoxyphenyl)cyclopentyl)methyl)-2,2,2-trifluo-
roacetamide as a white solid (242 mg, 0.765 mmol, yield: 88%).
[0215] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.75 (d, J=8.4 Hz,
1H), 6.58-6.62 (m, 2H), 5.98 (br, 1H), 3.85 (s, 3H), 3.79 (br, 2H),
3.40 (d, J=6.0 Hz, 2H), 1.75-1.85 (m, 8H); LC/MS 316.46
[M+H.sup.+], 632.90 [2M+H.sup.+].
Preparative Example 2: Preparation of
N-((1-(3-amino-4-methoxyphenyl)cyclohexyl)methyl)-2,2,2-trifluoroacetamid-
e
##STR00010##
[0216] Step 1: Preparation of
1-(4-methoxyphenyl)cyclohexanecarbonitrile
[0217] Sodium hydride (2.85 g, 71.3 mmol) was dissolved in
dimethylformamide (50 mL), to which 2-(4-methoxyphenyl)acetonitrile
(5.0 g, 33.97 mmol) and 1,5-dibromopentane (9.37 g, 40.77 mmol)
were loaded at 0.degree. C. The reaction mixture was stirred at
room temperature for 2 hours. Water was added thereto to terminate
the reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 1/1) to give the
target compound 1-(4-methoxyphenyl)cyclohexanecarbonitrile as a
white solid (5.2 g, 24.152 mmol, yield: 71%).
[0218] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.40 (d, J=9.0 Hz,
2H), 6.91 (d, J=8.7 Hz, 2H), 3.81 (s, 3H), 2.12-2.16 (m, 2H),
1.58-1.85 (m, 7H), 1.24-1.28 (m, 1H); LC/MS 216.1 [M+H.sup.+].
Step 2: Preparation of
(1-(4-methoxyphenyl)cyclohexyl)methaneamine
[0219] Lithium aluminum hydride (1.79 g, 47.38 mmol) was dissolved
in diethylether (51 mL), to which diethylether (5 mL) solution
containing 1-(4-methoxyphenyl)cyclopentane-1-carbonitrile (5.1 g,
23.69 mmol) prepared in step 1 was added at 0.degree. C. The
reaction mixture was stirred at room temperature for 4 hours. Water
and 2 N sodium hydroxide aqueous solution were added thereto at
0.degree. C. The reaction mixture was stirred for 20 minutes and
the produced solid was filtered. The filtrate was dried over sodium
sulfate, and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
(1-(4-methoxyphenyl)cyclohexyl)methaneamine as a yellow solid (4.5
g, 20.517 mmol, yield: 87%).
[0220] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.24 (d, J=9.0 Hz,
2H), 6.89 (d, J=8.7 Hz, 2H), 3.80 (s, 3H), 2.65 (s, 2H), 2.06-2.11
(m, 2H), 1.35-1.53 (m, 8H); LC/MS 220.03 [M+H.sup.+].
Step 3: Preparation of
2,2,2-trifluoro-N-((1-(4-methoxyphenyl)cyclohexyl)methyl)acetamide
[0221] (1-(4-methoxyphenyl)cyclohexyl)methaneamine (4.5 g, 20.52
mmol) prepared in step 2 was dissolved in dichloromethane (45 mL),
to which anhydrous trifluoroacetic acid (5.2 g, 24.62 mmol) and
triethylamine (7.1 mL, 51.29 mmol) were added at 0.degree. C. The
reaction mixture was stirred at room temperature for 2 hours. Water
was added thereto to terminate the reaction, followed by extraction
twice with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-((1-(4-methoxyphenyl)cyclohexyl)methyl)acetami-
de as a white solid (5.5 g, 17.441 mmol, yield: 85%).
[0222] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.25 (d, J=9.3 Hz,
2H), 6.93 (d, J=8.7 Hz, 2H), 5.81 (br, 1H), 3.82 (s, 3H), 3.40 (d,
J=6.3 Hz, 2H), 2.04-2.17 (m, 2H), 1.38-1.66 (m, 8H); LC/MS 316.06
[M+H.sup.+].
Step 4: Preparation of
2,2,2-trifluoro-N-((1-(4-methoxy-3-nitrophenyl)cyclohexyl)methyl)acetamid-
e
[0223]
2,2,2-trifluoro-N-((1-(4-methoxyphenyl)cyclohexyl)methyl)acetamide
(5.3 g, 16.79 mmol) prepared in step 3 was dissolved in
trifluoroacetic acid (50 ml), to which trifluoroacetic acid (12.5
ml) solution containing concentrated nitric acid (1.05 g, 16.59
mmol) dissolved therein was added at 0.degree. C. The reaction
mixture was stirred at 0.degree. C. for 2 hours. The reaction
mixture was distillated under reduced pressure, followed by
extraction twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-((1-(4-methoxy-3-nitrophenyl)cyclohexyl)methyl)acetamid-
e as a yellow solid (4.3 g, 11.934 mmol, yield: 71%).
[0224] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.82 (d, J=2.4 Hz,
1H), 7.52 (dd, J=2.1 Hz, 8.7 Hz, 1H), 7.12 (d, J=9.0 Hz, 1H), 5.18
(s, 1H), 3.98 (s, 3H), 3.45 (d, J=6.6 Hz, 2H), 2.06-2.14 (m, 2H),
1.22-1.69 (m, 8H); LC/MS 360.87 [M+H.sup.+], 720.78
[2M+H.sup.+].
Step 5: Preparation of
N-((1-(3-amino-4-methoxyphenyl)cyclohexyl)methyl)-2,2,2-trifluoroacetamid-
e
[0225]
2,2,2-trifluoro-N-((1-(4-methoxy-3-nitrophenyl)cyclohexyl)methyl)ac-
etamide (300 mg 0.837 mmol) prepared in step 4 was dissolved in
methanol (5 ml), to which 10 weight % Pd/C (30 mg) was added. The
mixture was stirred for 4 hours under a hydrogen gas balloon. The
solid generated in the reaction mixture was filtered with celite,
which was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
N-((1-(3-amino-4-methoxyphenyl)cyclohexyl)methyl)-2,2,2-trifluor-
oacetamide as a white solid (252 mg, 0.763 mmol, yield: 92%).
[0226] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.78 (d, J=8.4 Hz,
1H), 6.65-6.69 (m, 2H), 5.85 (br, 1H), 3.86 (s, 3H), 3.79 (br, 2H),
3.37 (d, J=6.0 Hz, 2H), 1.99-2.05 (m, 2H), 1.40-1.56 (m, 8H); LC/MS
330.48 [M+H.sup.+], 660.84 [2M+H.sup.+].
Preparative Example 3: Preparation of
N-(1-(3-amino-4-methoxybenzyl)cyclopropyl)-2,2,2-trifluoroacetamide
##STR00011##
[0227] Step 1: Preparation of
1-(4-methoxybenzyl)cyclopropane-1-amine
[0228] 2-(4-methoxyphenyl)acetonitrile (4.0 g, 27.18 mmol) was
dissolved in tetrahydrofuran/ether (30 mL/30 mL), to which titanium
isopropoxide (8.19 g, 54.36 mmol) was added at 0.degree. C. Then, 3
M ethylmagnesium bromide (18.1 mL, 54.36 mmol) was added thereto at
room temperature. The reaction mixture was stirred for 1 hour.
Boron trifluoride diethyl ether (7.71 g, 54.36 mmol) was added to
the reaction mixture, followed by stirring at room temperature for
1 hour. 2 N sodium hydroxide solution was added thereto to
terminate the reaction, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
1-(4-methoxybenzyl)cyclopropane-1-amine as a colorless oil (2.1 g,
11.84 mmol, yield: 44%).
[0229] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.17 (d, J=8.4 Hz,
2H), 6.86 (d, J=8.7 Hz, 2H), 3.79 (s, 3H), 2.66 (s, 2H), 1.45 (br,
2H), 0.58-0.62 (m, 4H); LC/MS 177.9.
Step 2: Preparation of
2,2,2-trifluoro-N-(1-(4-methoxybenzyl)cyclopropyl)acetamide
[0230] 1-(4-methoxybenzyl)cyclopropane-1-amine (1.0 g, 5.64 mmol)
was dissolved in dichloromethane (10 mL), to which anhydrous
trifluoroacetic acid (1.42 g, 6.77 mmol) and triethylamine (1.96
mL, 14.10 mmol) were added at 0.degree. C. The reaction mixture was
stirred at room temperature for 2 hours. Water was added thereto to
terminate the reaction, followed by extraction twice with
dichloromethane. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-(1-(4-methoxybenzyl)cyclopropyl)acetamide as a
white solid (1.21 g, 4.43 mmol, yield: 65%).
[0231] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.08 (d, J=8.4 Hz,
2H), 6.85 (d, J=8.7 Hz, 2H), 6.35 (br, 1H), 3.79 (s, 3H), 2.86 (s,
2H), 0.89-0.95 (m, 4H); LC/MS 274.0.
Step 3: Preparation of
2,2,2-trifluoro-N-(1-(4-methoxy-3-nitrobenzyl)cyclopropyl)acetamide
[0232] 2,2,2-trifluoro-N-(1-(4-methoxybenzyl)cyclopropyl)acetamide
(1.0 g, 3.65 mmol) prepared in step 1 was dissolved in
trifluoroacetic acid (10 mL), to which trifluoroacetic acid (1.0
mL) solution containing concentrated nitric acid (0.42 g, 4.03
mmol) dissolved therein was added at 0.degree. C. The reaction
mixture was stirred at 0.degree. C. for 2 hours. The reaction
mixture was distillated under reduced pressure, followed by
extraction twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-(1-(4-methoxy-3-nitrobenzyl)cyclopropyl)acetamide
as a yellow solid (718 mg, 2.26 mmol, yield: 62%).
[0233] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.67 (s, 1H), 7.32
(d, J=8.4 Hz, 1H), 7.04 (d, J=2.1 Hz, 8.4 Hz, 1H), 6.38 (s, br,
1H), 3.96 (s, 3H), 2.95 (s, 2H), 0.95 (s, 4H); LC/MS: 319.0
[M+H.sup.+].
Step 4: Preparation of
N-(1-(3-amino-4-methoxybenzyl)cyclopropyl)-2,2,2-trifluoroacetamide
[0234]
2,2,2-trifluoro-N-(1-(4-methoxy-3-nitrobenzyl)cyclopropyl)acetamide
(200 mg 0.837 mmol) prepared in step 3 was dissolved in methanol (5
ml), to which 10 weight % Pd/C (20 mg) was added. The mixture was
stirred for 4 hours under a hydrogen gas balloon. The solid
generated in the reaction mixture was filtered with celite, which
was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
N-(1-(3-amino-4-methoxybenzyl)cyclopropyl)-2,2,2-trifluoroacetamide
as a white solid (150 mg, 0.520 mmol, yield: 83%).
[0235] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.70-6.73 (m, 1H),
6.48-6.52 (m, 2H), 3.83 (s, 3H), 3.77 (br, 2H), 2.77 (d, J=1.8 Hz,
2H), 0.89 (br, 2H), 0.86 (br, 2H); LC/MS 289.1 [M+H.sup.+].
Preparative Example 4: Preparation of
N-(3-amino-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
##STR00012##
[0236] Step 1: Preparation of
2,2,2-trifluoro-N-(4-methoxyphenethyl)acetamide
[0237] 4-methoxyphenethylamine (12.0 g, 79.36 mmol) was dissolved
in dichloromethane (50 mL), to which trifluoroacetic anhydride
(13.5 mL, 95.2 mmol) and triethylamine (27.6 mL, 198.4 mmol) were
added at 0.degree. C. The reaction mixture was stirred at room
temperature for 3 hours. Water was added thereto to terminate the
reaction, followed by extraction twice with dichloromethane. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/1) to give the
target compound 2,2,2-trifluoro-N-(4-methoxyphenethyl)acetamide as
a white solid (19.0 g, 76.9 mmol, yield: 97%).
[0238] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 2.72 (t, J=7.2 Hz,
2H), 3.35-3.39 (m, 2H), 3.71 (s, 3H), 6.87 (d, J=8.4 Hz, 2H), 7.11
(d, J=8.7 Hz, 2H), 9.46 (s, 1H); LC/MS 248.30 [M+H.sup.+].
Step 2: Preparation of
2,2,2-trifluoro-N-(4-methoxy-3-nitrophenethyl)acetamide
[0239] 2,2,2-trifluoro-N-(4-methoxyphenethyl)acetamide (20.0 g,
80.89 mmol) prepared in step 1 was dissolved in trifluoroacetic
acid (206 mL), to which concentrated nitric acid (5.09 g, 80.89
mmol) was added at 0.degree. C. The reaction mixture was stirred at
room temperature for 2 hours. Water was added thereto to terminate
the reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/1) to give the
target compound
2,2,2-trifluoro-N-(4-methoxy-3-nitrophenethyl)acetamide as a white
solid (19.2 g, 65.7 mmol, yield: 81%).
[0240] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 2.82 (t, J=6.9 Hz,
2H), 3.42 (q, J=6.9, 12.9 Hz, 2H), 3.89 (s, 3H), 7.29 (d, J=8.7 Hz,
1H), 7.49 (dd, J=1.8, 8.4 Hz, 1H), 7.72 (d, J=1.8 Hz, 1H), 9.46 (s,
1H); LC/MS 293.28 [M+H.sup.+], 585.44 [2M+H.sup.+].
Step 3: Preparation of
N-(3-amino-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
[0241] 2,2,2-trifluoro-N-(4-methoxy-3-nitrophenethyl)acetamide (100
mg, 0.34 mmol) prepared in step 2 was dissolved in methanol (2 ml),
to which 10 weight % Pd/C (10 mg) was added. The mixture was
stirred for 4 hours under a hydrogen gas balloon. The solid
generated in the reaction mixture was filtered with celite, which
was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
N-(3-amino-4-methoxyphenethyl)-2,2,2-trifluoroacetamide as a white
solid (78 mg, yield: 88%).
[0242] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.73 (d, J=7.5 Hz,
1H), 6.51-6.53 (m, 2H), 6.34 (br, 1H), 3.84 (s, 3H), 3.48-3.57 (m,
4H), 2.71-2.76 (m, 2H); LC/MS 262.8 [M+H.sup.+], 5.25.0
[2M+H.sup.+].
Preparative Example 5: Preparation of
2-methoxy-5-(1-(piperidine-1-ylmethyl)cyclopentyl) aniline
##STR00013##
[0243] Step 1: Preparation of
(1-(4-methoxy-3-nitrophenyl)cyclopentyl) methaneamine
[0244]
2,2,2-trifluoro-N-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)a-
cetamide (600 mg, 1.74 mmol) was dissolved in ethanol (5 mL), to
which potassium carbonate (2.39 g, 17.36 mmol) aqueous solution
(2.5 mL) was added. The reaction mixture was stirred at 100 for 6
hours. The reaction mixture was distillated under reduced pressure,
followed by extraction twice with ethylacetate. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: methanol/chloroform) to give the target
compound (1-(4-methoxy-3-nitrophenyl)cyclopentyl)methaneamine as a
white solid (350 mg, 1.398 mmol, yield: 81%).
[0245] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.76 (d, J=2.4 Hz,
1H), 7.47 (dd, J=2.1 Hz, 8.4 Hz, 1H), 7.05 (d, J=8.7 Hz, 1H), 3.95
(s, 3H), 2.75 (s, 2H), 1.72-1.96 (m, 8H), 1.01 (br, 2H); LC/MS
250.9 [M+H.sup.+], 500.9 [2M+H.sup.+].
Step 2: Preparation of
1-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)piperidine
[0246] (1-(4-methoxy-3-nitrophenyl)cyclopentyl)methaneamine (100
mg, 0.39 mmol) prepared in step 1 was dissolved in acetonitrile (1
mL), to which 1,5-dibromopentane (92 mg, 0.39 mmol) and potassium
carbonate (110 mg, 0.79 mmol) were added. The reaction mixture was
stirred at 80.degree. C. for 15 hours. Water was added thereto to
terminate the reaction, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
1-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)piperidine as a
yellow solid (92 mg, 0.289 mmol, yield: 72%).
[0247] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.83 (d, J=2.4 Hz,
1H), 7.49 (dd, J=2.4 Hz, 9.0 Hz, 1H), 6.97 (d, J=9.0 Hz, 1H), 3.94
(s, 3H), 2.28 (s, 2H), 1.99-2.11 (m, 6H), 1.63-1.73 (m, 6H),
1.27-1.37 (m, 6H); LC/MS 318.8 [M+H.sup.+].
Step 3: Preparation of
2-methoxy-5-(1-(piperidine-1-ylmethyl)cyclopentyl)aniline
[0248] 1-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)piperidine
(70 mg, 0.22 mmol) prepared in step 2 was dissolved in methanol (2
ml), to which 10 weight % Pd/C (7 mg) was added. The mixture was
stirred for 4 hours under a hydrogen gas balloon. The solid
generated in the reaction mixture was filtered with celite, which
was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
2-methoxy-5-(1-(piperidine-1-ylmethyl)cyclopentyl)aniline as a
yellow solid (52 mg, 0.180 mmol, yield: 83%).
[0249] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.42-6.72 (m, 3H),
3.82 (s, 3H), 3.65 (br, 2H), 2.29 (s, 2H), 2.10-2.12 (m, 4H),
1.93-1.97 (m, 2H), 1.64-1.77 (m, 6H), 1.27-1.41 (m, 6H); LC/MS
289.2 [M+H.sup.+].
Preparative Example 6: Preparation of
2-methoxy-5-(1-(morpholinomethyl)cyclopentyl)aniline
##STR00014##
[0250] Step 1: Preparation of 2-(2-chloroethoxy)ethyl
4-methylbenzenesulfonate
[0251] 2-(2-chloroethoxy)ethane-1-ol (2.00 g, 16.1 mmol) was
dissolved in dichloromethane (20 mL), to which tosyl chloride (3.70
g, 19.3 mmol) and triethylamine (56 mL, 40.14 mmol) were added at
0.degree. C. The reaction mixture was stirred at room temperature
for 2 hours. Water was added thereto to terminate the reaction,
followed by extraction twice with dichloromethane. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 1/1) to give the
target compound 2-(2-chloroethoxy)ethyl 4-methylbenzenesulfonate as
a colorless solution (4.0 g, 14.349 mmol, yield: 89%).
[0252] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.81 (d, J=8.1 Hz,
2H), 7.35 (d, J=8.7 Hz, 2H), 4.18 (t, J=4.8 Hz, 2H), 3.66-3.73 (m,
4H), 3.55 (t, J=6.09 Hz, 2H), 2.45 (s, 3H); LC/MS 278.9
[M+H.sup.+].
Step 2: Preparation of
4-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)morpholine
[0253] 2-(2-chloroethoxy)ethyl 4-methylbenzenesulfonate (134 mg,
0.48 mmol) prepared in step 1 and potassium carbonate (165 mg, 1.19
mmol) were added to acetonitrile (1 mL) solution containing
(1-(4-methoxy-3-nitrophenyl)cyclopentyl)methaneamine (100 mg, 0.39
mmol) dissolved therein. The reaction mixture was stirred at
80.degree. C. for 15 hours. The reaction mixture was cooled to room
temperature and water was added to terminate the reaction, followed
by extraction twice with ethylacetate. The extracted organic layer
was dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 1/1) to give the target compound
4-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)morpholine as a
yellow solid (98 mg, 0.306 mmol, yield: 77%).
[0254] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.82 (s, 1H), 7.49
(dd, J=1.2 Hz, 8.4 Hz, 1H), 6.99 (d, J=8.7 Hz, 1H), 3.94 (s, 3H),
3.53 (t, J=3.9 Hz, 4H), 2.37 (s, 2H), 2.17 (t, J=3.9 Hz, 4H),
1.99-2.03 (m, 2H), 1.71-1.81 (m, 6H); LC/MS 320.8 [M+H.sup.+].
Step 3: Preparation of
2-methoxy-5-(1-(morpholinomethyl)cyclopentyl) aniline
[0255] 4-((1-(4-methoxy-3-nitrophenyl)cyclopentyl)methyl)morpholine
(85 mg, 0.27 mmol) prepared in step 2 was dissolved in methanol (2
ml), to which 10 weight % Pd/C (9 mg) was added. The mixture was
stirred for 4 hours under a hydrogen gas balloon. The solid
generated in the reaction mixture was filtered with celite, which
was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
2-methoxy-5-(1-(morpholinomethyl)cyclopentyl)aniline as a yellow
solid (71 mg, 0.244 mmol, yield: 92%).
[0256] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.66-6.69 (m, 3H),
3.82 (s, 3H), 3.71 (br, 2H), 3.52 (t, J=4.5 Hz, 4H), 2.34 (s, 2H),
2.14 (t, J=4.5 Hz, 4H), 1.93-1.97 (m, 2H), 1.66-1.78 (m, 6H); LC/MS
291.1 [M+H.sup.+].
Preparative Example 7: Preparation of
2-methoxy-5-(2-(piperidine-1-yl)ethyl)aniline
##STR00015##
[0257] Step 1: Preparation of
1-(4-methoxy-3-nitrophenethyl)piperidine
[0258] (4-methoxy-3-nitrophenyl)methaneamine (0.10 g, 0.51 mmol)
was dissolved in acetonitrile (2 mL), to which 1,5-dibromopentane
(140 mg, 0.61 mmol) and potassium carbonate (276 g, 2.00 mmol) were
added. The reaction mixture was stirred at 100.degree. C. for 15
hours. The reaction mixture was cooled to room temperature and
water was added to terminate the reaction, followed by extraction
twice with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
1-(4-methoxy-3-nitrophenethyl)piperidine as a colorless solution
(0.098 g, 0.371 mmol, yield: 73%).
[0259] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.70 (d, J=2.1 Hz,
1H), 7.38 (dd, J=2.1, 8.4 Hz, 1H), 6.99 (d, J=8.4 Hz, 1H), 3.94 (s,
3H), 2.77-2.82 (m, 2H), 2.50-2.56 (m, 2H), 2.45 (br, 4H), 1.58-1.63
(m, 4H), 1.45-1.47 (m, 2H); LC/MS 265.1 [M+H.sup.+].
Step 2: Preparation of
2-methoxy-5-(2-(piperidine-1-yl)ethyl)aniline
[0260] 1-(4-methoxy-3-nitrophenethyl)piperidine (60 mg, 0.25 mmol)
prepared in step 1 was dissolved in ethylacetate (2 mL), to which
10 weight % Pd/C (7 mg) was added. The mixture was stirred for 15
hours under a hydrogen gas balloon. The solid generated in the
reaction mixture was filtered with celite, which was washed with
ethylacetate. The solvent was eliminated by distillation under
reduced pressure. Then, purification was performed by silica gel
column chromatography (eluent: ethylacetate/hexane, 2/1) to give
the target compound 2-methoxy-5-(2-(piperidine-1-yl)ethyl)aniline
as a yellow solid (0.043 g, 0.183 mmol, yield: 75%).
[0261] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.69 (d, J=8.1 Hz,
1H), 6.53-6.57 (m, 2H), 3.82 (br, 2H), 3.81 (s, 3H), 2.67-2.72 (m,
2H), 2.48-2.56 (m, 6H), 1.59-1.67 (m, 4H), 1.45-1.47 (m, 2H); LC/MS
235.1 [M+H.sup.+].
Preparative Example 8: Preparation of
2-methoxy-5-(2-morpholinoethyl)aniline
##STR00016##
[0262] Step 1: Preparation of
2-(4-methoxy-3-nitrophenyl)ethane-1-amine
[0263] 2,2,2-trifluoro-N-(4-methoxy-3-nitrophenyl)ethane-1-amine
(3.0 g, 10.3 mmol) was dissolved in ethanol (15 mL), to which
potassium carbonate (5.7 g, 41.1 mmol) aqueous solution (15 mL) was
added. The reaction mixture was stirred at 90 for 5 hours. The
reaction mixture was distillated under reduced pressure, followed
by extraction twice with ethylacetate. The extracted organic layer
was dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/10) to give the target
compound 2-(4-methoxy-3-nitrophenyl)ethane-1-amine as a yellow
solid (1.2 g, 6.12 mmol, yield: 60%).
[0264] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.70 (d, J=2.1 Hz,
1H), 7.39 (dd, J=2.4, 8.7 Hz, 1H), 7.00 (d, J=8.7 Hz, 1H), 3.95 (s,
3H), 2.97 (t, J=6.9 Hz, 2H), 2.75 (t, J=6.9 Hz, 2H), 1.48 (br, 2H);
LC/MS 197.2 [M+H.sup.+].
Step 2: Preparation of 4-(4-methoxy-3-nitrophenethyl)morpholine
[0265] 2-(4-methoxy-3-nitrophenyl)ethane-1-amine (0.10 g, 0.51
mmol) prepared in step 1 was dissolved in acetonitrile (2 mL), to
which 2-(2-chloroethoxy)ethyl 4-methylbenzenesulfonate (0.17 g,
0.61 mmol) and potassium carbonate (276 g, 2.00 mmol) were added.
The reaction mixture was stirred at 100.degree. C. for 15 hours.
The reaction mixture was cooled to room temperature and water was
added to terminate the reaction, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
4-(4-methoxy-3-nitrophenethyl)morpholine as a yellow solution (0.92
g, 0.345 mmol, yield: 68%).
[0266] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.71 (d, J=2.1 Hz,
1H), 7.39 (dd, J=2.4, 8.7 Hz, 1H), 7.00 (d, J=8.4 Hz, 1H), 3.94 (s,
3H), 3.73 (t, J=4.8 Hz, 4H), 2.76-2.82 (m, 2H), 2.49-2.61 (m, 6H);
LC/MS 266.8 [M+H.sup.+].
Step 3: Preparation of 2-methoxy-5-(2-morpholinoethyl)aniline
[0267] 4-(4-methoxy-3-nitrophenethyl)morpholine (0.065 g, 0.244
mmol) was dissolved in ethylacetate (2 mL), to which 10 weight %
Pd/C (7 mg) was added. The mixture was stirred for 15 hours under a
hydrogen gas balloon. The solid generated in the reaction mixture
was filtered with celite, which was washed with ethylacetate. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/1) to give the
target compound 2-methoxy-5-(2-morpholinoethyl)aniline as a yellow
solid (0.042 g, 0.178 mmol, yield: 73%).
[0268] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.70 (d, J=7.8 Hz,
1H), 6.53-6.57 (m, 2H), 3.82 (s, 3H), 3.78 (br, 2H), 3.75 (t, 4H),
2.64-2.71 (m, 2H), 2.53-2.59 (m, 6H); LC/MS 237.1 [M+H.sup.+].
Preparative Example 9: Preparation of
N-(3-amino-4-methoxybenzyl)-2,2,2-trifluoroacetamide
##STR00017##
[0269] Step 1: Preparation of
2,2,2-trifluoro-N-(4-methoxybenzyl)acetamide
[0270] 4-methoxybenzylamine (2.0 g, 14.58 mmol) was dissolved in
dichloromethane (20 mL), to which anhydrous trifluoroacetic acid
(3.7 g, 17.49 mmol) and triethylamine (7.1 mL, 51.29 mmol) were
added at 0.degree. C. The reaction mixture was stirred at room
temperature for 2 hours. Water was added thereto to terminate the
reaction, followed by extraction twice with dichloromethane. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 1/1) to give the
target compound 2,2,2-trifluoro-N-(4-methoxybenzyl)acetamide as a
white solid (3.0 g, 12.87 mmol, yield: 88%).
[0271] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.22 (d, J=8.4 Hz,
2H), 6.90 (d, J=8.4 Hz, 2H), 6.53 (br, 1H), 4.46 (d, J=5.7 Hz, 2H),
3.81 (s, 3H)
Step 2: Preparation of
2,2,2-trifluoro-N-(4-methoxy-3-nitrobenzyl)acetamide
[0272] 2,2,2-trifluoro-N-(4-methoxybenzyl)acetamide (2.5 g, 10.72
mmol) prepared in step 1 was dissolved in trifluoroacetic acid (20
mL), to which trifluoroacetic acid (5 mL) solution containing
concentrated nitric acid (1.23 g, 11.79 mmol) dissolved therein was
added at 0.degree. C. The reaction mixture was stirred at room
temperature for 2 hours. The reaction mixture was distillated under
reduced pressure, followed by extraction twice with ethylacetate.
The extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 1/1) to give the
target compound
2,2,2-trifluoro-N-(4-methoxy-3-nitrobenzyl)acetamide as a yellow
solid (1.8 g, 6.47 mmol, yield: 60%).
[0273] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.79 (d, J=2.1 Hz,
1H), 7.53 (dd, J=8.7, 2.1 Hz, 1H), 7.09 (d, J=8.1 Hz, 1H), 6.76
(br, 1H), 4.52 (d, J=6.0 Hz, 2H), 3.97 (s, 3H); LC/MS 279.1
[M+H.sup.+].
Step 3: Preparation of
N-(3-amino-4-methoxybenzyl)-2,2,2-trifluoroacetamide
[0274] 2,2,2-trifluoro-N-(4-methoxy-3-nitrobenzyl)acetamide (1.0 g,
3.59 mmol) prepared in step 2 was dissolved in ethylacetate (10
mL), to which 10 weight % Pd/C (0.1 g) was added. The mixture was
stirred for 2 hours under a hydrogen gas balloon. The solid
generated in the reaction mixture was filtered with celite, which
was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
N-(3-amino-4-methoxybenzyl)-2,2,2-trifluoroacetamide as a white
solid (0.81 g, 3.26 mmol, yield: 89%).
[0275] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.74 (d, J=8.71
Hz, 1H), 6.63-6.65 (m, 2H), 4.39 (d, J=5.4 Hz, 2H), 3.86 (s, 3H)
3.26 (br, 2H); LC/MS 249.1 [M+H.sup.+]. Preparative Example 10:
Preparation of
2,5-dichloro-N-(4-fluoro-2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
##STR00018##
Step 1: Preparation of
(5-fluoro-2-nitrophenyl)(isopropyl)sulfane
[0276] 2,4-difluoronitrobenzene (2.00 g, 12.57 mmol) was dissolved
in dimethylformamide (150 mL), to which 2-propanethiol (0.86 g,
11.31 mmol) and potassium carbonate (4.34 g, 31.43 mmol) were
added. The reaction mixture was stirred at room temperature for
hours. Sodium hydroxide was added thereto to terminate the
reaction, followed by extraction twice with ethylacetate/hexane
(1/4). The extracted organic layer was washed with water and brine,
dried over sodium sulfate, filtered, and concentrated under reduced
pressure. Then, purification was performed by MPLC (medium pressure
liquid chromatography) to give the target compound
(5-fluoro-2-nitrophenyl)(isopropyl)sulfane (1.70 g, 7.90 mmol,
yield: 63%, about 10% of minor included).
[0277] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.27-8.22 (m, 1H),
7.15-7.08 (m, 1H), 6.95-6.89 (m, 1H), 3.57-3.46 (m, 1H), 1.44 (d,
J=6.0 Hz, 6H); EI/Ms 215 [H.sup.+].
Step 2: Preparation of
4-fluoro-2-(isopropylsulfonyl)-1-nitrobenzene
[0278] (5-fluoro-2-nitrophenyl)(isopropyl)sulfane (1.70 g, 6.16
mmol) prepared in step 1 was dissolved in dichloromethane (60 mL),
to which m-CPBA (m-chloroperoxybenzoic acid, 70%) (3.49 g, 14.16
mmol) was added at 0.degree. C. The reaction mixture was stirred at
room temperature for 16 hours. Upon completion of the reaction, a
new spot was formed under (5-fluoro-2-nitrophenyl)
(isopropyl)sulfane, which was confirmed by TLC. The resulting solid
was filtered and washed three times with sodium bicarbonate (aq.).
The solid was washed with water and brine. The organic layer was
dried over sodium sulfate and concentrated under reduced pressure.
Then, purification was performed by MPLC to give the target
compound 4-fluoro-2-(isopropylsulfonyl)-1-nitrobenzene (1.20 g,
4.85 mmol, yield: 90%).
[0279] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.26-8.21 (m, 1H),
7.88-7.83 (m, 2H), 3.32-3.23 (m, 1H), 1.36 (d, J=6.0 Hz, 6H); EI/Ms
247 [H.sup.+].
Step 3: Preparation of 4-fluoro-2-(isopropylsulfonyl) aniline
[0280] 4-fluoro-2-(isopropylsulfonyl)-1-nitrobenzene (3.00 g, 12.13
mmol) prepared in step 2 was dissolved in ethanol, to which 10
weight % Pd/C (0.30 g) was added. The mixture was stirred at room
temperature for 15 hours while purging hydrogen gas. Pd/C was
filtered and concentrated under reduced pressure. Then,
purification was performed by MPLC to give the target compound
4-fluoro-2-(isopropylsulfonyl) aniline (1.00 g, 4.60 mmol, yield:
57%).
[0281] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.83 (br, s, 1H),
8.62-8.57 (m, 1H), 7.66-7.63 (m, 1H), 7.48 (m, 1H), 3.28-3.18 (m,
1H), 1.34 (d, J=6.9 Hz, 6H); EI/Ms 217[H.sup.+].
Step 4: Preparation of
2,5-dichloro-N-(4-fluoro-2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
[0282] 2,4,5-trichloropyrimidine (1.21 g, 6.58 mmol) was dissolved
in DMSO (dimethylformamide, 80 mL), to which sodium hydride (0.29
g, 7.23 mmol) was added at 0.degree. C. And
4-fluoro-2-(isopropylsulfonyl) aniline (1.00 g, 4.60 mmol) prepared
in step 3 was added thereto, which was stirred at room temperature
for 15 hours. Water was added thereto to terminate the reaction,
followed by neutralization with 1 N HCl. Upon completion of the
reaction, a new spot was formed under 2,4,5-trichloropyrimidine,
which was confirmed by TLC. The reactant was extracted with
ethylacetate. The ethylacetate layer was washed with water and
brine, dried over sodium sulfate, and concentrated under reduced
pressure. Then, purification was performed by MPLC to give the
target compound
2,5-dichloro-N-(4-fluoro-2-(isopropylsulfonyl)phenyl)pyrimidine--
4-amine (0.40 g, 1.10 mmol, yield: 17%).
[0283] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.83 (br, s, 1H),
8.62-8.57 (m, 1H), 7.66-7.63 (m, 1H), 7.48 (m, 1H), 3.28-3.18 (m,
1H), 1.34 (d, J=6.9 Hz, 6H); EI/MS 363 [H.sup.+].
Preparative Example 11: Preparation of
2,5-dichloro-N-(5-fluoro-2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
##STR00019##
[0284] Step 1: Preparation of
(4-fluoro-2-nitrophenyl)(isopropyl)sulfane
[0285] 2,5-difluoronitrobenzene (5.00 g, 31.43 mmol) was dissolved
in dimethylformamide, to which potassium carbonate (8.69 g, 62.86
mmol) and 2-propanethiol (0.30 mL, 5.66 mmol) were added, followed
by reaction at room temperature for 15 hours. Sodium hydroxide was
added thereto to terminate the reaction, followed by extraction
twice with ethylacetate/hexane (1/4). The extracted organic layer
was washed with water and brine, dried over sodium sulfate,
filtered, and concentrated under reduced pressure to give the
target compound (4-fluoro-2-nitrophenyl) (isopropyl)sulfane (6.00
g, 27.88 mmol, yield: 89%).
[0286] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.83-7.79 (m, 1H),
7.51-7.46 (m, 1H), 7.39-7.27 (m, 1H), 3.57-3.48 (m, 1H) 1.38 (d,
J=6.9 Hz, 6H); EI/Ms 215 [H.sup.+].
Step 2: Preparation of
4-fluoro-2-(isopropylsulfonyl)-1-nitrobenzene
[0287] (4-fluoro-2-nitrophenyl) (isopropyl)sulfane (6.00 g, 27.88
mmol) prepared in step 1 was dissolved in dichloromethane (100 mL),
to which m-CPBA (70%) (10.58 g, 61.32 mmol) was added at 0.degree.
C. The reaction mixture was stirred at room temperature overnight.
Upon completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. The resulting solid
was filtered and washed with sodium bicarbonate (aq.). The solid
was washed with water and brine. The organic layer was dried over
magnesium sulfate and concentrated under reduced pressure. Then,
purification was performed by MPLC to give the target compound
4-fluoro-2-(isopropylsulfonyl)-1-nitrobenzene (3.40 g, 13.75 mmol,
yield: 49%).
[0288] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.16-8.12 (m, 1H),
7.56-7.53 (m, 1H), 7.49-7.43 (m, 1H), 4.00-3.91 (m, 1H), 1.42 (d,
J=6.9 Hz, 6H); EI/Ms 248 [H.sup.+].
Step 3: Preparation of 2-fluoro-6-(isopropylsulfonyl)aniline
[0289] 4-fluoro-2-(isopropylsulfonyl)-1-nitrobenzene (3.40 g, 13.75
mmol) prepared in step 2 was dissolved in methanol (100 ml), to
which zinc (4.50 g, 68.76 mmol), ammonium formate (4.15 g, 68.76
mmol), and 10 weight % Pd/C (0.30 g) were added. The mixture was
stirred at room temperature for 2 hours. Upon completion of the
reaction, a new spot was formed under the starting material, which
was confirmed by TLC. Pd/C was filtered and the reaction mixture
was concentrated under reduced pressure. Then, purification was
performed by MPLC to give the target compound
2-fluoro-6-(isopropylsulfonyl)aniline (2.10 g, 9.67 mmol, yield:
76%).
[0290] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.46-7.43 (m, 1H),
7.23-7.17 (m, 1H), 6.77-6.70 (m, 1H), 5.17 (br, s, 2H), 3.37-3.28
(m, 1H), 1.33 (d, J=6.9 Hz, 6H); EI/MS 217 [H.sup.+].
Step 4: Preparation of
2,5-dichloro-N-(5-fluoro-2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
[0291] 2,4,5-trichloropyrimidine (2.05 g, 11.18 mmol) was dissolved
in dimethylformamide (100 mL), to which sodium hydride (60%, 0.54
g, 7.82 mmol) was added at 0.degree. C.
2-fluoro-6-(isopropylsulfonyl)aniline (1.70 g, 22.36 mmol) prepared
in step 3 was added thereto, which was stirred at room temperature
for 14 hours. Water was added thereto to terminate the reaction,
followed by neutralization with 1 N HCl. Upon completion of the
reaction, a new spot was formed under the starting material, which
was confirmed by TLC. The reaction mixture was extracted with
ethylacetate. The ethylacetate layer was washed with water and
brine, dried over sodium sulfate, and concentrated under reduced
pressure. Then, purification was performed by MPLC to give the
target compound
2,5-dichloro-N-(5-fluoro-2-(isopropylsulfonyl)phenyl)pyrimidine--
4-amine (1.10 g, 3.02 mmol, yield: 27%).
[0292] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.56 (s, 1H), 8.29
(s, 1H), 7.80-7.78 (m, 1H), 7.55-7.47 (m, 2H), 3.11-3.01 (m, 1H),
1.27 (d, J=6.9 Hz, 6H); LC/MS 365 [M+H.sup.+].
Preparative Example 12: Preparation of
2,5-dichloro-N-(2-fluoro-6-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
##STR00020##
[0293] Step 1: Preparation of
(5-fluoro-2-nitrophenyl)(isopropyl)sulfane
[0294] 2,6-difluoronitrobenzene (5.00 g, 31.43 mmol) was dissolved
in dimethylformamide, to which potassium carbonate (8.69 g, 62.86
mmol) and 2-propanethiol (0.30 mL, 5.66 mmol) were added, followed
by reaction at 50.degree. C. for 15 hours. Upon completion of the
reaction, the reaction mixture was cooled to room temperature.
Sodium hydroxide (aq.) was added thereto to terminate the reaction,
followed by extraction twice with ethylacetate/hexane (1:4). The
extracted organic layer was washed 3 times with water and brine,
dried over sodium sulfate, and concentrated under reduced pressure
to give the target compound (5-fluoro-2-nitrophenyl)
(isopropyl)sulfane (5.20 g, 27.41 mmol, yield: 77%). Without any
additional purification process, the reaction of step 2 was carried
out.
[0295] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.46-7.39 (m, 1H),
7.34-7.31 (m, 1H), 7.15-7.08 (m, 1H), 3.52-3.43 (m, 1H), 1.32 (d,
J=6.6 Hz, 6H); EI/MS 215 [H.sup.+].
Step 2: Preparation of
1-fluoro-3-(isopropylsulfonyl)-2-nitrobenzene
[0296] (5-fluoro-2-nitrophenyl)(isopropyl)sulfane (5.20 g, 24.15
mmol) prepared in step 1 was dissolved in dichloromethane (100 mL),
to which m-CPBA (70%) (12.51 g, 50.73 mmol) was added at 0.degree.
C. The reaction mixture was stirred at room temperature overnight.
Upon completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. The resulting solid
was filtered and washed twice with sodium bicarbonate (aq.). The
solid was washed with water and brine. The organic layer was dried
over sodium sulfate and concentrated under reduced pressure. Then,
purification was performed by MPLC to give the target compound
1-fluoro-3-(isopropylsulfonyl)-2-nitrobenzene (3.20 g, 12.94 mmol,
yield: 54%).
[0297] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.16-8.12 (m, 1H),
7.56-7.53 (m, 1H), 7.49-7.43 (m, 1H), 4.00-3.91 (m, 1H), 1.42 (d,
J=6.9 Hz, 6H); EI/Ms 248 [H.sup.+].
Step 3: Preparation of 2-fluoro-6-(isopropylsulfonyl)aniline
[0298] 1-fluoro-3-(isopropylsulfonyl)-2-nitrobenzene (3.00 g, 12.13
mmol) prepared in step 2 was dissolved in ethylacetate (50 mL), to
which 10 weight % Pd/C (0.30 g) was added. The mixture was stirred
at room temperature for 16 hours while purging hydrogen gas. Pd/C
was filtered and the reaction mixture was concentrated under
reduced pressure. Then, purification was performed by MPLC to give
the target compound 2-fluoro-6-(isopropylsulfonyl)aniline (2.50 g,
11.97 mmol, yield: 95%).
[0299] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.43-7.41 (m, 1H),
7.21-7.15 (m, 1H), 6.72-6.71 (m, 1H), 5.17 (br, s, 2H), 3.33-3.29
(m, 1H), 1.31 (d, J=6.6 Hz, 6H); EI/Ms 217 [H.sup.+].
Step 4: Preparation of
2,5-dichloro-N-(2-fluoro-6-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
[0300] 2,4,5-trichloropyrimidine (0.30 g, 1.64 mmol) was dissolved
in dimethylformamide (40 mL), to which sodium hydride (60%, 0.13 g,
3.29 mmol) was added at 0.degree. C.
2-fluoro-6-(isopropylsulfonyl)aniline (0.25 g, 1.15 mmol) prepared
in step 3 was added thereto, followed by stirring at room
temperature for 14 hours. Upon completion of the reaction, a new
spot was formed under 2,4,5-trichloropyrimidine, which was
confirmed by TLC. Water was added thereto to terminate the
reaction, followed by neutralization with 1 N HCl. The reaction
mixture was extracted with ethylacetate. The ethylacetate layer was
washed with water and brine, dried over sodium sulfate, and
concentrated under reduced pressure. Then, purification was
performed by MPLC to give the target compound
2,5-dichloro-N-(2-fluoro-6-(isopropylsulfonyl)phenyl)pyrimidine--
4-amine (0.20 g, 0.55 mmol, yield: 33%).
[0301] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.55 (s, 1H), 8.29
(s, 1H), 7.80-7.78 (m, 1H), 7.52-7.47 (m, 2H), 3.08-3.03 (m, 1H),
1.27 (d, J=6.9 Hz, 6H); EI/MS 217 [H.sup.+].
Preparative Example 13: Preparation of
N-(2-(3-amino-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
##STR00021##
[0302] Step 1: Preparation of
2-(4-methoxyphenyl)-2-methylpropanenitrile
[0303] Sodium-tert-butoxide (13.06 g, 135.89 mmol) was added to
dimethylformamide (30 mL) and tetrahydrofuran (30 mL), to which
2-(4-methoxyphenyl)acetonitrile (5.00 g, 33.97 mmol) was added at
5.degree. C. Methyliodide (8.44 mL, 135.89 mmol) was added thereto
at 5.degree. C., followed by stirring at 10.degree. C. for 4 hours.
The reaction mixture was cooled in an ice bath and added with 2 N
HCl. Upon completion of the reaction, a new spot was formed under
the starting material, which was confirmed by TLC. The reaction
mixture was extracted with ethylacetate. The ethylacetate layer was
washed with water and brine, dried over sodium sulfate, and
concentrated under reduced pressure. Then, purification was
performed by MPLC to give the target compound
2-(4-methoxyphenyl)-2-methylpropanenitrile (4.00 g, 22.83 mmol,
yield: 67%).
[0304] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.40 (d, J=6.0 Hz,
2H), 6.92 (d, J=6.0 Hz, 2H), 3.82 (s, 3H), 1.70 (s, 6H); EI/MS 161
[M+].
[0305] In step 1, 2-(4-methoxyphenyl)propanenitrile was obtained in
addition to the compound
2-(4-methoxyphenyl)-2-methylpropanenitrile.
[0306] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.96-7.93 (m, 1H),
7.40-7.37 (m, 1H), 6.92-6.88 (m, 2H), 3.85-3.82 (m, 3H), 1.71 (s,
3H); EI/MS 175 [M.sup.+].
Step 2: Preparation of
2-(4-methoxyphenyl)-2-methylpropane-1-amine
[0307] 2-(4-methoxyphenyl)-2-methylpropanenitrile (2.00 g, 11.41
mmol) prepared in step 1 was dissolved in diethylether (100 mL),
and the temperature was lowered to 0.degree. C. Lithium aluminum
hydride (0.52 g, 13.70 mmol) was added thereto, followed by
stirring at room temperature for 4 hours. Upon completion of the
reaction, a new spot was formed under the starting material, which
was confirmed by TLC. The reaction mixture was cooled in an ice
bath. 2 N sodium hydroxide was added to terminate the reaction,
followed by separating the diethylether layer. The water layer was
extracted twice with ethylacetate, followed by washing with water
and brine. The organic layer was dried over sodium sulfate and
concentrated under reduced pressure. Then, purification was
performed by MPLC to give the target compound
2-(4-methoxyphenyl)-2-methylpropane-1-amine (1.75 g, 9.76 mmol,
yield: 86%).
[0308] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.27 (d, J=6.0 Hz,
2H), 6.89 (d, J=6.0 Hz, 2H), 3.80 (s, 3H), 2.76 (s, 2H), 1.28 (s,
6H); EI/MS 179 [M.sup.+].
Step 3: Preparation of
2-(4-methoxyphenyl)-2-methylpropane-1-amine
[0309] 2-(4-methoxyphenyl)-2-methylpropane-1-amine (1.70 g, 9.48
mmol) prepared in step 2 was dissolved in dichloromethane (100 mL),
to which triethanolamine (3.96 mL, 28.44 mmol) was added at
0.degree. C. Lithium aluminum hydride (0.52 g, 13.70 mmol) was
added thereto, followed by stirring at room temperature for 4
hours. Upon completion of the reaction, a new spot was formed under
the starting material, which was confirmed by TLC. The reaction
mixture was cooled in an ice bath. 2 N sodium hydroxide was added
to terminate the reaction, followed by separating the diethylether
layer. The water layer was extracted twice with ethylacetate,
followed by washing with water and brine. The organic layer was
dried over sodium sulfate and concentrated under reduced pressure.
Then, purification was performed by MPLC to give the target
compound 2-(4-methoxyphenyl)-2-methylpropane-1-amine (1.90 g, 6.90
mmol, yield: 73%).
[0310] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.28 (d, J=8.4 Hz,
2H), 6.92 (d, J=8.7 Hz, 2H), 5.86 (br, s, 1H), 3.82 (s, 3H), 3.51
(d, J=6.0 Hz, 2H), 1.35 (s, 6H); EI/MS 275 [M.sup.+].
Step 4: Preparation of
2,2,2-trifluoro-N-(2-(4-methoxy-3-nitrophenyl)-2-methylpropyl)acetamide
[0311] 2-(4-methoxyphenyl)-2-methylpropane-1-amine (1.90 g, 6.90
mmol) prepared in step 3 was dissolved in acetonitrile (50 mL), to
which trifluoroacetic acid (3.84 mL, 27.61 mmol) was added. The
temperature was lowered to -10.degree. C. Potassium nitrate (0.59
g, 6.90 mmol) was slowly added thereto, followed by stirring.
[0312] Upon completion of the reaction, a new spot was formed under
the starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
potassium carbonate. The water layer was extracted twice with
ethylacetate. The ethylacetate layer was washed with water and
brine, dried over sodium sulfate, and concentrated under reduced
pressure. Then, purification was performed by MPLC to give the
target compound
2,2,2-trifluoro-N-(2-(4-methoxy-3-nitrophenyl)-2-methylpropyl)acetamide
(2.00 g, 6.24 mmol, yield: 91%).
[0313] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.84 (d, J=2.4 Hz,
1H), 7.56 (dd, J=6.0, 2.4 Hz, 1H), 7.11 (d, J=6.0 Hz, 1H), 6.03
(br, s, 1H), 3.97 (s, 3H), 3.55-3.53 (m, 2H), 1.39 (s, 6H); LC/MS
321 [M+H.sup.+].
Step 5: Preparation of
N-(2-(3-amino-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
[0314]
N-(2-(3-amino-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroaceta-
mide (2.00 g, 6.24 mmol) was dissolved in ethanol (100 mL), to
which 10 weight % Pd/C (0.20 g) was added. The mixture was stirred
at room temperature overnight while purging hydrogen gas. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. 10 weight was
filtered and the reaction mixture was concentrated under reduced
pressure and dried to give the target compound
N-(2-(3-amino-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
(1.25 g, 4.31 mmol, yield: 69%).
[0315] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.77-6.75 (m, 1H),
6.70-6.64 (m, 2H), 5.91 (br, s, 1H), 3.86-3.84 (m, 5H), 3.48-3.46
(m, 2H), 1.26 (s, 6H); LC/MS 290 [M+H.sup.+].
Preparative Example 13: Preparation of
N-(3-(3-amino-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide
trifluoroethanone
##STR00022##
[0316] Step 1: Preparation of
2,2,2-trifluoro-N-(3-(4-methoxyphenyl)propyl)acetamide
[0317] 3-(4-methoxyphenyl)propane-1-amine hydrochloride (2.0 g, 9.9
mmol) was dissolved in dichloromethane (20 mL), to which anhydrous
trifluoroacetic acid (2.0 g, 11.96 mmol) and triethylamine (4.13
ml, 29.8 mmol) were added at 0.degree. C. The reaction mixture was
stirred at room temperature for 2 hours. Water was added thereto to
terminate the reaction, followed by extraction twice with
dichloromethane. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-(3-(4-methoxyphenyl)propyl)acetamide as a white
solid (2.3 g, 8.80 mmol, yield: 89%).
[0318] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.09 (d, J=8.1 Hz,
2H), 6.84 (d, J=8.4 Hz, 2H), 6.25 (br, 1H), 3.79 (s, 3H), 3.8 (q,
J=6.6 Hz, 2H), 2.63 (t, J=7.2 Hz, 2H), 1.89 (pent, J=7.2 Hz, 2H);
LC/MS 262.1 [M+H.sup.+].
Step 2: Preparation of
2,2,2-trifluoro-N-(3-(4-methoxy-3-nitrophenyl)propyl)acetamide
[0319] 2,2,2-trifluoro-N-(3-(4-methoxyphenyl)propyl)acetamide (2.0
g, 7.66 mmol) prepared in step 1 was dissolved in trifluoroacetic
acid (20 mL), to which trifluoroacetic acid (10 mL) solution
containing concentrated nitric acid (0.88 g, 8.42 mmol) dissolved
therein was added at 0.degree. C. The reaction mixture was stirred
at room temperature for 2 hours. The reaction mixture was
distillated under reduced pressure, followed by extraction twice
with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
2,2,2-trifluoro-N-(3-(4-methoxy-3-nitrophenyl)propyl)acetamide as a
yellow solid (2.02 g, 6.59 mmol, yield: 86%) .sup.1H-NMR (300 MHz,
CDCl.sub.3) .delta. 7.68 (d, J=2.1 Hz, 1H), 7.37 (dd, J=2.4, 8.7
Hz, 1H), 7.03 (d, J=8.7 Hz, 1H), 6.55 (br, 1H), 3.94 (s, 3H), 3.8
(q, J=6.9 Hz, 2H), 2.63 (t, J=7.5 Hz, 2H), 1.89 (pent, J=7.5 Hz,
2H); LC/MS 307.2 [M+H.sup.+].
Step 3: Preparation of
N-(3-(3-amino-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide
trifluoroethanone
[0320]
2,2,2-trifluoro-N-(3-(4-methoxy-3-nitrophenyl)propyl)acetamide (2.0
g, 6.53 mmol) prepared in step 2 was dissolved in methanol (20 mL),
to which 10 weight % Pd/C (0.20 g, 10%) was added.
[0321] The mixture was stirred at room temperature for 4 hours
under a hydrogen gas balloon. The solid generated in the reaction
mixture was filtered with celite, which was washed with methanol.
The solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/1) to give the
target compound
N-(3-(3-amino-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide
trifluoroethanone as a yellow solid (1.6 g, 5.79 mmol, yield:
89%).
[0322] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.70 (d, J=8.1 Hz,
1H), 6.50-6.53 (m, 2H), 6.34 (br, 1H), 3.82 (s, 3H), 3.78 (br, 2H),
3.35 (q, J=7.2 Hz, 2H), 1.86 (pent, J=6.9 Hz, 2H); LC/MS 277.1
[M+H.sup.+], 553.3 [2M+H.sup.+].
Preparative Example 15: Preparation of
2-(3-amino-4-methoxyphenyl)acetonitrile
##STR00023##
[0323] Step 1: Preparation of
2-(4-methoxy-3-nitrophenyl)acetonitrile
[0324] 2-(4-methoxyphenyl)acetonitrile (0.20 g, 1.36 mmol) was
dissolved in acetonitrile (10 mL), to which trifluoroacetic acid
(0.76 mL, 5.44 mmol) was added. The temperature thereof was lowered
to -10.degree. C. Potassium nitrate (0.12 g, 1.360.61 mmol) was
slowly added thereto, followed by stirring. Upon completion of the
reaction, a new spot was formed under the starting material, which
was confirmed by TLC. Water was added thereto to terminate the
reaction, followed by neutralization with potassium carbonate. The
water layer was extracted twice with ethylacetate. The ethylacetate
layer was washed with water and brine, dried over sodium sulfate,
and concentrated under reduced pressure. Then, purification was
performed by MPLC to give the target compound
2-(4-methoxy-3-nitrophenyl)acetonitrile (1.80 g, 9.37 mmol, yield:
69%).
[0325] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.83 (s, 1H), 7.57
(dd, J=8.7, 2.4 Hz, 1H), 7.15 (d, J=8.7 Hz, 1H), 3.99 (s, 3H), 3.77
(s, 2H); LC/MS 192 [M+H.sup.+].
Step 2: Preparation of 2-(3-amino-4-methoxyphenyl)acetonitrile
[0326] 2-(4-methoxy-3-nitrophenyl)acetonitrile (1.80 g, 9.37 mmol)
prepared in step 1 was dissolved in ethanol (10 mL), to which 10
weight % Pd/C (0.94 g, 0.94 mmol) was added. The mixture was
stirred while purging hydrogen gas. Upon completion of the
reaction, a new spot was formed under the starting material, which
was confirmed by TLC. Water was added thereto to terminate the
reaction, followed by neutralization with potassium carbonate. The
water layer was extracted twice with ethylacetate. The ethylacetate
layer was washed with water and brine, dried over sodium sulfate,
and concentrated under reduced pressure. Then, purification was
performed by MPLC to give the target compound
2-(3-amino-4-methoxyphenyl)acetonitrile (1.30 g, 8.32 mmol, yield:
89%)
[0327] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.75-6.73 (m, 1H),
6.65-6.62 (m, 2H), 3.84 (s, 3H), 3.61 (s, 2H); LC/MS 163
[M+H.sup.+]. Preparative Example 16: Preparation of
2-(3-amino-4-methoxyphenyl) acetic acid
##STR00024##
Step 1: Preparation of 2-(4-methoxy-3-nitrophenyl)acetic acid
[0328] 4-methoxyphenylacetic acid (5.00 g, 30.09 mmol) was
dissolved in acetonitrile (450 mL), to which trifluoroacetic acid
(16.73 mL, 120.36 mmol) was added. The temperature thereof was
lowered to -10.degree. C. Potassium nitrate (2.56 g, 30.09 mmol)
was slowly added thereto, followed by stirring. Upon completion of
the reaction, a new spot was formed under the starting material,
which was confirmed by TLC. Water was added thereto to terminate
the reaction, followed by neutralization with potassium carbonate.
The water layer was extracted twice with ethylacetate. The
ethylacetate layer was washed with water and brine, dried over
sodium sulfate, and concentrated under reduced pressure. Then,
recrystallization was performed by using MC/Hex
(methylchloride/hexane) to give the target compound
2-(4-methoxy-3-nitrophenyl)acetic acid (4.30 g, 20.36 mmol, yield:
68%).
[0329] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.81 (s, 1H),
7.50-7.47 (m, 1H), 7.08 (d, J=8.7 Hz, 1H), 3.96 (s, 3H), 3.67 (s,
2H); LC/MS 212 [M+H.sup.+].
Step 2: Preparation of 2-(3-amino-4-methoxyphenyl)acetic acid
[0330] 2-(4-methoxy-3-nitrophenyl)acetic acid (1.30 g, 6.16 mmol)
prepared in step 1 was dissolved in methanol (150 mL), to which 10
weight % Pd/C (0.62 g, 0.62 mmol) was added. The mixture was
stirred at room temperature for 15 hours while purging hydrogen
gas. Upon completion of the reaction, a new spot was formed under
the starting material, which was confirmed by TLC. 10 weight % Pd/C
was filtered and the reaction mixture was concentrated under
reduced pressure. Then, purification was performed by MPLC to give
the target compound 2-(3-amino-4-methoxyphenyl)acetic acid (1.00 g,
5.52 mmol, yield: 90%)
[0331] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.74-6.72 (m, 1H),
6.65-6.62 (m, 2H), 4.67 (br, s, 3H), 3.83 (s, 3H), 3.50 (s, 2H);
LC/MS 182 [M+H.sup.+]. Preparative Example 17: Preparation of
2,2,2-trifluoro-1-(piperazine-1-yl)ethane-1-one
##STR00025##
[0332] Piperazine (5.05 g, 58 mmol) was dissolved in
dichloromethane (50 mL), to which anhydrous trifluoroacetic acid
(1.2 g, 5.8 mmol) was added at 0.degree. C. The reaction mixture
was stirred at room temperature for 4 hours. Water was added
thereto to terminate the reaction, followed by extraction twice
with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
2,2,2-trifluoro-1-(piperazine-1-yl)ethane-1-one as a white solid
(200 mg, 1.10 mmol, yield: 2%).
[0333] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 3.64-3.68 (m, 1H),
3.59 (br, 2H), 2.91-2.94 (m, 4H), 1.91 (br, 1H)
Preparative Example 18: Preparation of
N-(5-amino-2-bromo-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
##STR00026##
[0335] N-(3-amino-4-methoxyphenethyl)-2,2,2-trifluoroacetamide (5.0
g, 19 mmol) was dissolved in methanol (25 mL), followed by
stirring. N-bromosuccinimide (3.7 g, 21 mmol) was dissolved in 4 mL
of dimethylformamide, which was added to the solution prepared
above at 0.degree. C. The reaction mixture was stirred at room
temperature for 2 hours. Thiosodium sulfate (aq.) was added thereto
to terminate the reaction, followed by extraction with
ethylacetate. The organic layer was washed with brine, dried over
magnesium sulfate, and concentrated under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 1/2) to give the target compound
N-(5-amino-2-bromo-4-methoxyphenethyl)-2,2,2-trifluoroacetamide as
a white solid (4.7 g, 14 mmol, yield: 72%).
[0336] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.94 (s, 1H), 6.57
(s, 1H), 6.37 (s, br, 1H), 3.86 (s, 3H), 3.59 (q, J=6.9 Hz, 2H),
2.89 (t, J=6.3 Hz, 1H); LC/MS 341.00 [M+H.sup.+].
Preparative Example 19: Preparation of
N-(5-amino-4-methoxy-2-(1-methyl-1H-pyrazole-4-yl)phenethyl)-2,2,2-triflu-
oroacetamide
##STR00027##
[0338]
N-(5-amino-2-bromo-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
(100 mg, 0.30 mmol) was dissolved in n-butanol (3 mL), to which
1-methylpyrazoleboronicacidpinacolester (61 mg, 0.3 mmol), SPhos
(16.0 mg, 0.04 mmol), sodium carbonate (155 mg, 1.47 mmol), and
Pd.sub.2(dba).sub.3 (tris(dibenzylideneacetone)dipalladium(0), 16.0
mg, 0.02 mmol) were added while stirring. Gas was eliminated from
the reaction mixture, followed by heating at 115.degree. C.
overnight. The reaction mixture was filtered with celite, washed
with dichloromethane, concentrated under reduced pressure, and
extracted with ethylacetate. The organic layer was washed with
brine, dried over magnesium sulfate, filtered, and concentrated
under reduced pressure. Then, purification was performed by silica
gel column chromatography (eluent: ethylacetate/hexane, 1/1) to
give the target compound
(5-amino-4-methoxy-2-(1-methyl-1H-pyrazole-4-yl)phenethyl)-2,2,2-trifluor-
oacetamide as a brown oil (30.0 mg, 0.09 mmol, yield: 15%).
[0339] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.48 (s, 1H), 7.41
(s, 1H), 6.68 (s, 1H), 6.58 (s, 1H), 6.23 (s, br, 1H), 3.96 (s,
3H), 3.84 (s, 1H), 3.44 (q, J=7.2 Hz, 2H), 2.84 (t, J=7.2 Hz
2H)
Preparative Example 20: Preparation of
2-(4-amino-5-methoxy-2-methylphenyl) acetonitrile
##STR00028##
[0340] Step 1: Preparation of 2-(4-nitro-5-methoxy-2-methylphenyl)
acetonitrile
[0341] Sodium hydroxide (5.74 g, 144 mmol) was dissolved in
anhydrous dimethylsulfoxide (15.0 mL), to which anhydrous
dimethylsulfoxide (15.0 mL) solution containing
4-methyl-2-nitroanisole (2.40 g, 14.4 mmol) and
phenylthioacetonitrile (2.14 g, 14.4 mmol) dissolved therein was
added at 30.degree. C., followed by stirring at room temperature
for one hour. Ice and 6 N HCl aqueous solution were added thereto
to terminate the reaction, followed by extraction twice with
dichloromethane. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/3) to give the target compound
2-(4-nitro-5-methoxy-2-methylphenyl) acetonitrile as a yellow solid
(2.31 g, 11.2 mmol, yield; 78%).
[0342] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.75 (s, 1H), 7.16
(s, 1H), 4.00 (s, 3H), 3.75 (s, 2H), 2.33 (s, 3H); LC/MS 207.1
[M+H.sup.+].
Step 2: Preparation of 2-(4-amino-5-methoxy-2-methylphenyl)
acetonitrile
[0343] 2-(4-nitro-5-methoxy-2-methylphenyl) acetonitrile (450 mg,
2.18 mmol) prepared in step 1 was dissolved in methanol (25 mL), to
which 10 weight % Pd/C (45.0 mg, 0.422 mmol) was added. The mixture
was stirred for 2 hours under a hydrogen gas balloon. The solid
generated in the reaction mixture was filtered with celite, which
was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/3) to give the target compound
2-(4-amino-5-methoxy-2-methylphenyl) acetonitrile as a white solid
(350 mg, 1.98 mmol, yield: 91%).
[0344] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.76 (s, 1H), 6.57
(s, 1H), 3.87 (s, 3H), 3.79 (s, br, 2H), 3.59 (s, 2H), 2.21 (s,
3H); LC/MS 177.1 [M+H.sup.+].
Preparative Example 21: Preparation of
2-(4-amino-5-methoxy-2-methylphenyl)-2-methylpropanenitrile
##STR00029##
[0345] Step 1: Preparation of
2-(5-methoxy-2-methyl-4-nitrophenyl)-2-methylpropanenitrile
[0346] Sodium hydride (0.804 g, 20.2 mmol) was dissolved in
dimethylformamide (15 mL), to which dimethylformamide (10 mL)
solution containing 2-(4-nitro-5-methoxy-2-methylphenyl)
acetonitrile (1.66 g, 8.05 mmol) dissolved therein was added at
0.degree. C., followed by stirring for 20 minutes. Methyliodide
(1.10 mL, 17.7 mmol) was added thereto, followed by stirring at
room temperature for 8 hours. Ice was added thereto to terminate
the reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. The generated solid was recrystallized by using water to
give the target compound
2-(5-methoxy-2-methyl-4-nitrophenyl)-2-methylpropanenitrile as a
white solid (1.77 g, 7.57 mmol yield: 94%).
[0347] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.74 (s, 1H), 7.06
(s, 1H), 3.96 (s, 3H), 2.62 (s, 3H), 1.83 (s, 6H); LC/MS 235.10
[M+H.sup.+].
Step 2: Preparation of
2-(4-amino-5-methoxy-2-methylphenyl)-2-methylpropanenitrile
[0348] 2-(5-methoxy-2-methyl-4-nitrophenyl)-2-methylpropanenitrile
(450 mg, 1.92 mmol) prepared in step 1 was dissolved in methanol
(25 mL), to which 10 weight % Pd/C (45.0 mg, 0.422 mmol) was added.
The mixture was stirred for 12 hours under a hydrogen gas balloon.
The solid generated in the reaction mixture was filtered with
celite, which was washed with methanol. The solvent was eliminated
by distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/3) to give the target compound
2-(4-amino-5-methoxy-2-methylphenyl)-2-methylpropanenitrile as a
white solid (350 mg, 1.71 mmol, yield: 89%).
[0349] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.75 (s, 1H), 6.59
(s, 1H), 3.86 (s, 3H), 3.78 (s, br, 2H), 2.51 (s, 3H), 1.78 (s,
6H); LC/MS 205.10 [M+H.sup.+].
Preparative Example 22: Preparation of
N-(2-(4-amino-5-methoxy-2-methylphenyl)propane-2-yl)-2,2,2-trifluoroaceta-
mide
##STR00030##
[0350] Step 1: Preparation of
2-(5-methoxy-2-methyl-4-nitrophenyl)-2-methylpropaneamide
[0351] 2-(5-methoxy-2-methyl-4-nitrophenyl)-2-methylpropanenitrile
(500 mg, 2.13 mmol) was dissolved in water (8 mL), to which
sulfuric acid (7.00 mL) was added at room temperature. The reaction
mixture was stirred at 100.degree. C. for 4 hours. The reaction
mixture was extracted twice with ethylacetate. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/9) to give the
target compound
2-(5-methoxy-2-methyl-4-nitrophenyl)-2-methylpropaneamide as a
yellow solid (420 mg, 1.66 mmol, yield: 78%).
[0352] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.70 (s, 1H), 7.14
(s, 1H), 5.33 (s, br, 1H), 5.17 (s, br, 1H), 3.98 (s, 3H), 2.34 (s,
3H), 1.61 (s, 6H); LC/MS 253.1 [M+H.sup.+].
Step 2: Preparation of
2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-amine
[0353] 2-(5-methoxy-2-methyl-4-nitrophenyl)-2-methylpropaneamide
(100 mg, 0.396 mmol) prepared in step 1 was dissolved in
acetonitrile/water (1/1, 2 mL), to which
bistrifluoroacetoxyiodobenzene (171 mg, 0.396 mmol) was added at
room temperature, followed by stirring for 12 hours. The reaction
mixture was diluted with water (5 mL) and sodium hydrogen carbonate
(5 mL) and extracted twice with ethylacetate. The extracted organic
layer was dried over sodium sulfate and then filtered. The solvent
was eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-amine as a white
solid (80.0 mg, 0.356 mmol, yield: 89%).
[0354] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.68 (s, 1H), 7.45
(s, 1H), 3.96 (s, 3H), 2.57 (s, 3H), 1.58 (s, 6H), 1.54 (s, br,
2H); LC/MS 225.1 [M+H.sup.+].
Step 3: Preparation of
2,2,2-trifluoro-N-(2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-yl)aceta-
mide
[0355] 2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-amine (80.0
mg, 0.356 mmol) prepared in step 2 was dissolved in dichloromethane
(5 mL), to which anhydrous trifluoroacetic acid (89.9 mg, 0.428
mmol) and triethylamine (90.1 mg, 0.892 mmol) were added at
0.degree. C. The reaction mixture was stirred at room temperature
for 30 minutes. Water was added thereto to terminate the reaction,
followed by extraction twice with dichloromethane. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/3) to give the
target compound
2,2,2-trifluoro-N-(2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-yl)aceta-
mide as a white solid (95.0 mg, 0.296 mmol, yield: 83%).
[0356] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.69 (s, 1H), 7.09
(s, 1H), 6.47 (s, br, 1H), 3.96 (s, 3H), 2.41 (s, 2H), 1.83 (s,
6H); LC/MS 321.1 [M+H.sup.+].
Step 4: Preparation of
N-(2-(4-amino-5-methoxy-2-methylphenyl)propane-2-yl)-2,2,2-trifluoroaceta-
mide
[0357]
2,2,2-trifluoro-N-(2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-yl-
)acetamide (95.0 mg, 0.296 mmol) prepared in step 3 was dissolved
in methanol (10 mL), to which 10 weight % Pd/C (10.0 mg, 0.094
mmol) was added. The mixture was stirred for 2 hours under a
hydrogen gas balloon. The solid generated in the reaction mixture
was filtered with celite, which was washed with methanol. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/3) to give the
target compound
N-(2-(4-amino-5-methoxy-2-methylphenyl)propane-2-yl)-2,2,2-trifluoroaceta-
mide as a white solid (54.0 mg, 0.186 mmol, yield: 63%).
[0358] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.82 (s, 1H), 6.53
(s, 1H), 6.36 (s, br, 1H), 3.84 (s, 3H), 3.73 (s, br, 2H), 2.33 (s,
3H), 1.83 (s, 6H); LC/MS 291.1 [M+H.sup.+].
Preparative Example 23: Preparation of
N-(2-(4-amino-5-methoxy-2-methylphenyl)propane-2-yl)formamide
##STR00031##
[0359] Step 1: Preparation of
N-(2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-yl)formamide
[0360] 2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-amine (250 mg,
1.11 mmol) was dissolved in ethylformate (10 mL), followed by
reflux-stirring at 65 for 12 hours. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/9) to give the target compound
N-(2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-yl)formamide as a
white solid (220 mg, 0.872 mmol, yield: 78%).
[0361] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.15 (s, 0.6H),
8.01-7.96 (m, 0.3H), 7.73 (s, 0.4H) 7.70 (s, 0.6H), 7.15 (s, 1H),
6.10-6.06 (m, 0.3H), 5.73 (s, br, 0.6H), 3.99 (s, 1H), 3.98 (s,
2H), 2.49 (s, 1H), 2.46 (s, 2H), 1.80 (s, 4H), 1.78 (s, 2H); LC/MS
253.1 [M+H.sup.+].
Step 2: Preparation of
N-(2-(4-amino-5-methoxy-2-methylphenyl)propane-2-yl)formamide
[0362]
N-(2-(5-methoxy-2-methyl-4-nitrophenyl)propane-2-yl)formamide (220
mg, 0.872 mmol) prepared in step 1 was dissolved in methanol (25
mL), to which 10 weight % Pd/C (25.0 mg, 0.234 mmol) was added. The
mixture was stirred for 4 hours under a hydrogen gas balloon. The
solid generated in the reaction mixture was filtered with celite,
which was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/3) to give the target compound
N-(2-(4-amino-5-methoxy-2-methylphenyl)propane-2-yl)formamide as a
white solid (170 mg, 0.764 mmol, yield: 87%).
[0363] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.11 (s, 0.3H),
8.00-7.96 (m, 0.7H), 6.82 (s, 1H), 6.53 (s, 1H), 5.92-5.88 (m,
0.6H), 5.56 (s, br, 0.3H), 3.83 (s, 3H), 3.73 (s, br, 2H), 2.37 (s,
1H), 2.33 (s, 2H), 1.80 (s, 2H), 1.69 (s, 4H); LC/MS 223.2
[M+H.sup.4].
Preparative Example 24: Preparation of
N-(2-(4-amino-5-methoxy-[1,1'-biphenyl]-2-yl)ethylethyl-2,2,2-trifluoroac-
etamide
##STR00032##
[0365]
N-(2-bromo-4-methoxy-5-nitrophenethyl)-2,2,2-trifluoroacetamide
(200 mg, 0.59 mmol) was dissolved in n-butanol (7 mL), to which
phenylboronic acid (286 mg, 2.35 mmol), SPhos (16.0 mg, 0.04 mmol),
sodium carbonate (310 mg, 2.93 mmol), and Pd.sub.2(dba).sub.3 (16.0
mg, 0.02 mmol) were added while stirring. Gas was eliminated from
the reaction mixture, followed by heating at 115.degree. C.
overnight. The reaction mixture was filtered with celite, washed
with dichloromethane, concentrated under reduced pressure, and
extracted with ethylacetate. The organic layer was washed with
brine, dried over magnesium sulfate, filtered, and concentrated
under reduced pressure. Then, column chromatography was performed
by using ethylacetate/hexane (4/1) to give the target compound
N-(2-(4-amino-5-methoxy-[1,1'-biphenyl]-2-yl)ethyl)-2,2,2-trifluoroacetam-
ide (185 mg, 0.32 mmol, yield: 93%).
Preparative Example 25: Preparation of
N-(4-amino-5-methoxy-2-methylbenzyl)-2,2,2-trifluoroacetamide
##STR00033##
[0366] Step 1: Preparation of
2-(5-methoxy-2-methyl-4-nitrophenyl)acetamide
[0367] 2-(5-methoxy-2-methyl-4-nitrophenyl)acetonitrile (900 mg,
4.36 mmol) was dissolved in HCl (10.0 mL) at room temperature. The
reaction mixture was stirred at 30 for 48 hours. The reaction
mixture was diluted with water, followed by extraction with
ethylacetate (150 ml). The extracted organic layer was concentrated
under reduced pressure. Then, purification was performed by
recrystallization to give the target compound
2-(5-methoxy-2-methyl-4-nitrophenyl)acetamide as a white solid (690
mg, 3.08 mmol, yield: 70%).
[0368] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.75 (s, 1H), 6.97
(s, 1H), 5.52 (s, br, 1H), 5.37 (s, br, 1H), 3.97 (s, 3H), 3.64 (s,
2H), 2.33 (s, 3H); LC/MS 224.9 [M+H.sup.+].
Step 2: Preparation of
(5-methoxy-2-methyl-4-nitrophenyl)methaneamine
[0369] 2-(5-methoxy-2-methyl-4-nitrophenyl)acetamide (600 mg, 2.68
mmol) prepared in step 1 was dissolved in acetonitrile/water(1:1),
which was added to [bis(trifluoroacetoxy)iodo]benzene (1151 mg,
2.675 mmol), followed by stirring for 12 hours. The reaction
mixture was diluted with water (5.0 ml), to which sodium hydrogen
carbonate solution was added, followed by extraction with
ethylacetate (15 ml). The extracted organic layer was concentrated
under reduced pressure. Then, column chromatography was performed
(eluent: methanol/methylchloride, 1/9) to give the target compound
(5-methoxy-2-methyl-4-nitrophenyl)methaneamine as a yellow solid
(400 mg, 2.04 mmol, yield: 76%).
[0370] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.69 (s, 1H), 7.24
(s, 1H), 3.97 (s, 3H), 3.90 (s, 2H), 2.26 (s, 3H), 1.49 (s, br,
2H); LC/MS 197.1 [M+H.sup.+].
Step 3: Preparation of
2,2,2-trifluoro-N-(5-methoxy-2-methyl-4-nitrobenzyl)acetamide
[0371] (5-methoxy-2-methyl-4-nitrophenyl)methaneamine (150 mg,
0.764 mmol) was dissolved in dichloromethane (15.0 ml) and
trifluoroaceticanhydride (193 mg, 0.917 mmol), to which
triethylamine (193 mg, 1.91 mmol) was added. The reaction mixture
was stirred at room temperature for 30 minutes. Water (5.0 ml) was
added thereto to terminate the reaction, followed by extraction
twice with dichloromethane (10 ml). The extracted organic layer was
washed with water and brine, and dried over sodium sulfate. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/3) to give the
target compound
2,2,2-trifluoro-N-(5-methoxy-2-methyl-4-nitrobenzyl)acetamide as a
white solid (150 mg, 0.581 mmol, yield: 76%).
[0372] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.70 (s, 1H), 6.96
(s, 1H), 6.53 (s, br, 1H), 4.56 (d, J=5.9 Hz, 2H), 3.93 (s, 3H),
2.32 (s, 2H); LC/MS 293.0 [M+H.sup.+].
Step 4: Preparation of
N-(4-amino-5-methoxy-2-methylbenzyl)-2,2,2-trifluoroacetamide
[0373]
2,2,2-trifluoro-N-(5-methoxy-2-methyl-4-nitrobenzyl)acetamide (150
mg, 0.513 mmol) prepared in step 3 was dissolved in methanol (20.0
mL), to which 10 weight % Pd/C (15.0 mg, 0.140 mmol) was added. The
mixture was stirred at room temperature for 2 hours under a
hydrogen gas balloon. The reaction mixture was filtered with
celite. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: acetate/hexane, 3/7) to give the target
compound
N-(4-amino-5-methoxy-2-methylbenzyl)-2,2,2-trifluoroacetamide as a
white solid (110 mg, 0.419 mmol, yield: 82%).
[0374] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 6.67 (s, 1H), 6.58
(s, 1H), 6.25 (s, br, 1H), 3.85 (s, 3H), 3.83 (s, br, 2H), 2.21 (s,
3H); LC/MS 263.1 [M+H.sup.+]. Preparative Example 26: Preparation
of N-(4-amino-5-methoxy-2-methylbenzyl) formamide
##STR00034##
Step 1: Preparation of
N-(5-methoxy-2-methyl-4-nitrobenzyl)formamide
[0375] (5-methoxy-2-methyl-4-nitrocyclohexyl)methaneamine (250 mg,
1.27 mmol) was dissolved in ethylformate (10 mL), followed by
reflux-stirring at 65.degree. C. for 4 hours. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
N-(5-methoxy-2-methyl-4-nitrobenzyl)formamide as a white solid (150
mg, 0.669 mmol, yield: 52%).
[0376] 1H NMR (300 MHz, CDCl3) 8.33 (s, 1H), 7.68 (s, 1H), 6.99 (s,
1H), 5.88 (s, br, 1H), 4.50 (d, J=6.0 Hz, 2H) 3.93 (s, 3H), 2.31
(s, 3H); LC/MS 225.1 [M+H.sup.+].
Step 2: Preparation of N-(4-amino-5-methoxy-2-methylbenzyl)
formamide
[0377] N-(5-methoxy-2-methyl-4-nitrobenzyl)formamide (150 mg, 0.668
mmol) prepared in step 1 was dissolved in methanol (15 mL), to
which 10 weight % Pd/C (15.0 mg, 0.140 mmol) was added. The mixture
was stirred for 5 hours under a hydrogen gas balloon. The solid
generated in the reaction mixture was filtered with celite, which
was washed with methanol. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/3) to give the target compound
N-(4-amino-5-methoxy-2-methylbenzyl) formamide as a white solid
(110 mg, 0.566 mmol, yield: 85%).
[0378] 1H NMR (300 MHz, CDCl3) 8.20 (s, 1H), 6.67 (s, 1H), 6.54 (s,
1H), 5.53 (s, br, 1H), 4.37 (d, J=5.30 Hz, 2H) 3.82 (s, 3H), 3.75
(s, br, 2H), 2.19 (s, 3H); LC/MS 194.1 [M+H.sup.+].
Example 1: Preparation of
N2-(5-(1-(aminomethyl)cyclopentyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00035##
[0379] Step 1: Preparation of
N-((1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl-
)amino)-4-methoxyphenyl)cyclopentyl)methyl)-2,2,2-trifluoroacetamide
[0380]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (75
mg, 0.22 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (75 mg, 0.24 mmol) prepared in preparative
example 1 was added, followed by stirring at 80.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
N-((1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimi-
dine-2-yl)amino)-4-methoxyphenyl)cyclopentyl)methyl)-2,2,2-trifluoroacetam-
ide as a white solid (81 mg, 0.129 mmol, yield: 60%).
[0381] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.26 (s, 1H), 8.48
(d, J=8.4 Hz, 1H), 8.29 (s, 1H), 8.18 (s, 1H), 7.93 (d, J=8.1 Hz,
1H), 7.59-7.65 (m, 1H), 7.53 (s, 1H), 7.23-7.28 (m, 1H), 6.82-6.88
(m, 2H), 6.01 (br, 1H), 3.92 (s, 3H), 3.36 (d, J=5.7 Hz, 2H), 3.27
(sept J=6.9 Hz, 1H), 1.32 (d J=6.9 Hz, 6H); LC/MS 626.0
[M+H.sup.+].
Step 2: Preparation of
N2-(5-(1-(aminomethyl)cyclopentyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0382]
N-((1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-
e-2-yl)amino)-4-methoxyphenyl)cyclopentyl)methyl)-2,2,2-trifluoroacetamide
(60 mg, 0.09 mmol) was dissolved in ethanol (2 mL), to which
potassium carbonate (132 mg, 0.96 mmol) aqueous solution (1 mL) was
added, followed by stirring at 100.degree. C. for 15 hours. The
reaction mixture was distillated under reduced pressure, followed
by extraction twice with ethylacetate. The extracted organic layer
was dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/10) to give the target
compound
N2-(5-(1-(aminomethyl)cyclopentyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid (49 mg,
0.092 mmol, yield: 98%).
[0383] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.47 (br, 1H),
8.45 (d, J=8.1 Hz, 1H), 8.19 (s, 2H), 7.91 (d, J=8.1 Hz, 1H),
7.58-7.63 (m, 1H), 7.51 (s, 1H), 7.21-7.27 (m, 1H), 6.81-6.88 (m,
2H), 3.89 (s, 3H), 3.28 (sept J=6.9 Hz, 1H), 2.61 (s, 2H),
1.60-1.69 (m, 8H), 1.32 (d, J=6.9 Hz, 6H); LC/MS 530.0
[M+H.sup.+].
Example 2: Preparation of
N2-(5-(1-(aminomethyl)cyclohexyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopro-
pylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00036##
[0384] Step 1: Preparation of
N-((1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl-
)amino)-4-methoxyphenyl)cyclohexyl)methyl)-2,2,2-trifluoroacetamide
[0385]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (75
mg, 0.22 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (75 mg, 0.24 mmol) prepared in preparative
example 2 was added, followed by stirring at 80.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
N-((1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimi-
dine-2-yl)amino)-4-methoxyphenyl)cyclohexyl)methyl)-2,2,2-trifluoroacetami-
de as a white solid (89 mg, 0.139 mmol, yield: 64%).
[0386] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.51
(d, J=8.1 Hz, 1H), 8.39 (s, 1H), 8.18 (s, 1H), 7.92 (d, J=7.8 Hz,
1H), 7.61-7.66 (m, 1H), 7.53 (s, 1H), 7.24-7.28 (m, 1H), 6.90 (br,
2H), 5.89 (br, 1H), 3.93 (s, 3H), 3.37 (d, J=5.1 Hz, 2H), 3.26
(sept J=6.9 Hz, 1H), 1.91 (br, 2H), 1.51-1.64 (m, 4H), 1.40 (br,
4H), 1.32 (d, J=6.9 Hz, 6H); LC/MS 640.0 [M+H.sup.+].
Step 2: Preparation of
N2-(5-(1-(aminomethyl)cyclohexyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopro-
pylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0387]
N-((1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-
e-2-yl)amino)-4-methoxyphenyl)cyclohexyl)methyl)-2,2,2-trifluoroacetamide
(75 mg, 0.12 mmol) prepared in step 1 was dissolved in ethanol (2
mL), to which potassium carbonate (162 mg, 1.17 mmol) aqueous
solution (1 mL) was added, followed by stirring at 100.degree. C.
for 15 hours. The reaction mixture was distillated under reduced
pressure, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/10) to give the
target compound
N2-(5-(1-(aminomethyl)cyclohexyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopro-
pylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid (49 mg,
0.092 mmol, yield: 98%).
[0388] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.51 (br, 1H),
8.49 (d, J=8.1 Hz, 1H), 8.28 (s, 1H), 8.19 (s, 1H), 7.91 (d, J=8.1
Hz, 1H), 7.63 (t, J=7.8 Hz, 1H), 7.51 (s, 1H), 7.22-7.27 (m, 1H),
6.85-6.94 (m, 2H), 3.89 (s, 3H), 3.28 (sept J=6.9 Hz, 1H), 2.62 (s,
2H), 1.89 (br, 2H), 1.41-1.44 (m, 6H), 1.32 (d, J=6.9 Hz, 6H), 1.10
(br, 2H); LC/MS 544 [M+H.sup.+].
Example 3: Preparation of
N2-(5-((1-aminocyclopropyl)methyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00037##
[0389] Step 1: Preparation of
N-(1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-4-methoxybenzyl)cyclopropyl)-2,2,2-trifluoroacetamide
[0390]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (75
mg, 0.22 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (75 mg, 0.24 mmol) prepared in preparative
example 3 was added, followed by stirring at 80.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
N-(1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxybenzyl)cyclopropyl)-2,2,2-trifluoroacetamide
as a white solid (46 mg, 0.077 mmol, yield: 37%).
[0391] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.59 (s, 1H), 8.54
(d, J=7.5 Hz, 1H), 8.18 (d, J=10.2 Hz, 2H), 7.94 (d, J=7.8 Hz, 1H),
7.58-7.65 (m, 2H), 7.26-7.29 (m, 2H), 6.83 (d, J=7.8 Hz, 1H), 6.74
(d, J=7.8 Hz, 1H), 6.35 (s, 1H), 3.91 (s, 3H), 3.27 (sept J=6.9 Hz,
1H), 2.79 (s, 2H), 1.58 (s, 2H), 1.33 (d, J=6.9 Hz, 6H), 0.79 (br,
2H), 0.73 (br, 2H); LC/MS 598.0 [M+H.sup.+].
Step 2: Preparation of
N2-(5-((1-aminocyclopropyl)methyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0392]
N-(1-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxybenzyl)cyclopropyl)-2,2,2-trifluoroacetamide
(35 mg, 0.06 mmol) prepared in step 1 was dissolved in ethanol (2
mL), to which potassium carbonate (81 mg, 0.56 mmol) aqueous
solution (1 mL) was added, followed by stirring at 100.degree. C.
for 15 hours. The reaction mixture was distillated under reduced
pressure, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/10) to give the
target compound
N2-(5-((1-aminocyclopropyl)methyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid (16 mg,
0.032 mmol, yield: 55%).
[0393] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.52
(d, J=8.1 Hz, 1H), 8.20 (d, J=11.1 Hz, 2H), 7.94 (d, J=8.1 Hz, 1H),
7.60-7.63 (m, 2H), 7.26-7.29 (m, 2H), 6.84 (s, 2H), 3.90 (s, 3H),
3.26 (sept J=6.9 Hz, 1H), 2.59 (s, 2H), 1.46 (br, 2H), 1.32 (d,
J=6.9 Hz, 6H), 0.49 (br, 2H), 0.32 (br, 2H); LC/MS 502.0
[M+H.sup.+].
Example 4: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)p-
henyl)pyrimidine-2,4-diamine
##STR00038##
[0394] Step 1: Preparation of
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
[0395]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (50
mg, 0.14 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (42 mg, 0.16 mmol) prepared in preparative
example 4 was added, followed by stirring at 80.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide as a
white solid (54 mg, 0.129 mmol, yield: 66%).
[0396] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H), 8.53
(d, J=8.1 Hz, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 7.94 (d, J=7.5 Hz,
1H), 7.59-7.67 (m, 2H), 7.27 (br, 1H), 6.84 (d, J=6.6 Hz, 1H), 6.77
(d, J=8.1 Hz, 1H), 6.27 (br, 1H), 3.91 (s, 3H), 3.47-3.49 (m, 2H),
3.27 (hept, J=6.9 Hz, 1H), 2.76 (br, 2H), 1.32 (d, J=6.9 Hz, 6H;
LC/MS 571.7 [M+H.sup.+].
Step 2: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)p-
henyl)pyrimidine-2,4-diamine
[0397]
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide (50 mg, 0.09
mmol) prepared in step 1 was dissolved in ethanol (2 mL), to which
potassium carbonate (121 mg, 0.87 mmol) aqueous solution (1 mL) was
added, followed by stirring at 100.degree. C. for 15 hours. The
reaction mixture was distillated under reduced pressure, followed
by extraction twice with ethylacetate. The extracted organic layer
was dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/10) to give the target
compound
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)p-
henyl)pyrimidine-2,4-diamine as a white solid (35 mg, 0.092 mmol,
yield: 85%).
[0398] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.49 (br, 1H),
8.53 (d, J=8.4 Hz, 1H), 8.18 (s, 1H), 8.13 (s, 1H), 7.93 (d, J=8.1
Hz, 1H), 7.66 (t, J=7.8 Hz, 1H), 7.59 (s, 1H), 7.26-7.30 (m, 1H),
6.81 (br, 2H), 3.88 (s, 3H), 3.26 (hept, J=6.9 Hz, 1H), 2.81 (t,
J=6.9 Hz, 2H), 2.61 (t, J=6.9 Hz, 2H), 1.31 (d, J=6.9 Hz, 6H), 1.20
(br, 2H); LC/MS 475.9 [M+H.sup.+], 951.3 [2M+H.sup.+].
Example 5: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl-N2-(2-methoxy-5-(1-(piperidine-1-
-ylmethyl)cyclopentyl) phenyl)pyrimidine-2,4-diamine
##STR00039##
[0400]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (50
mg, 0.14 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (46 mg, 0.16 mmol) prepared in preparative
example 5 was added, followed by stirring at 80.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl-N2-(2-methoxy-5-(1-(pip-
eridine-1-ylmethyl)cyclopentyl) phenyl)pyrimidine-2,4-diamine as a
white solid (33 mg, 0.055 mmol, yield: 33%).
[0401] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.47 (s, 1H), 8.46
(d, J=8.4 Hz, 1H), 8.18 (s, 1H), 8.10 (br, 1H), 7.90 (dd, J=1.2 Hz,
8.1 Hz, 1H), 7.58 (t, J=7.5 Hz, 1H), 7.44 (s, 1H), 7.22 (t, J=7.8
Hz, 1H), 6.94 (dd, J=2.1 Hz, 8.4 Hz, 1H), 6.78 (d, J=8.4 Hz, 1H),
3.87 (s, 3H), 3.28 (sept, J=6.6 Hz, 1H), 2.23 (s, 2H), 2.08 (br,
4H), 1.79 (br, 3H), 1.57 (br, 7H), 1.34-1.40 (m, 3H), 1.32 (d,
J=6.6 Hz, 6H), 1.21-1.25 (m, 3H); LC/MS 598.3 [M+H.sup.+].
Example 6: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-2-methoxy-5-(1-(morpholinome-
thyl)cyclopentyl)phenyl)pyrimidine-2,4-diamine
##STR00040##
[0403]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (50
mg, 0.14 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (46 mg, 0.16 mmol) prepared in preparative
example 6 was added, followed by stirring at 100.degree. C. for 24
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(1-(mo-
rpholinomethyl)cyclopentyl)phenyl)pyrimidine-2,4-diamine as a white
solid (26 mg, 0.043 mmol, yield: 30%).
[0404] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.49 (s, 1H), 8.49
(d, J=8.4 Hz, 1H), 8.19 (s, 1H), 8.17 (br, 1H), 7.90 (d, J=7.8 Hz,
1H), 7.59 (t, J=7.5 Hz, 1H), 7.43 (s, 1H), 7.23 (t, J=7.8 Hz, 1H),
6.99 (dd, J=1.8 Hz, 8.4 Hz, 1H), 6.78 (d, J=8.4 Hz, 1H), 3.87 (s,
3H), 3.49 (t, J=4.5 Hz, 4H), 3.28 (sept, J=6.6 Hz, 1H), 2.30 (s,
2H), 2.12 (t, J=4.5 Hz, 4H), 1.61-1.84 (m, 8H), 1.32 (d, J=6.6 Hz,
6H); LC/MS 600.1 [M+H.sup.+].
Example 7: Preparation of
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)acetamide
##STR00041##
[0406]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which trimethylamine (11 mg, 0.11 mmol) and acetic anhydride (11
mg, 0.11 mmol) were added, followed by stirring at room temperature
for 3 hours. Water was added thereto to terminate the reaction,
followed by extraction twice with dichloromethane. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: dichloromethane/methanol, 10/1) to give the
target compound
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)acetamide as a white solid (47 mg, 0.091 mmol,
yield: 87%).
[0407] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.57 (s, 1H),
8.57-8.54 (m, 1H), 8.20-8.18 (m, 2H), 7.96-7.94 (m, 1H), 7.67-7.28
(m, 2H), 6.84-6.82 (m, 2H), 5.42-5.36 (m, 1H), 3.92 (s, 3H), 3.40
(s, 2H), 3.28-3.26 (m, 1H), 2.71-2.70 (m, 2H), 2.25 (s, 1H), 1.94
(s, 3H), 1.32 (s, 6H)
Example 8: Preparation of
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl) methanesulfonamide
##STR00042##
[0409]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which methanesulfonylchloride (13 mg, 0.12 mmol) was added at
0.degree. C. Trimethylamine (11 mg, 0.11 mmol) was added thereto,
followed by stirring at room temperature for 6 hours. Water was
added thereto to terminate the reaction, followed by extraction
twice with dichloromethane. The extracted organic layer was dried
over sodium sulfate and then filtered. The solvent was eliminated
by distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
dichloromethane/methanol, 10/1) to give the target compound
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)methanesulfonamide as a white solid (55 mg, 0.10
mmol, yield: 95%).
[0410] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. d 9.55 (s, 1H),
8.54 (d, J=8.4 Hz, 1H), 8.19 (s, 1H), 7.95 (d, J=7.8 Hz, 1H) 7.69
(t, J=7.8 Hz, 1H), 7.57 (s, 1H), 6.8-6.78 (m, 1H), 3.90 (s, 3H),
3.32-3.24 (m, 3H), 2.82 (s, 3H), 2.77 (t, J=6.3 Hz, 2H), 1.33 (d,
J=6.9 Hz, 6H)
Example 9: Preparation of
5-chloro-N2-(5-(2-(dimethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyl-
sulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00043##
[0412]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in tetrahydrofuran (1 mL), to
which trimethylamine (21 mg, 0.21 mmol) and methyliodide (15 mg,
0.105 mmol) were added. The reaction mixture was reflux-stirred for
4 hours. Water was added thereto to terminate the reaction,
followed by extraction twice with dichloromethane. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: dichloromethane/methanol, 10/1) to give the
target compounds
5-chloro-N2-(5-(2-(dimethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyl-
sulfonyl)phenyl)pyrimidine-2,4-diamine (Rf 0.6; 10 mg, 0.020 mmol,
yield: 19%) and
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(me-
thylamino)ethyl)phenyl)pyrimidine-2,4-diamine (Rf 0.7; 27 mg, 0.055
mmol, yield: 52%) as white solids.
[0413] The following NMR and LC/MS data are the values obtained
from
5-chloro-N2-(5-(2-(dimethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyl-
sulfonyl)phenyl)pyrimidine-2,4-diamine.
[0414] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. d 9.55 (s, 1H),
8.54 (d, J=8.7 Hz, 1H), 8.16 (d, J=6.3 Hz, 2H), 7.87 (d, J=7.8 Hz,
1H), 7.63-7.58 (m, 1H), 7.46 (s, 1H), 3.83 (s, 3H), 3.61-3.59 (m,
1H), 2.62 (s, 6H), 1.64 (d, J=9.6 Hz, 6H)
Example 10: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(methylamino-
)ethyl)phenyl)pyrimidine-2,4-diamine
##STR00044##
[0416] Example 10 was performed in the same manner as described in
Example 9. As a result, the target compounds
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(methylamino-
)ethyl)phenyl)pyrimidine-2,4-diamine (Rf 0.7; 27 mg, 0.055 mmol,
yield: 52%) and
5-chloro-N2-(5-(2-(dimethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (Rf 0.6; 10 mg,
0.020 mmol, yield: 19%), the compound prepared in Example 9, were
obtained.
[0417] The following NMR and LC/MS data are the values obtained
from
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(methylamino-
)ethyl)phenyl)pyrimidine-2,4-diamine.
[0418] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.55-9.49 (m, 1H),
8.50-8.47 (m, 1H), 8.12 (s, 2H), 7.87-7.84 (s, 1H), 7.64-7.59 (m,
1H), 7.43 (s, 1H), 6.85-6.75 (m, 2H), 3.81 (s, 3H), 3.63 (br, s,
4H), 3.22-3.18 (m, 1H), 3.07 (s, 3H), 2.63 (s, 1H), 2.57 (s, 2H),
2.10 (s, 1H), 2.01-1.95 (m, 1H), 1.25-1.23 (d, J=6.3 Hz, 6H).
Example 11: Preparation of
N2-(5-(2-(benzylamino)ethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine
##STR00045##
[0420]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (2 mL), to
which sodium sulfate (15 mg, 0.11 mmol) and benzaldehyde (10 mg,
0.090 mmol) were added, followed by stirring at room temperature
for 4 hours. The solid generated in the mixture was filtered, and
the solvent was distillated under reduced pressure. The mixture was
dissolved in methanol (2 mL), to which sodium borohydride was
added, followed by stirring for 1 hour. Water was added thereto to
terminate the reaction, followed by extraction twice with
dichloromethane. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
dichloromethane/methanol, 10/1) to give the target compound
N2-(5-(2-(benzylamino)ethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine as a white solid (28 mg, 0.49
mmol, yield: 47%).
[0421] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (m, 1H), 8.56
(d, J=8.1 Hz, 1H), 8.14 (s, 2H), 7.92 (dd, J=7.8 Hz, 7.5 Hz, 1H),
7.68-7.65 (m, 1H), 7.55 (s, 1H), 7.32-7.30 (m, 4H), 6.8 (s, 2H),
3.87 (s, 3H), 3.80 (s, 2H), 3.28-3.18 (m, 1H), 2.82 (s, 4H), 1.31
(d, J=6.9H z, 6H); LC/MS (ESI) m/z 566.3 [M+H].sup.+
Example 12: Preparation of
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-2-phenylacetamide
##STR00046##
[0423]
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulf-
onyl)phenyl)pyrimidine-2,4-diamine (50.0 mg, 0.105 mmol) was
dissolved in dichloromethane (2 mL), to which trimethylamine (16
mg, 0.16 mmol) and phenylacetylchloride (16 mg, 0.11 mmol) were
added at 0.degree. C., followed by stirring at room temperature for
4 hours. Water was added thereto to terminate the reaction,
followed by extraction twice with dichloromethane. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: dichloromethane/methanol, 10/1) to give the
target compound
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-2-phenylacetamide as a white solid (36 mg, 0.49
mmol, yield: 58%).
[0424] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.49 (s, 1H), 8.44
(d, J=8.1 Hz, 1H), 8.17 (s, 1H), 8.02 (s, 1H), 7.89 (dd, J=8.1, 7.8
Hz, 1H), 7.59 (s, 2H), 7.16-7.14 (m, 3H), 6.75 (d, J=8.1 Hz, 1H),
6.62-6.59 (m, 1H), 5.28-5.26 (m, 1H), 3.88 (s, 3H), 3.50 (s, 2H),
3.33-3.21 (m, 3H), 2.59-2.54 (m, 2H), 1.30 (d, J=6.6 Hz, 6H); LC/MS
(ESI) m/z 594.12 [M+H].sup.+
Example 13: Preparation of
5-chloro-N2-(5-(2-(ethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropylsul-
fonyl)phenyl)pyrimidine-2,4-diamine
##STR00047##
[0426]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(67.0 mg, 0.180 mmol) was dissolved in tetrahydrofuran (2.7 mL), to
which trimethylamine (103 mg, 0.798 mmol) and ethyliodide (133 mg,
0.795 mmol) were added, followed by stirring at room temperature
for 4 hours. Water was added thereto to terminate the reaction,
followed by extraction twice with dichloromethane. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: dichloromethane/methanol, 10/1) to give the
target compounds
5-chloro-N2-(5-(2-(ethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropylsul-
fonyl)phenyl)pyrimidine-2,4-diamine (Rf 0.6; 19.8 mg, 0.0393 mmol,
yield: 22%) and
5-chloro-N2-(5-(2-(diethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(i-
sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (Rf 0.7; 18.0 mg,
0.0338 mmol, yield: 19%) as white solids.
[0427] The following NMR and LC/MS data are the values obtained
from
5-chloro-N2-(5-(2-(ethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropylsul-
fonyl)phenyl)pyrimidine-2,4-diamine.
[0428] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.62 (s, 1H), 8.60
(d, J=4.8 Hz, 1H), 8.23 (d, J=6.9 Hz, 2H), 7.94 (d, J=4.2 Hz, 1H),
7.74-7.71 (m, 1H), 7.52 (s, 1H), 7.36-7.33 (m, 1H), 6.95 (d, J=4.8
Hz, 1H), 6.86 (d, J=4.8 Hz, 1H), 3.90 (s, 3H), 3.69 (s, 1H),
3.29-3.26 (m, 1H), 3.24 (d, J=3 Hz, 4H), 3.13 (d, J=4.5 Hz, 2H),
1.54 (t, J=4.2 Hz, 3H), 1.34 (d, J=3.9 Hz, 6H); LC/MS (ESI) m/z 504
[M+H].sup.+.
Example 14: Preparation of
5-chloro-N2-(5-(2-(diethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00048##
[0430] Example 14 was performed in the same manner as described in
Example 13. As a result, the target compounds
5-chloro-N2-(5-(2-(diethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine (Rf 0.7; 18.0 mg, 0.0338
mmol, yield: 19%) and
5-chloro-N2-(5-(2-(ethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropylsul-
fonyl)phenyl)pyrimidine-2,4-diamine (Rf 0.6; 19.8 mg, 0.0393 mmol,
yield: 22%), the compound prepared in Example 13, were
obtained.
[0431] The following NMR and LC/MS data are the values obtained
from
5-chloro-N2-(5-(2-(diethylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine.
[0432] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.67 (s, 1H), 8.65
(d, J=5.1 Hz, 1H), 8.27 (s, 1H), 8.23 (s, 1H), 7.96 (dd, J=4.8 Hz,
4.5 Hz, 1H), 7.71-7.69 (m, 1H), 7.34 (s, 1H), 6.94 (dd, J=5.1 Hz,
6.88 (d, J=5.1 Hz, 1H), 3.93 (s, 3H), 3.69-3.61 (m, 4H), 3.32-3.27
(m, 1H), 3.18 (d, J=3.9 Hz, 5H), 1.46-1.43 (m, 6H), 1.36 (d, J=4.2
Hz, 6H); LC/MS (ESI) m/z 532 [M+H].sup.+.
Example 15: Preparation of
5-chloro-N2-(5-(2-(isopropylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropy-
lsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00049##
[0434]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dimethylformamide (1 mL), to
which cesium hydroxide-water (103 mg, 0.210 mmol) and
2-bromopropane (133 mg, 0.105 mmol) were added, followed by
stirring at room temperature for 48 hours. Water was added thereto
to terminate the reaction, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
dichloromethane/methanol, 10/1) to give the target compound
5-chloro-N2-(5-(2-(isopropylamino)ethyl)-2-methoxyphenyl)-N4-(2-(isopropy-
lsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid (8.0 mg,
0.015 mmol, yield: 15%).
[0435] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.57 (s, 1H), 8.60
(d, J=8.1 Hz, 1H), 8.20 (s, 1H), 8.16 (s, 1H), 7.92 (dd, J=1.2 Hz,
8.1 Hz), 7.73-7.68 (m, 1H), 7.50 (s, 1H), 7.32 (d, J=7.2 Hz, 1H),
6.88-6.79 (m, 2H), 3.87 (s, 3H)
Example 16: Preparation of
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylurea
##STR00050##
[0437]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which triethylamine (16 mg, 0.16 mmol) and ethylisocyanate (9.1 mg,
0.16 mmol) were added at 0.degree. C., followed by stirring at room
temperature for 18 hours. Water was added thereto to terminate the
reaction, followed by extraction twice with dichloromethane. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate) to give the target compound
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylurea as a white solid (20 mg, 0.037
mmol, yield: 35%).
[0438] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.9.46 (s, 1H), 8.46
(d, J=8.4 Hz, 1H), 8.09 (d, J=9 Hz, 2H), 7.87 (dd, J=1.2 Hz, 7.8
Hz, 1H), 7.61-7.49 (m, 1H), 7.49 (s, 1H), 6.77-6.70 (m, 2H),
4.10-4.03 (m, 2H), 3.81 (s, 1H), 3.28-3.20 (m, 2H), 3.18 (d, J=6.9
Hz, 1H), 3.13-3.02 (m, 2H), 2.62-2.58 (m, 2H), 1.53 (s, 1H), 1.25
(d, J=6.9 Hz, 6H), 1.03-0.98 (m, 3H); LC/MS (ESI) m/z 547.0
[M+H].sup.+
Example 17: Preparation of
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-cyclohexylurea
##STR00051##
[0440]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which triethylamine (16 mg, 0.16 mmol) and cyclohexylisocyanate
(12.5 mg, 0.100 mmol) were added at 0.degree. C., followed by
stirring at room temperature for 18 hours. Water was added thereto
to terminate the reaction, followed by extraction twice with
dichloromethane. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 5/1) to give the target compound
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-cyclohexylurea as a white solid (48 mg, 0.080
mmol, yield: 76%).
[0441] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, 1H), 8.53
(d, J=8.4 Hz, 1H), 8.17 (d, J=12.3 Hz, 2H), 7.93 (d, J=7.8 Hz, 1H),
7.67-7.62 (m, 1H), 7.58 (s, 1H), 7.29-7.24 (m, 1H), 6.84-6.77 (m,
1H), 4.17-4.08 (m, 3H), 3.88 (s, 1H), 3.33-3.19 (m, 3H), 2.69 (t,
J=6.6 Hz, 2H), 1.87-1.84 (m, 2H), 1.68-1.55 (m, 4H), 1.32 (d, J=6.9
Hz, 6H), 1.25-1.08 (m, 4H); LC/MS (ESI) m/z 603.1 [M+H]+.sup.+.
Example 18: Preparation of
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-phenylurea
##STR00052##
[0443]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which triethylamine (16 mg, 0.16 mmol) and phenylisocyanate (12 mg,
0.10 mmol) were added at 0.degree. C., followed by stirring at room
temperature for 18 hours. Water was added thereto to terminate the
reaction, followed by extraction twice with dichloromethane. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 1/1) to give the
target compound
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-phenylurea as a white solid (36 mg, 0.042
mmol, yield: 42%).
[0444] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.51 (s, 1H), 8.50
(d, J=8.4 Hz, 1H), 8.13 (s, 1H), 7.91 (dd, J=1.2 Hz, 7.8 Hz, 1H),
7.67-7.61 (m, 1H), 7.56 (s, 1H), 7.24-7.17 (m, 4H), 7.05-7.01 (m,
1H), 6.79 (s, 2H), 6.42 (s, 1H), 4.80-4.76 (m, 1H), 4.15-4.08 (m,
1H), 3.86 (s, 3H), 3.41-3.35 (m, 1H), 3.27-3.18 (m, 1H), 2.71 (t,
J=6.6 Hz, 2H), 1.68 (s, 1H), 1.30 (d, J=6.9 Hz, 6H), 1.25-1.23 (m,
1H); LC/MS (ESI) m/z 597.0 [M+H].sup.+.
Example 19: Preparation of
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-methylthiourea
##STR00053##
[0446]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which triethylamine (16 mg, 0.16 mmol) and methylisothiocyanate
(7.3 mg, 0.10 mmol) were added at 0.degree. C., followed by
stirring at room temperature for 18 hours. Water was added thereto
to terminate the reaction, followed by extraction twice with
dichloromethane. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 1/1) to give the target compound
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-methylthiourea as a white solid (35 mg, 0.060
mmol, yield: 60%).
[0447] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.48 (s, 1H), 8.48
(d, J=8.4 Hz, 1H), 8.12 (d, J=4.8 Hz, 2H), 7.87 (d, J=7.8 Hz, 1H),
7.61 (t, J=7.5 Hz, 1H), 7.50 (s, 1H), 6.75 (br, s, 2H), 5.67-5.62
(m, 1H), 5.51 (br, s, 1H), 4.08-4.01 (m, 1H), 3.82 (s, 3H),
3.569-3.55 (m, 2H), 3.24-3.14 (m, 1H), 2.81 (d, J=4.2 Hz, 3H), 2.74
(t, J=6.6 Hz, 2H), 1.97 (s, 1H), 1.26 (d, J=6.6 Hz, 6H; LC/MS (ESI)
m/z 550.9 [M+H].sup.+.
Example 20: Preparation of
1-benzyl-3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2--
ylamino)-4-methoxyphenethyl)thiourea
##STR00054##
[0449]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which triethylamine (16 mg, 0.16 mmol) and benzylisothiocyanate (15
mg, 0.10 mmol) were added at 0.degree. C., followed by stirring at
room temperature for 18 hours. Water was added thereto to terminate
the reaction, followed by extraction twice with dichloromethane.
The extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate) to give the target compound
1-benzyl-3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2--
ylamino)-4-methoxyphenethyl)thiourea as a white solid (28 mg, 0.043
mmol, yield: 43%).
[0450] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H), 8.52
(d, J=4.8 Hz, 1H), 8.16 (d, J=4.5 Hz, 2H), 7.95 (dd, J=0.9, 4.8 Hz,
1H), 7.66-7.65 (m, 1H), 7.58 (s, 1H), 7.31-7.28 (m, 3H), 7.22 (d,
J=4.2 Hz, 2H), 6.81 (d, J=4.8 Hz, 1H), 6.75-6.74 (m, 1H), 4.50 (br,
s, 2H), 4.16 (m, 1H), 3.91 (s, 3H), 3.61 (br, s, 2H), 3.29-3.24 (m,
1H), 2.77 (t, J=3.9 Hz, 2H), 1.62 (br, s, 1H), 1.33 (d, J=4.2 Hz,
6H), 1.29-1.26 (m, 2H); LC/MS (ESI) m/z 627.0 [M+H].sup.+.
Example 21: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperidine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine
##STR00055##
[0452]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (50
mg, 0.14 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (0.04 g, 0.16 mmol) prepared in preparative
example 7 was added, followed by stirring at 100.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/10) to give the target
compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperidine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine as a white solid (0.036 g,
0.066 mmol, yield: 46%).
[0453] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.57
(d, J=8.4 Hz, 1H), 8.18 (s, 1H), 8.13 (s, 1H), 7.92 (d, J=7.8 Hz,
1H), 7.67 (t, J=7.5 Hz, 1H), 7.57 (s, 1H), 7.23-7.28 (m, 1H), 6.82
(s, 2H), 3.88 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H), 2.66-2.71 (m,
2H), 2.36-2.46 (m, 6H), 1.58-1.62 (m, 4H), 1.44-1.45 (m, 2H), 1.32
(d, J=6.9 Hz, 6H); LC/MS 544.0 [M+H.sup.+].
Example 22: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-morpholinoet-
hyl)phenyl)pyrimidine-2,4-diamine
##STR00056##
[0455]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (50
mg, 0.14 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (0.1 mL),
to which the compound (0.04 g, 0.16 mmol) prepared in preparative
example 8 was added, followed by stirring at 100.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/10) to give the target
compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-morpholinoet-
hyl)phenyl)pyrimidine-2,4-diamine as a white solid (0.038 g, 0.069
mmol, yield: 48%).
[0456] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H), 8.59
(d, J=8.4 Hz, 1H), 8.18 (s, 1H), 8.15 (s, 1H), 7.92 (dd, J=1.5, 8.1
Hz, 1H), 7.67 (t, J=7.2 Hz, 1H), 7.57 (s, 1H), 7.23-7.27 (m, 1H),
6.82 (s, 2H), 3.88 (s, 3H), 3.71-3.79 (m, 4H), 3.26 (sept, J=6.9
Hz, 1H), 2.66-2.72 (m, 2H), 2.44-2.59 (m, 6H), 1.32 (d, J=6.9 Hz,
6H); LC/MS 546.1 [M+H.sup.+].
Example 23: Preparation of
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylthiourea
##STR00057##
[0458]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dichloromethane (1 mL), to
which triethylamine (16 mg, 0.16 mmol) and ethylisothiocyanate (8.7
mg, 0.10 mmol) were added at 0.degree. C., followed by stirring at
room temperature for 18 hours. Water was added thereto to terminate
the reaction, followed by extraction twice with dichloromethane.
The extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/1) to give the
target compound
1-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-3-ethylthiourea as a white solid (36.5 mg,
0.060 mmol, yield: 60%).
[0459] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.58 (s, 1H), 8.57
(d, J=4.8 Hz, 1H), 8.22 (d, J=6 Hz, 2H), 7.96 (dd, J=0.6, 4.8 Hz,
1H), 7.70-7.66 (m, 1H), 7.60 (s, 1H), 6.87-6.81 (m, 2H), 4.16-4.12
(m, 1H), 3.92 (s, 1H), 3.66-3.65 (m, 2H), 3.31-3.26 (m, 2H),
2.83-2.80 (m, 2H), 1.60 (br, s, 1H), 1.35 (d, J=4.2 Hz, 6H), 1.29
(t, J=4.2 Hz, 1H), 1.17-1.14 (m, 3H); LC/MS (ESI) m/z 565.0
[M+H].sup.+.
Example 24: Preparation of
3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)propanoate
##STR00058##
[0461]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in methanol (1 mL), to which
methyl acrylate (8.6 mg, 0.10 mmol) was added at 0.degree. C.,
followed by stirring at room temperature for 18 hours. Water was
added thereto to terminate the reaction, followed by extraction
twice with dichloromethane. The extracted organic layer was dried
over sodium sulfate and then filtered. The solvent was eliminated
by distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound methyl
3-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)propanoate as a yellow oil (17.8 mg, 0.030
mmol, yield: 30%).
[0462] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.55 (s, 1H)),
8.57 (d, J=8.7 Hz, 1H), 8.18 (s, 2H), 7.94 (d, J=0.9, 8.4 Hz, 1H),
7.72-7.66 (m, 1H), 7.55 (s, 1H), 6.84 (s, 2H), 3.89 (s, 3H), 3.67
(s, 3H), 3.05-2.94 (m, 7H), 2.78 (s, 2H), 1.33 (d, J=6.9 Hz, 6H),
1.23-1.20 (m, 2H); LC/MS (ESI) m/z 564.0 [M+H].sup.+.
Example 25: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(pyrimidine--
2-ylamino)ethyl)phenyl)pyrimidine-2,4-diamine
##STR00059##
[0464]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in isopropanol (1 mL), to which
potassium carbonate (26 mg, 0.19 mmol) and 2-chloropyrimidine (11
mg, 0.10 mmol) were added at 0.degree. C., followed by stirring at
110.degree. C. for 45 minutes in a microwave reactor. Water was
added thereto to terminate the reaction, followed by extraction
twice with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 2/1) to give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(py-
rimidine-2-ylamino)ethyl)phenyl)pyrimidine-2,4-diamine as a white
solid (31 mg, yield: 59%).
[0465] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.47 (s, 1H), 8.52
(d, J=8.4 Hz, 1H), 8.25-8.24 (m, 2H), 8.18 (s, 1H), 7.92 (d, J=7.8
Hz, 1H), 7.66-7.60 (m, 2H), 6.82 (s, 2H), 6.51 (br, s, 1H),
5.05-5.01 (m, 1H), 3.88 (s, 3H), 3.65-3.63 (m, 1H), 3.54-3.52 (m,
2H), 3.28-3.22 (m, 1H), 2.79-2.74 (m, 2H), 1.30 (d, J=6.9 Hz, 6H);
LC/MS (ESI) m/z 556.1 [M+H].sup.+.
Example 26: Preparation of methyl
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetate
##STR00060##
[0467]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in tetrahydrofuran (1 mL), to
which methylbromoacetate (15 mg, 0.10 mmol) and triethylamine (10
mg, 0.10 mmol) were added at 0.degree. C., followed by stirring at
room temperature for 4 hours. Water was added thereto to terminate
the reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/10) to give the
target compound methyl
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetate as a white solid (28 mg, yield:
49%).
[0468] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.52 (s, 1H), 8.56
(d, J=8.4 Hz, 1H), 8.17 (s, 1H), 8.14 (s, 1H), 7.94 (d, J=7.8 Hz,
1H), 7.73-7.64 (m, 2H), 7.56-7.51 (m, 1H), 6.82 (s, 2H), 3.88 (s,
3H), 3.70 (s, 3H), 3.37 (s, 2H), 3.28-3.21 (m, 1H), 2.77 (d, J=6.3
Hz, 2H), 2.71 (d, J=6.0 Hz, 2H), 1.32 (d, J=6.9 Hz, 6H), 0.89-0.83
(m, 4H)
Example 27: Preparation of
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetic acid
##STR00061##
[0470] Methyl
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenethylamino)pyrimidine-2-ylamin-
o)-4-methoxyphenethylamino)acetate (15 mg, 0.027 mmol) was
dissolved in ethylacetate, to which water was added, followed by
reflux-stirring for 12 hours. The reaction mixture was
concentrated, to which isopropanol was added. The reaction mixture
was washed with isopropanol, filtered, and concentrated. As a
result, the target compound
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethylamino)acetic acid was obtained as a white solid
(4 mg, yield: 29%).
[0471] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.50 (s, 1H), 8.52
(br, s, 1H), 8.18-8.00 (m, 1H), 7.99-7.94 (m, 1H), 7.82-7.79 (m,
1H), 7.64-7.60 (m, 1H), 6.83-6.66 (m, 2H), 3.90-3.55 (m, 5H),
3.20-3.02 (m, 5H), 2.04 (s, 1H), 1.31 (d, J=21 Hz, 6H); LC/MS (ESI)
m/z 535.8 [M+H].sup.+.
Example 28: Preparation of
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxybenzyl)-2,2,2-trifluoroacetamide
##STR00062##
[0473]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine/2,5--
dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (50 mg,
0.14 mmol) was dissolved in 0.08 M HCl.ethoxyethanol (1 mL), to
which the compound (0.04 g, 0.16 mmol) prepared in preparative
example 9 was added, followed by stirring at 80.degree. C. for 15
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxybenzyl)-2,2,2-trifluoroacetamide as a white solid
(0.055 g, 0.098 mmol, yield: 69%).
[0474] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H), 8.51
(d, J=8.4 Hz, 1H), 8.29 (s, 1H), 8.16 (s, 1H), 7.91 (d, J=7.8 Hz,
1H), 7.65 (t, J=7.8 Hz, 1H), 7.59 (s, 1H), 7.28 (t, J=7.5 Hz, 1H),
6.84-6.91 (m, 2H), 6.54 (br, 1H), 4.37 (d, J=5.4 Hz, 2H), 3.91 (s,
3H), 3.24 (sept, J=6.9 Hz, 1H), 1.30 (d, J=6.9 Hz, 6H); LC/MS 558.4
[M+H.sup.+].
Example 29: Preparation of
N2-(5-(aminomethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)ph-
enyl)pyrimidine-2,4-diamine
##STR00063##
[0476] The compound (40 mg, 0.07 mmol) prepared in example 28 was
dissolved in ethanol (2 mL), to which potassium carbonate (180 mg,
0.72 mmol) aqueous solution (0.05 mL) was added, followed by
stirring at 90 for 1 hour. The reaction mixture was distillated
under reduced pressure, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
N2-(5-(aminomethyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)ph-
enyl)pyrimidine-2,4-diamine as a white solid (0.02 g, 0.04 mmol,
yield: 61%).
[0477] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.44 (d, J=8.1 Hz,
1H), 8.15 (s, 1H), 7.89-7.93 (m, 2H), 7.67 (t, J=6.9 Hz, 1H), 7.36
(t, J=6.9 Hz, 1H), 6.94-7.03 (m, 2H), 3.87 (s, 3H), 3.59 (s, 2H),
3.33 (sept, J=6.9 Hz, 1H), 1.24 (d, J=6.9 Hz, 6H); LC/MS 462.3
[M+H.sup.+].
Example 30: Preparation of
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxyphenethyl)-2,2,2-trifluoroacetamide
##STR00064##
[0479]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine/2,5--
dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (50 mg,
0.14 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (1 mL), to
which N-(3-amino-4-methoxyphenethyl)-2,2,2-trifluoroacetamide (0.04
g, 0.16 mmol) was added, followed by stirring at 80.degree. C. for
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/1) to give the target compound
N-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2--
ylamino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide as a white
solid (0.055 g, 0.098 mmol, yield: 69%).
[0480] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H), 8.53
(d, J=8.1 Hz, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 7.94 (d, J=7.5 Hz,
1H), 7.59-7.67 (m, 2H), 7.27 (br, 1H), 6.84 (d, J=6.6 Hz, 1H), 6.77
(d, J=8.1 Hz, 1H), 6.27 (br, 1H), 3.91 (s, 3H), 3.47-3.49 (m, 2H),
3.27 (hept, J=6.9 Hz, 1H), 2.76 (br, 2H), 1.32 (d, J=6.9 Hz, 6H;
LC/MS 571.7 [M+H.sup.+].
Example 31: Preparation of
N2-(5-(2-aminoethyl)-2-isopropoxyphenyl)-5-chloro-N4-(2-(isopropylsulfony-
l)phenyl)pyrimidine-2,4-diamine
##STR00065##
[0481] Step 1: Preparation of
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-hydroxyphenethyl)-2,2,2-trifluoroacetamide
[0482] The compound (0.45 g, 0.79 mmol) prepared in example 30 was
dissolved in dichloromethane (5 mL), to which borontribromide (0.59
g, 2.36 mmol) was added at 0.degree. C., followed by stirring at
room temperature for 4 hours. Water was added thereto to terminate
the reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 1/1) to give the
target compound
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-hydroxyphenethyl)-2,2,2-trifluoroacetamide as a white solid
(0.22 g, 0.394 mmol, yield: 50%).
[0483] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.66 (br, 1H),
9.44-9.47 (m, 2H), 8.53 (d, J=7.2 Hz, 1H), 8.24-8.25 (m, 2H), 7.80
(d, J=8.1 Hz, 1H), 7.64 (t, J=7.2 Hz, 1H), 7.50 (s, 1H), 7.31 (t,
J=7.8 Hz, 1H), 6.72-6.81 (m, 2H), 3.44 (sept, J=6.9 Hz, 1H),
3.24-3.29 (m, 2H), 2.61 (t, J=7.5 Hz, 2H), 1.14 (d, J=6.9 Hz, 6H);
LC/MS 558.0 [M+H.sup.+].
Step 2: Preparation of
N-(3-((4-chloro-3-((2-(isopropylsulfonyl)phenyl)amino)phenyl)amino)-4-iso-
propoxyphenethyl)-2,2,2-trifluoroacetamide
[0484]
N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-4-hydroxyphenethyl)-2,2,2-trifluoroacetamide (0.10 g,
0.18 mmol) prepared in step 1 was dissolved in dichloromethane (1
mL), to which isopropanol (13 mg, 0.22 mmol), triphenylphosphine
(0.071 g, 0.27 mmol), and diethylazodicarboxylate (0.055 g, 0.27
mmol) were added, followed by stirring at room temperature for 4
hours. Water was added thereto to terminate the reaction, followed
by extraction twice with dichloromethane. The extracted organic
layer was dried over sodium sulfate and then filtered. The solvent
was eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 1/1) to give the target compound
N-(3-((4-chloro-3-((2-(isopropylsulfonyl)phenyl)amino)phenyl)amino)-4-iso-
propoxyphenethyl)-2,2,2-trifluoroacetamide as a white solid (0.082
g, 0.137 mmol, yield: 76%).
[0485] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.55 (br, 1H),
8.52 (d, J=8.1 Hz, 1H), 8.18-8.19 (m, 2H), 7.94 (d, J=8.1 Hz, 1H),
7.59-7.66 (m, 2H), 7.26-7.29 (m, 2H), 6.85 (d, J=8.4 Hz, 1H), 6.85
(d, J=8.1 Hz, 1H), 3.58 (sept, J=6.0 Hz, 1H), 3.45 (q, J=6.9 Hz,
2H), 3.27 (sept, J=6.9 Hz, 1H), 2.72 (t, J=6.6 Hz, 2H), 1.39 (d,
J=6.0 Hz, 6H), 1.32 (d, J=6.9 Hz, 6H); LC/MS 600.1 [M+H.sup.+].
Step 3: Preparation of
N2-(5-(2-aminoethyl)-2-isopropoxyphenyl)-5-chloro-N4-(2-(isopropylsulfony-
l)phenyl)pyrimidine-2,4-diamine
[0486]
N-(3-((4-chloro-3-((2-(isopropylsulfonyl)phenyl)amino)phenyl)amino)-
-4-isopropoxyphenethyl)-2,2,2-trifluoroacetamide (0.05 g, 0.08
mmol) prepared in step 2 was dissolved in ethanol (5 mL), to which
potassium carbonate (0.05 g, 0.33 mmol) aqueous solution (1 mL) was
added, followed by stirring at 90 for 2 hours. The reaction mixture
was distillated under reduced pressure, followed by extraction
twice with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
N2-(5-(2-aminoethyl)-2-isopropoxyphenyl)-5-chloro-N4-(2-(isopropylsulfony-
l)phenyl)pyrimidine-2,4-diamine as a white solid (0.032 g, 0.063
mmol, yield: 76%).
[0487] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.49 (br, 1H),
8.53 (d, J=7.8 Hz, 1H), 8.18 (s, 1H), 8.13 (s, 1H), 7.94 (dd,
J=7.8, 1.2 Hz, 1H), 7.62-7.68 (m, 2H), 7.28-7.31 (m, 1H), 6.83 (d,
J=8.4 Hz, 1H), 6.76 (dd, J=8.1, 1.8 Hz, 1H), 3.57 (sept, J=6.0 Hz,
1H), 3.27 (sept, J=6.9 Hz, 1H), 2.79 (t, J=6.9 Hz, 2H), 2.59 (t,
J=6.9 Hz, 2H), 1.57 (s, 1H), 1.38 (d, J=6.0 Hz, 6H), 1.32 (d, J=6.9
Hz, 6H); LC/MS 504.0 [M+H.sup.+].
Example 32: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(4-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00066##
[0488] Step 1: Preparation of
N-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
[0489] The compound (39.9 mg, 0.19 mmol) prepared in preparative
example 9 and the compound (A, 70 mg, 0.19 mmol) prepared in
preparative example 10 were dissolved in 0.08 M HCl-ethoxyethanol
(2.5 mL), followed by stirring at 100.degree. C. for 18 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
1 N HCl. The reaction mixture was extracted with ethylacetate. The
ethylacetate layer was washed with water and brine, dried over
sodium sulfate, and concentrated under reduced pressure. Then,
purification was performed by MPLC to give the target compound
N-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide (20 mg,
0.03 mmol, yield: 18%).
[0490] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.18-8.16 (m, 2H),
7.95 (s, 1H), 7.85-8.82 (m, 1H), 7.61 (s, 1H), 7.51-7.44 (m, 2H),
6.81 (m, 1H), 6.71 (m, 1H), 3.87-7.84 (m, 3H), 3.46-3.39 (m, 2H),
3.15-3.10 (m, 1H), 2.61-2.57 (m, 2H), 1.25 (d, J=6.9 Hz, 6H); LC/MS
590 [M+H.sup.+].
Step 2: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(4-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine
[0491]
N-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyri-
midine-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
(40.0 mg, 0.07 mmol) prepared in step 1 and potassium carbonate
(37.5 mg, 0.27 mmol) were dissolved in ethanol/water (3/1, 5 mL),
followed by stirring at 90.degree. C. for 3 hours. Upon completion
of the reaction, a new spot was formed under the starting material,
which was confirmed by TLC. Ethanol was concentrated under reduced
pressure, which was dissolved in ethylacetate. The reaction mixture
was washed with water. The organic layer was dried over sodium
sulfate and concentrated under reduced pressure. As a result, the
target compound
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(4-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine was obtained (12 mg, 0.02
mmol, yield: 35%).
[0492] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.25 (s, 1H),
8.50-8.46 (m, 1H), 8.18 (s, 1H), 8.08 (s, 1H), 7.68-7.66 (m, 1H),
7.57 (s, 1H), 7.40 (m, 1H), 6.82 (m, 2H), 3.89 (s, 3H), 3.29-3.25
(m, 1H), 2.84-2.82 (m, 2H), 2.64-2.60 (m, 2H), 1.34 (d, J=6.9 Hz,
6H); LC/MS 494 [M+H.sup.+].
Example 33: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(5-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride
##STR00067##
[0493] Step 1: Preparation of
N-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
[0494] The compound (28.8 mg, 0.11 mmol) prepared in preparative
example 9 and the compound (50 mg, 0.14 mmol) prepared in
preparative example 11 were dissolved in 0.08 M HCl-ethoxyethanol
(1 mL), followed by stirring at 100.degree. C. for 18 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
1 N HCl. The reaction mixture was extracted with ethylacetate. The
ethylacetate layer was washed with water and brine, dried over
sodium sulfate, and concentrated under reduced pressure. Then,
purification was performed by MPLC to give the target compound
N-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide (13 mg,
0.02 mmol, yield: 16%).
[0495] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.18-8.16 (m, 2H),
7.95 (s, 1H), 7.85-8.82 (m, 1H), 7.61 (s, 1H), 7.51-7.44 (m, 2H),
6.81 (m, 1H), 6.71 (m, 1H), 3.87-7.84 (m, 3H), 3.46-3.39 (m, 2H),
3.15-3.10 (m, 1H), 2.61-2.57 (m, 2H), 1.25 (d, J=6.9 Hz, 6H); LC/MS
590 [M+H.sup.+].
Step 2: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(5-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride
[0496] The compound (13.0 mg, 0.02 mmol) prepared in step 1 was
dissolved in ethanol (2 mL), to which water (0.5 mL) containing
potassium carbonate (11.0 mg, 0.08 mmol) dissolved therein was
added, followed by stirring at 90.degree. C. for 3 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Ethanol was
concentrated under reduced pressure, which was dissolved in MC. The
reaction mixture was washed with water and brine. The MC layer was
dried over sodium sulfate and concentrated under reduced pressure.
Ether was added thereto. 4 M HCl-dioxane was also added thereto,
followed by stirring for 1 hour. The generated solid was filtered
and dried. As a result, the target compound
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(5-fluoro-2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride was obtained (5
mg, 0.01 mmol, yield: 51%).
[0497] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.20 (s, 1H),
7.96-7.94 (m, 1H), 7.73-7.70 (m, 2H), 7.55 (s, 1H), 6.99-6.96 (m,
2H), 3.87 (s, 3H), 3.47-3.43 (m, 1H), 3.07-3.04 (m, 2H), 3.73-3.70
(m, 2H), 1.26 (d, J=18.5 Hz, 6H); LC/MS 494 [M+H.sup.+].
Example 34: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-fluoro-6-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride
##STR00068##
[0498] Step 1: Preparation of
N-(3-((5-chloro-4-((2-fluoro-6-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
[0499] The compound (28.8 mg, 0.11 mmol) prepared in preparative
example 9 and the compound (50 mg, 0.14 mmol) prepared in
preparative example 12 were dissolved in 0.08 M HCl-ethoxyethanol
(1 mL), followed by stirring at 100.degree. C. for 18 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
1 N HCl. The reaction mixture was extracted with ethylacetate. The
ethylacetate layer was washed with water and brine, dried over
sodium sulfate, and concentrated under reduced pressure. Then,
purification was performed by MPLC to give the target compound
N-(3-((5-chloro-4-((2-fluoro-6-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide (12 mg,
0.02 mmol, yield: 15%).
[0500] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.18-8.16 (m, 2H),
7.95 (s, 1H), 7.84-8.82 (m, 1H), 7.61 (s, 1H), 7.53-7.44 (m, 2H),
6.81 (m, 1H), 6.71 (m, 1H), 3.87-7.84 (m, 3H), 3.43-3.42 (m, 2H),
3.15-3.10 (m, 1H), 2.61-2.57 (m, 2H), 1.25 (d, J=6.9 Hz, 6H); LC/MS
590 [M+H.sup.+].
Step 2: Preparation of
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-fluoro-6-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride
[0501]
N-(3-((5-chloro-4-((2-fluoro-6-(isopropylsulfonyl)phenyl)amino)pyri-
midine-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
(12.0 mg, 0.02 mmol) prepared in step 1 was dissolved in ethanol (2
mL), to which water (0.5 mL) containing potassium carbonate (11.0
mg, 0.08 mmol) dissolved therein was added, followed by stirring at
90.degree. C. for 3 hours. Upon completion of the reaction, a new
spot was formed under the starting material, which was confirmed by
TLC. Ethanol was concentrated under reduced pressure, which was
dissolved in MC. The reaction mixture was washed with water and
brine. The MC layer was dried over sodium sulfate and concentrated
under reduced pressure. Ether was added thereto. 4 M HCl-dioxane
was also added thereto, followed by stirring for 1 hour. The
generated solid was filtered and dried. As a result, the target
compound
N2-(5-(2-aminoethyl)-2-methoxyphenyl)-5-chloro-N4-(2-fluoro-6-(i-
sopropylsulfonyl)phenyl)pyrimidine-2,4-diaminehydrochloride was
obtained (6 mg, 0.01 mmol, yield: 61%).
[0502] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.25 (s, 1H),
7.98-7.96 (m, 1H), 7.78-7.70 (m, 2H), 7.34 (s, 1H), 7.09-7.07 (m,
1H), 7.03-7.01 (m, 1H), 3.87 (s, 3H), 3.47-3.44 (m, 1H), 3.08-3.05
(m, 2H), 2.75-2.73 (m, 2H), 1.27 (d, J=17 Hz, 6H); LC/MS 494
[M+H.sup.+].
Example 35: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00069##
[0503] Step 1: Preparation of
N-(2-(3-((5-chloro-4-((4-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
[0504]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine/2,5--
dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (70 mg,
0.29 mmol) and the compound (67.0 mg, 0.23 mmol) prepared in
preparative example 13 were dissolved in 0.08 M HCl-ethoxyethanol
(3 mL), followed by stirring at 100.degree. C. for 18 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
sodium hydrogen carbonate aqueous solution. The reaction mixture
was extracted with ethylacetate. The ethylacetate layer was washed
with water and brine, dried over sodium sulfate, and concentrated
under reduced pressure. Then, purification was performed by MPLC
and recrystallization was also performed by using MC/Hex to give
the target compound
N-(2-(3-((5-chloro-4-((4-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
(32 mg, 0.05 mmol, yield: 23%).
[0505] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.51
(d, J=7.8 Hz, 1H), 8.36 (s, 1H), 8.19 (s, 1H), 7.94 (d, J=8.1 Hz,
1H), 7.65-7.60 (m, 1H), 7.53 (s, 1H), 7.28-7.23 (m, 1H), 6.94-6.85
(m, 2H), 6.01 (br, s, 1H), 3.92 (s, 3H), 3.44 (d, J=6.0 Hz, 2H),
3.29-3.25 (m, 1H), 1.33 (d, J=6.9 Hz, 6H), 1.24 (s, 6H); LC/MS 600
[M+H.sup.+].
Step 2: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0506]
N-(2-(3-((5-chloro-4-((4-fluoro-2-(isopropylsulfonyl)phenyl)amino)p-
yrimidine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacet-
amide (32 mg, 0.05 mmol) prepared in step 1 was dissolved in
ethanol (3 mL), to which water (1.5 mL) containing potassium
carbonate (29.5 mg, 0.21 mmol) dissolved therein was added,
followed by stirring at 90.degree. C. for 3 hours. Upon completion
of the reaction, a new spot was formed under the starting material,
which was confirmed by TLC. Ethanol was concentrated under reduced
pressure. Water was added thereto, followed by extraction with
ethylacetate. The ethylacetate layer was washed with water and
brine, dried over sodium sulfate, and concentrated under reduced
pressure. Ether was added thereto. 4 M HCl-dioxane was also added
thereto, followed by stirring for 1 hour. The generated solid was
filtered and dried. As a result, the target compound
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine was obtained (17 mg,
0.03 mmol, yield: 68%).
[0507] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.35 (m, 1H), 8.18
(s, 1H), 7.99-7.96 (m, 1H), 7.70-7.68 (m, 1H), 7.53-7.40 (m, 3H),
7.19-7.16 (m, 1H), 3.87 (s, 3H), 3.44-3.40 (m, 1H), 1.35 (s, 6H),
1.28 (d, J=6.6 Hz, 6H); LC/MS 505 [M+H.sup.4].
Example 36: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(4-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00070##
[0508] Step 1: Preparation of
N-(2-(3-((5-chloro-4-((4-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
[0509] The compound (70 mg, 0.19 mmol) prepared in preparative
example 10 and the compound (44.6 mg, 0.15 mmol) prepared in
preparative example 13 were dissolved in 0.08 M HCl-ethoxyethanol
(2.5 mL), followed by stirring at 100.degree. C. for 18 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
1 N HCl. The reaction mixture was extracted with ethylacetate.
[0510] The ethylacetate layer was washed with water and brine,
dried over sodium sulfate, and concentrated under reduced pressure.
Then, purification was performed by MPLC and recrystallization was
also performed by MC/Hex to give the target compound
N-(2-(3-((5-chloro-4-((4-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
(37 mg, 0.06 mmol, yield: 32%).
[0511] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.32 (s, 1H),
8.50-8.45 (m, 1H), 8.35 (s, 1H), 8.18 (s, 1H), 7.67 (dd, J=8.1, 3.0
Hz, 1H), 7.47 (s, 1H), 7.39-7.32 (m, 1H), 6.95-6.86 (m, 2H), 6.05
(br, s, 1H), 3.92 (s, 3H), 3.47 (d, J=5.7 Hz, 2H), 3.32-3.23 (m,
1H), 1.34 (d, J=6.9 Hz, 6H), 1.27 (s, 6H); LC/MS 618
[M+H.sup.+].
Step 2: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(4-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0512]
N-(2-(3-((5-chloro-4-((4-fluoro-2-(isopropylsulfonyl)phenyl)amino)p-
yrimidine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacet-
amide (37.0 mg, 0.06 mmol) prepared in step 1 was dissolved in
ethanol (2 mL), to which water (0.5 mL) containing potassium
carbonate (33.1 mg, 0.248 mmol) dissolved therein was added,
followed by stirring at 90.degree. C. for 3 hours. Upon completion
of the reaction, a new spot was formed under the starting material,
which was confirmed by TLC. Ethanol was concentrated under reduced
pressure, which was dissolved in MC. The reaction mixture was
washed with water and brine. The MC layer was dried over sodium
sulfate and concentrated under reduced pressure. Ether was added
thereto. 4 M HCl-dioxane was also added thereto, followed by
stirring for 1 hour. The generated solid was filtered and dried. As
a result, the target compound
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(4-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine was obtained
(20 mg, 0.04 mmol, yield: 65%).
[0513] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.29 (br, s, 1H),
8.21 (s, 1H), 7.78 (dd, J=51.5, 26.5 Hz, 1H), 7.55 (s, 1H),
7.50-7.47 (m, 2H), 7.22-7.20 (m, 1H), 3.90 (s, 3H), 3.50 (m, 1H),
3.16 (m, 2H), 1.40 (s, 6H), 1.32 (d, J=50 Hz, 6H); LC/MS 522
[M+H.sup.+].
Example 37: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(5-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00071##
[0514] Step 1: Preparation of
N-(2-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
[0515] The compound (70 mg, 0.19 mmol) prepared in preparative
example 11 and the compound (44.63 mg, 0.15 mmol) prepared in
preparative example 13 were dissolved in 0.08 M HCl-ethoxyethanol
(2.5 mL), followed by stirring at 100.degree. C. for 18 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
1 N HCl. The reaction mixture was extracted with ethylacetate.
[0516] The ethylacetate layer was washed with water and brine,
dried over sodium sulfate, and concentrated under reduced pressure.
Then, purification was performed by MPLC and recrystallization was
also performed by MC/Hex to give the target compound
N-(2-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
(20 mg, 0.03 mmol, yield: 17%).
[0517] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.31-8.27 (m, 2H),
8.17 (s, 1H), 7.82-7.80 (m, 1H), 7.49-7.44 (m, 3H), 6.85-6.81 (m,
2H), 5.98 (br, s, 1H), 3.88 (s, 3H), 3.41-3.38 (m, 2H), 3.16-3.12
(m, 1H), 1.29 (d, J=6.9 Hz, 6H), 1.21 (s, 6H); LC/MS 619
[M+H.sup.+].
Step 2: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(5-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0518]
N-(2-(3-((5-chloro-4-((5-fluoro-2-(isopropylsulfonyl)phenyl)amino)p-
yrimidine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacet-
amide (12.0 mg, 0.02 mmol) prepared in step 1 was dissolved in
ethanol (2 mL), to which water (0.5 mL) containing potassium
carbonate (11.0 mg, 0.08 mmol) dissolved therein was added,
followed by stirring at 90.degree. C. for 3 hours. Upon completion
of the reaction, a new spot was formed under the starting material,
which was confirmed by TLC. Ethanol was concentrated under reduced
pressure, which was dissolved in MC. The reaction mixture was
washed with water and brine. The MC layer was dried over sodium
sulfate and concentrated under reduced pressure. Ether was added
thereto. 4 M HCl-dioxane was also added thereto, followed by
stirring for 1 hour. The generated solid was filtered and dried. As
a result, the target compound
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(5-fluo-
ro-2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine was obtained
(12 mg, 0.02 mmol, yield: 80%).
[0519] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.19 (s, 1H),
7.90-7.89 (m, 1H), 7.74-7.69 (m, 2H), 7.41-7.38 (m, 2H), 7.13-7.11
(m, 1H), 3.87 (s, 3H), 3.45 (m, 1H), 3.11 (m, 2H), 1.36 (s, 6H),
1.28 (d, J=60.5 Hz, 6H); LC/MS 522 [M+H.sup.+].
Example 38: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-fluo-
ro-6-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00072##
[0520] Step 1: Preparation of
N-(2-(3-((5-chloro-4-((2-fluoro-6-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
[0521] The compound (70 mg, 0.19 mmol) prepared in preparative
example 12 and the compound (44.63 mg, 0.15 mmol) prepared in
preparative example 13 were dissolved in 0.08 M HCl-ethoxyethanol
(2.5 mL), followed by stirring at 100.degree. C. for 18 hours. Upon
completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
1 N HCl. The reaction mixture was extracted with ethylacetate. The
ethylacetate layer was washed with water and brine, dried over
sodium sulfate, and concentrated under reduced pressure. Then,
purification was performed by MPLC and recrystallization was also
performed by MC/Hex to give the target compound
N-(2-(3-((5-chloro-4-((2-fluoro-6-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacetamide
(19 mg, 0.03 mmol, yield: 16%).
[0522] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.31-8.27 (m, 2H),
8.17 (s, 1H), 7.82-7.80 (m, 1H), 7.49-7.42 (m, 3H), 6.85-6.81 (m,
2H), 5.98 (br, s, 1H), 3.88 (s, 3H), 3.41-3.39 (m, 2H), 3.17-3.12
(m, 1H), 1.29 (d, J=6.9 Hz, 6H), 1.21 (s, 6H); LC/MS 619
[M+H.sup.+].
Step 2: Preparation of
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-fluo-
ro-6-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0523]
N-(2-(3-((5-chloro-4-((2-fluoro-6-(isopropylsulfonyl)phenyl)amino)p-
yrimidine-2-yl)amino)-4-methoxyphenyl)-2-methylpropyl)-2,2,2-trifluoroacet-
amide (19.0 mg, 0.03 mmol) prepared in step 1 was dissolved in
ethanol (2 mL), to which water (0.5 mL) containing potassium
carbonate (17.0 mg, 0.12 mmol) dissolved therein was added,
followed by stirring at 90.degree. C. for 3 hours. Upon completion
of the reaction, a new spot was formed under the starting material,
which was confirmed by TLC. Ethanol was concentrated under reduced
pressure, which was dissolved in MC. The reaction mixture was
washed with water and brine. The MC layer was dried over sodium
sulfate and concentrated under reduced pressure. Ether was added
thereto. 4 M HCl-dioxane was also added thereto, followed by
stirring for 1 hour. The generated solid was filtered and dried. As
a result, the target compound
N2-(5-(1-amino-2-methylpropane-2-yl)-2-methoxyphenyl)-5-chloro-N4-(2-fluo-
ro-6-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine was obtained
(13 mg, 0.02 mmol, yield: 83%).
[0524] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.18 (s, 1H),
7.90-7.89 (m, 1H), 7.74-7.67 (m, 2H), 7.45 (s, 1H), 7.37-7.35 (m,
1H), 7.11-7.10 (m, 1H), 3.87 (s, 3H), 3.45 (m, 1H), 3.10 (m, 2H),
1.35 (s, 6H), 1.28 (d, J=60.5 Hz, 6H); LC/MS 522 [M+H.sup.+].
Example 39: Preparation of
2,2'-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamin-
o)-4-methoxyphenethylazeindiyl)diethanol
##STR00073##
[0526]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(50.0 mg, 0.105 mmol) was dissolved in dimethylformamide (1 mL), to
which cesium carbonate (85 mg, 0.26 mmol) and bromoethanol (19 mg,
0.16 mmol) were added at 0.degree. C., followed by stirring at room
temperature for 18 hours. Water was added thereto to terminate the
reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/1) to give the
target compound
2,2'-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamin-
o)-4-methoxyphenethylazeindiyl)diethanol as a white solid (13 mg,
yield: 24%).
[0527] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.55
(d, J=4.8 Hz, 8.21 (s, 1H), 8.16 (s, 1H), 7.96 (d, J=4.8 Hz, 1H),
7.68-7.65 (m, 1H), 7.61 (s, 1H), 6.86-6.80 (m, 2H), 4.77 (br, s,
1H), 4.20 (s, 2H), 3.91 (s, 3H), 3.80 (s, 2H), 3.35 (d, J=3.6 Hz,
2H), 3.32-3.27 (m, 1H), 2.72-2.69 (m, 2H), 2.32-2.31 (m, 1H), 1.34
(d, J=3.9 Hz, 6H); LC/MS (ESI) m/z 563.8 [M+H]+.
Example 40: Preparation of
N-(3-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide
##STR00074##
[0529] 2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)
pyrimidine-4-amine (100 mg, 0.29 mmol) was dissolved in 0.08M
HCl-ethoxyethanol (1 mL), to which the compound (80 mg, 0.29 mmol)
prepared in preparative example 14 was added, followed by stirring
at 80.degree. C. for hours. The temperature of the reaction
temperature was lowered to room temperature. The reaction mixture
was neutralized with sodium hydrogen carbonate aqueous solution,
followed by extraction twice with ethylacetate. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/1) to give the
target compound
N-(3-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide as a white
solid (0.48 g, 0.82 mmol, yield: 59%).
[0530] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.55
(d, J=8.7 Hz, 1H), 8.18 (s, 1H), 8.14 (s, 1H), 7.93 (d, J=8.1 Hz,
1H), 7.65 (t, J=7.2 Hz, 1H), 7.57 (s, 1H), 7.26-7.31 (m, 1H),
6.76-6.84 (m, 2H), 6.24 (br, 1H), 3.89 (s, 3H), 3.22-3.35 (m, 3H),
2.58 (t, J=7.2 Hz, 2H), 1.80 (pent, J=7.5 Hz, 2H), 1.31 (d, J=6.9
Hz, 6H); LC/MS 586.2 [M+H.sup.+].
Example 41: Preparation of
N2-(5-(3-aminopropyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)-
phenyl)pyrimidine-2,4-diamine
##STR00075##
[0532]
N-(3-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenyl)propyl)-2,2,2-trifluoroacetamide (0.1
g, 0.17 mmol) prepared in example 40 was dissolved in ethanol (2
mL), to which potassium carbonate (90 mg, 0.68 mmol) aqueous
solution (1 mL), followed by stirring at 90 for 2 hours. The
reaction mixture was distillated under reduced pressure, followed
by extraction twice with ethylacetate. The extracted organic layer
was dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/10) to give the target
compound
N2-(5-(3-aminopropyl)-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsulfonyl)-
phenyl)pyrimidine-2,4-diamine as a white solid (32 mg, 0.065 mmol,
yield: 76%).
[0533] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.49 (br, 1H),
8.53 (d, J=8.4 Hz, 1H), 8.18 (s, 1H), 8.12 (s, 1H), 7.93 (d, J=7.8
Hz, 1H), 7.59-7.67 (m, 2H), 7.24-7.28 (m, 1H), 6.79 (s, 2H), 3.88
(s, 3H), 3.26 (sept, J=6.9 Hz, 1H), 2.65 (t, J=6.6 Hz, 2H), 2.52
(t, J=7.5 Hz, 2H), 1.63 (pent, J=7.5 Hz, 2H), 1.31 (d, J=6.9 Hz,
6H); LC/MS 490.2 [M+H.sup.+].
Example 42: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetamide
##STR00076##
[0534] Step 1: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetonitrile
[0535]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(373.6 mg, 1.08 mmol) and the compound (140.0 mg, 0.86 mmol)
prepared in preparative example 15 were dissolved in 0.08 M
HCl-ethoxyethanol (10 mL), followed by stirring at 90.degree. C.
Upon completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, followed by neutralization with
sodium hydrogen carbonate. The water layer was extracted twice with
ethylacetate. The ethylacetate layer was washed with water and
brine, dried over sodium sulfate, and concentrated under reduced
pressure. Then, purification was performed by MPLC to give the
target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetonitrile (0.60 mg, 1.27 mmol, yield:
55%).
[0536] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.49
(d, J=8.4 Hz, 1H), 8.29 (s, 1H), 8.20 (s, 1H), 7.97-7.94 (m, 1H),
7.70-7.63 (m, 2H), 7.34-7.29 (m, 1H), 6.95-6.85 (m, 2H), 3.92 (s,
3H), 3.55 (s, 2H), 3.28-3.24 (m, 1H), 1.33 (d, J=6.9 Hz, 6H); LC/MS
472 [M+H.sup.+].
Step 2: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetamide
[0537] 2-(4-methoxyphenyl)acetonitrile (20 mg, 0.14 mmol),
acetaldoxime (39.2 g, 0.41 mmol), and Cu.sup.II-4A (20 mg) were
dissolved in methanol (2 mL), followed by stirring at 80.degree. C.
for 15 hours. The generated solid was filtered, which was washed
with methanol. The reaction mixture was concentrated under reduced
pressure and the solvent was filtered. Then, purification was
performed by MPLC to give the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetamide (13 mg, 0.03 mmol, yield: 66%).
[0538] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, 1H),
8.50-8.47 (m, 1H), 8.25 (s, 1H), 7.95-7.93 (m, 1H), 7.68-7.65 (m,
2H), 7.31-7.26 (m, 1H), 6.87 (m, 2H), 5.41-5.33 (m, 2H), 3.92 (s,
3H), 3.44 (s, 2H), 3.26-3.25 (m, 1H), 1.32 (d, J=6.9 Hz, 6H); LC/MS
490 [M+H.sup.+].
Example 43: Preparation of 2-ethoxyethyl
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetate
##STR00077##
[0540]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(0.81 g, 2.35 mmol) and the compound (0.34 g, 1.88 mmol) prepared
in preparative example 16 were dissolved in 0.08 M
HCl-ethoxyethanol (15 mL), followed by stirring at 90.degree. C.
Upon completion of the reaction, a new spot was formed under the
starting material, which was confirmed by TLC. Water was added
thereto to terminate the reaction, and the water layer was
extracted twice with ethylacetate. The ethylacetate layer was
washed with water and brine, dried over sodium sulfate, and
concentrated under reduced pressure. Then, purification was
performed by MPLC to give the target compound 2-ethoxyethyl
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetate (460 mg, 0.82 mmol, yield: 35%).
[0541] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.48 (s, 1H), 8.52
(d, J=8.4 Hz, 1H), 8.20-8.17 (m, 2H), 7.94 (d, J=8.4 Hz, 1H),
7.72-7.67 (m, 1H), 7.61 (s, 1H), 7.31-7.28 (m, 1H), 6.92-6.82 (m,
2H), 4.24-4.21 (m, 2H), 3.89 (s, 3H), 3.64-3.61 (m, 2H), 3.54-3.47
(m, 4H), 3.30-3.21 (m, 1H), 1.33 (d, J=6.9 Hz, 6H); LC/MS 563
[M+H.sup.+].
Example 44: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetic acid
[0542] Method 1
##STR00078##
[0543] The compound (0.40 g, 0.71 mmol) prepared in example 43 was
dissolved in methanol (120 mL), to which sodium hydroxide (0.37 g,
14.20 mmol) and water (40 mL) were added, followed by reaction.
Upon completion of the reaction, the reaction mixture was dissolved
in MC, which was acidized to pH 3 with concentrated hydrochloric
acid. The organic layer was washed with water and brine, dried over
sodium sulfate, and concentrated under reduced pressure. Then,
recrystallization was performed by MC/Hex to give the target
compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)acetic acid (0.21 g, 0.43 mmol, yield:
60%).
[0544] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.52 (s, 1H), 8.48
(d, J=7.8 Hz, 1H), 8.17 (m, 2H), 7.94 (d, J=7.8 Hz, 1H), 7.74-7.66
(m, 2H), 7.31-7.28 (m, 1H), 6.90-6.87 (m, 2H), 3.90 (s, 3H), 3.49
(m, 2H), 3.24-3.18 (m, 1H), 1.31 (d, J=6.9 Hz, 6H); LC/MS 491
[M+H.sup.+].
[0545] Method 2
##STR00079##
[0546]
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-4-methoxyphenyl)acetonitrile (100 mg, 0.20 mmol) was
dissolved in 1,4-dioxane, to which sulfuric acid (0.21 mL, 2.00
mmol) was added. The temperature thereof was raised to 100.degree.
C., followed by reaction for 3 days. Upon completion of the
reaction, the reaction mixture was concentrated under reduced
pressure, diluted with water, extracted with ethylacetate, washed
with sodium hydrogen carbonate, water and brine, and dried over
sodium carbonate. As a result, the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-methoxyphenyl)acetic acid was obtained (45 mg, 0.09
mmol, yield: 45%).
[0547] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.52 (s, 1H), 8.48
(d, J=7.8 Hz, 1H), 8.17 (m, 2H), 7.94 (d, J=7.8 Hz, 1H), 7.74 7 66
(m, 2H), 7.31-7 28 (m, 1H), 6.90-6.87 (m, 2H), 3.90 (S, 3H), 3.49
(m, 2H), 3.24-3.18 (m, 1H), 1.31 (d, J=6.9 Hz, 6H); LC/MS 491
[M+H.sup.+].
Example 45: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-morpholinoethane-1-one
##STR00080##
[0549]
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-methoxyphenyl)acetic acid (100 mg, 0.20 mmol) was dissolved
in dichloroethane (15 mL), to which EDCI
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; 47.4 mg, 0.31 mmol)
and DMAP (4-dimethylaminopyridine; cat. 2.4 mg, 0.02 mmol) were
added. Then, morpholine (0.026 mL, 0.31 mmol) was added thereto,
followed by stirring at room temperature overnight. Water was added
thereto to terminate the reaction. The reaction mixture was washed
with water and brine, and dried over magnesium sulfate. Then,
purification was performed by MPLC to give the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-morpholinoethane-1-one (45 mg, 0.08 mmol,
yield: 63.0%).
[0550] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H),
8.59-8.56 (m, 1H), 8.20-8.17 (m, 2H), 7.94-7.92 (m, 1H), 7.69-7.64
(m, 1H), 7.56 (s, 1H), 7.26 (m, 1H), 6.85 (m, 2H), 3.90 (s, 3H),
3.64-3.61 (m, 6H), 3.50 (m, 2H), 3.41 (m, 2H), 3.28-3.23 (m, 1H),
1.33 (d, J=6.6 Hz, 6H); LC/MS (ESI) m/z 504.2 [M+H.sup.+].
Example 46: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperidine-1-yl)ethane-1-one
##STR00081##
[0552]
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-methoxyphenyl)acetic acid (100 mg, 0.20 mmol) was dissolved
in dichloroethane (15 mL), to which EDCI (47.4 mg, 0.31 mmol) and
DMAP (cat. 2.4 mg, 0.02 mmol) were added. Then, morpholine (0.026
mL, 0.31 mmol) was added thereto, followed by reaction at room
temperature. Water was added thereto to terminate the reaction. The
reaction mixture was washed with water and brine, and dried over
magnesium sulfate. Then, purification was performed by MPLC to give
the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperidine-1-yl)ethane-1-one (26 mg, 0.05
mmol, yield: 36%).
[0553] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, 1H),
8.57-8.55 (m, 1H), 8.17 (s, 2H), 7.94-7.91 (m, 1H), 7.70-7.64 (m,
1H), 7.56 (s, 1H), 7.27-7.23 (m, 1H), 6.85 (m, 2H), 3.89 (s, 3H),
3.58-3.55 (m, 4H), 3.30-3.34 (m, 2H), 3.28-3.21 (m, 1H), 1.50-1.56
(m, 4H), 1.37-1.31 (m, 2H), 1.33 (d, J=6.9 Hz, 6H); LC/MS (ESI) m/z
559 [M+H.sup.+].
Example 47: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(hydroxymethyl)acetamide
##STR00082##
[0555]
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-methoxyphenyl)acetic acid (100 mg, 0.20 mmol) was dissolved
in dichloroethane (15 mL), to which EDCI (47.4 mg, 0.31 mmol) and
DMAP (cat. 2.4 mg, 0.02 mmol) were added. Then, ethanolamine (0.019
mL, 0.31 mmol) was added thereto, followed by reaction at room
temperature. Water was added thereto to terminate the reaction. The
reaction mixture was washed with water and brine, and dried over
magnesium sulfate. Then, purification was performed by MPLC to give
the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(hydroxymethyl)acetamide (50 mg, 0.010 mmol,
yield: 72%).
[0556] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.57 (s, 1H),
8.53-8.51 (m, 1H), 8.20-8.17 (m, 2H), 7.95-7.92 (m, 1H), 7.70-7.65
(m, 1H), 7.59 (s, 1H), 7.33-7.26 (m, 1H), 6.87 (m, 2H), 5.90 (br,
s, 1H), 3.92 (s, 3H), 3.66 (m, 2H), 3.48 (m, 2H), 3.36-3.34 (m,
2H), 3.27-3.22 (m, 1H), 2.81 (br, s, 1H), 1.33 (d, J=6.6 Hz, 6H);
LC/MS (ESI) m/z 504.2 [M+H.sup.4].
Example 48: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperazine-1-yl)ethane-1-one
##STR00083##
[0557] Step 1: Preparation of
1-(4-(2-(3-((5-chloro-4-((2-(isopropylsulfonyl phenyl amino
pyrimidine-2-yl)amino)-4-methoxyphenyl) acetyl
piperazine-1-yl-2,2,2-trifluoroethane-1-one
[0558]
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-methoxyphenyl)acetic acid (1000 mg, 0.204 mmol) and the
compound (45 mg, 0.24 mmol) prepared in preparative example 17 were
dissolved in dichloromethane (2 mL), to which EDCI.HCl (59 mg, 0.31
mmol) and DMAP (2 mg) were added, followed by stirring at room
temperature for 15 hours. Water was added thereto to terminate the
reaction, followed by extraction twice with dichloromethane. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/1o) to give the
target compound
1-(4-(2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-4-methoxyphenyl)acetyl)piperazine-1-yl)-2,2,2-trifluoroethane-1--
one as a white solid (95 mg, yield: 71%).
[0559] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.59 (s, 1H), 8.58
(d, J=8.1 Hz, 1H), 8.24 (s, 1H), 8.16 (s, 1H), 7.93 (d, J=7.5 Hz,
1H), 7.67 (t, J=7.5 Hz, 1H), 7.55 (s, 1H), 7.23-7.29 (m, 1H), 3.90
(s, 3H), 3.67 (br, 5H), 3.39-3.55 (m, 5H), 3.25 (hept, J=6.9 Hz,
1H), 1.32 (d, J=6.9 Hz, 6H); LC/MS 655.3 [M+H].sup.+.
Step 2: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperazine-1-yl)ethane-1-one
[0560]
1-(4-(2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-4-methoxyphenyl)acetyl)piperazine-1-yl)-2,2,2-trifluoroeth-
ane-1-one (50 mg, 0.076 mmol) prepared in step 1 was dissolved in
ethanol (2 mL), to which potassium carbonate (42 mg, 0.31 mmol)
aqueous solution (1 mL) was added, followed by stirring at
90.degree. C. for 10 minutes. The reaction mixture was distillated
under reduced pressure, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-1-(piperazine-1-yl)ethane-1-one as a white
solid (35 mg, yield: 83%).
[0561] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.56
(d, J=8.4 Hz, 1H), 8.18 (br, 2H), 7.92 (d, J=7.8 Hz, 1H), 7.67 (t,
J=7.8 Hz, 1H), 7.56 (s, 1H), 7.23-7.28 (m, 1H), 6.85 (s, 2H), 3.89
(s, 3H), 3.59 (br, 4h), 3.83 (br, 2H), 3.26 (hept, J=6.6 Hz, 1H),
2.82 (br, 2H), 2.69 (br, 2H), 1.32 (d, J=6.6 Hz, 6H); LC/MS 559.2
[M+H].sup.+.
Example 49: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(pyridine-4-yl)acetamide
##STR00084##
[0563]
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-methoxyphenyl)acetic acid (100 mg, 0.20 mmol) was dissolved
in dichloroethane (15 mL), to which EDCI (47.4 mg, 0.31 mmol) and
DMAP (cat. 2.4 mg, 0.02 mmol) were added. Then, aminopyridine
(0.019 mL, 0.31 mmol) was added thereto, followed by reaction at
room temperature. Water was added thereto to terminate the
reaction. The reaction mixture was washed with water and brine, and
dried over magnesium sulfate. Then, purification was performed by
MPLC to give the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-(pyridine-4-yl)acetamide
[0564] (35 mg, 0.06 mmol, yield: 31%).
[0565] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, 1H),
8.49-8.41 (m, 3H), 8.30 (s, 1H), 8.16 (s, 1H), 7.93-7.91 (m, 1H),
7.67-7.61 (m, 2H), 7.41-7.36 (m, 3H), 7.26 (m, 1H), 6.91 (s, 2H),
3.94 (s, 3H), 3.62 (s, 2H), 3.20-3.17 (m, 1H), 1.28 (m, 6H); LC/MS
(ESI) m/z 548 [M+H.sup.+].
Example 50: Preparation of
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-phenylacetamide
##STR00085##
[0567]
2-(3-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-methoxyphenyl)acetic acid (100 mg, 0.20 mmol) was dissolved
in dichloroethane (15 mL), to which EDCI (47.4 mg, 0.31 mmol) and
triethanolamine (0.06 mL, 0.31 mmol) were added. Then,
aminopyridine (0.019 mL, 0.31 mmol) was added thereto, followed by
reaction at room temperature. Water was added thereto to terminate
the reaction. The reaction mixture was washed with water and brine,
and dried over magnesium sulfate. Then, purification was performed
by MPLC to give the target compound
2-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxyphenyl)-N-phenylacetamide (34 mg, 0.06 mmol, yield:
28%).
[0568] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.48 (s, 1H),
8.46-8.43 (m, 1H), 8.30 (s, 1H), 8.16 (s, 1H), 7.92-7.90 (m, 1H),
7.69-7.62 (m, 2H), 7.39-7.37 (m, 2H), 7.32-7.23 (m, 2H), 7.13 (br,
s, 1H), 7.09-7.04 (m, 1H), 6.91 (s, 2H), 3.94 (s, 3H), 3.57 (s,
2H), 3.19-3.12 (m, 1H), 1.26 (d, J=6.6 Hz, 6H); LC/MS (ESI) m/z 565
[M+H.sup.+].
Example 51: Preparation of
N2-(5-(2-aminoethyl)-4-bromo-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine
##STR00086##
[0569] Step 1: Preparation of
N-(2-bromo-5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine--
2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
[0570]
N-(2-bromo-5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrim-
idine-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide (50
mg, 0.14 mmol) and
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(60.0 mg, 0.17 mmol) were added to 0.08 M HCl.ethoxyethanol (1.6
mL), which was heated at 90 overnight. Ethoxyethanol was removed
from the reaction mixture. Sodium hydrogen carbonate aqueous
solution was added thereto, followed by extraction with
ethylacetate. The organic layer was washed with brine, dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure. Then, column chromatography was performed (eluent:
ethylacetate/hexane, 1/2) to give the target compound
N-(2-bromo-5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine--
2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide as a
yellow solid (48.0 mg, 0.07 mmol, yield: 52%).
[0571] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.62 (s, 1H), 8.51
(d, J=8.4 Hz, 1H), 8.30 (s, 1H), 8.20 (s, 1H), 7.96 (dd, J=7.8, 1.2
Hz, 1H), 7.67 (t, J=7.2 Hz, 1H), 7.50 (s, 1H), 7.32 (t, J=6.9 Hz,
1H), 7.07 (s, 1H), 6.33 (s, 1H), 3.93 (s, 3H), 3.58-3.50 (m, 2H),
3.33-3.24 (m, 2H), 2.92 (t, J=6.9 Hz, 2H), 1.34 (d, J=6.9 Hz, 6H);
LC/MS 650.00 [M+H.sup.+].
Step 2: Preparation of
N2-(5-(2-aminoethyl)-4-bromo-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine
[0572]
N-(2-bromo-5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrim-
idine-2-yl)amino)-4-methoxyphenethyl)-2,2,2-trifluoroacetamide
(30.0 mg, 0.06 mmol) prepared in step 1 was dissolved in
tetrahydrofuran (2 mL), to which water (1 mL) containing lithium
hydroxide dissolved therein and methanol (1 mL) were added,
followed by stirring at room temperature for 4 hours. The reaction
mixture was extracted with ethylacetate, washed with brine, dried
over magnesium sulfate, filtered, and concentrated under reduced
pressure. Then, column chromatography was performed (eluent:
ethylacetate/hexane, 3/1) to give the target compound
N2-(5-(2-aminoethyl)-4-bromo-2-methoxyphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine as a yellow solid (13 mg, 0.02
mmol, yield: 32%).
[0573] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, 1H), 8.50
(d, J=8.7 Hz, 1H), 8.21 (s, 1H), 8.17 (s, 1H), 7.93 (dd, J=7.8, 1.5
Hz, 1H), 7.66 (t, J=1.2 Hz, 1H), 7.45 (s, 1H), 7.30 (d, J=7.2 Hz,
1H), 7.03 (s, 1H), 3.88 (s, 1H), 3.29-3.20 (m, 1H), 2.87 (d, J=5.7
Hz, 2H), 2.81 (d, J=6.3 Hz, 2H), 1.30 (d, J=6.9 Hz, 6H); LC/MS
554.06 [M+H.sup.+].
Example 52: Preparation of
N2-(5-(2-aminoethyl)-2-methoxy-4-(1-methyl-1H-pyrazole-4-yl)phenyl)-5-chl-
oro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00087##
[0574] Step 1: Preparation of
N-(5-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxy-2-(1-methyl-1-pyrazole-4-yl)phenethyl)-2,2,2-trifluoroacetamide
[0575] The compound (30 mg, 0.09 mmol) prepared in preparative
example 19 and
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(36.0 mg, 0.11 mmol) were dissolved in 0.08 M HCl.ethoxyethanol
(1.6 mL), which was heated at 100.degree. C. overnight.
Ethoxyethanol was removed from the reaction mixture, followed by
extraction with ethylacetate. The organic layer was washed with
brine, dried over magnesium sulfate, filtered, and concentrated
under reduced pressure. Then, purification was performed by silica
gel column chromatography (eluent: ethylacetate/hexane, 4/1) to
give the target compound
N-(5-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamino)--
4-methoxy-2-(1-methyl-1H-pyrazole-4-yl)phenethyl)-2,2,2-trifluoroacetamide
(30.0 mg, 0.05 mmol, yield: 53%).
[0576] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.61 (s, 1H), 8.58
(d, J=8.1 Hz, 1H), 8.28 (s, 1H), 8.21 (s, 1H), 7.96 (d, J=7.8 Hz,
1H), 7.68 (t, J=7.8 Hz, 1H), 7.59 (s, 1H), 7.55 (s, 1H), 7.50 (s,
1H), 7.28 (t, J=6.6 Hz, 1H), 6.82 (s, 1H), 6.24 (s, 1H), 4.00 (s,
3H), 3.93 (s, 3H), 3.40-3.52 (m, 2H), 2.89 (t, J=6.9 Hz, 2H), 2.15
(s, 1H), 1.35 (d, J=6.9 Hz, 6H)
Step 2: Preparation of
N2-(5-(2-aminoethyl)-2-methoxy-4-(1-methyl-1H-pyrazole-4-yl)phenyl)-5-chl-
oro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0577]
N-(5-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-methoxy-2-(1-methyl-1H-pyrazole-4-yl)phenethyl)-2,2,2-trifluoroace-
tamide (30.0 mg, 0.05 mmol) prepared in step 1 was dissolved in
tetrahydrofuran (1 mL), to which water (0.5 mL) containing lithium
hydroxide dissolved therein was added, followed by stirring at room
temperature for 3 hours with methanol (0.5 mL). The reaction
mixture was extracted twice ethylacetate. The organic layer was
washed with brine, dried over magnesium sulfate, filtered, and
concentrated under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 3/1) to give the target compound
N2-(5-(2-aminoethyl)-2-methoxy-4-(1-methyl-1H-pyrazole-4-yl)phen-
yl)-5-chloro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
(7.00 mg, 0.01 mmol, yield: 27%).
[0578] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.23 (s, 2H), 8.03
(d, J=7.8 Hz, 1H), 7.90 (s, 1H), 7.79-7.65 (m, 2H), 7.56 (t, J=7.5
Hz, 1H), 7.40 (s, 1H), 7.06 (s, 1H), 4.00 (s, 3H), 3.86 (s, 3H),
3.53-3.36 (m, 1H), 2.98 (s, 4H), 1.27 (d, J=5.4 Hz, 6H); LC/MS
556.2 [M+H.sup.+].
Example 53: Preparation of
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)acetonitrile
##STR00088##
[0580]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (472
mg, 1.36 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (1.0 mL),
to which the compound (200 mg, 1.13 mmol) prepared in preparative
example 20 was added, followed by stirring at 80.degree. C. for 12
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-5-methoxy-2-methylphenyl)acetonitrile as a white solid
(450 mg, 0.926 mmol, yield: 81%).
[0581] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, br, 1H),
8.53 (d, J=8.3 Hz, 1H), 8.18 (s, 1H), 8.13 (s, 1H), 7.94 (d, J=7.9
Hz, 1H), 7.64 (t, J=8.4 Hz, 1H), 7.55 (s, br, 1H), 7.28 (t, J=7.8
Hz, 1H), 6.86 (s, 1H), 3.91 (s, 3H), 3.63 (s, 2H), 3.26 (sept,
J=6.9 Hz, 1H), 2.17 (s, 3H), 1.31 (d, J=6.9 Hz, 6H); LC/MS 485.9
[M+H.sup.+].
Example 54: Preparation of
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)-2-methylpropanenitrile
##STR00089##
[0583]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (472
mg, 1.36 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (1.0 mL),
to which the compound (200 mg, 0.979 mmol) prepared in preparative
example 21 was added, followed by stirring at 80.degree. C. for 12
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-5-methoxy-2-methylphenyl)-2-methylpropanenitrile as a
white solid (433 mg, 0.875 mmol, yield: 86%).
[0584] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, br, 1H),
8.52 (d, J=8.3 Hz, 1H), 8.18 (s, 1H), 8.12 (s, 1H), 7.94 (d, J=7.9
Hz, 1H), 7.66 (t, J=7.3 Hz, 1H), 7.53 (s, br, 1H), 7.28 (t, J=7.8
Hz, 1H), 6.83 (s, 1H), 3.90 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H),
2.44 (s, 3H), 1.79 (s, 6H), 1.32 (d, J=6.9 Hz, 6H); LC/MS 513.8
[M+H.sup.+].
Example 55: Preparation of
N2-(4-(2-aminoethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropyls-
ulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00090##
[0586]
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-5-methoxy-2-methylphenyl)acetonitrile (200 mg, 0.411
mmol) was dissolved in tetrahydrofuran (2 mL), to which 1.0 M
BH.sub.3/THF (boran/tetrahydrofuran; 177 mg, 2.06 mmol) was added
at 0.degree. C., followed by stirring at room temperature for 12
hours. Methanol was added thereto to terminate the reaction, which
was distillated under reduced pressure. 1.5 N HCl (25.0 mL) was
added thereto, followed by extraction twice with ethylacetate. The
water layer was basified with sodium hydroxide aqueous solution,
followed by extraction twice with ethylacetate. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/9) to give the
target compound
N2-(4-(2-aminoethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(i-
sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as a yellow solid
(90.0 mg, 0.185 mmol, yield: 45%).
[0587] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.51 (s, br, 1H),
8.57 (d, J=8.3 Hz, 1H), 8.15 (s, 1H), 8.01 (s, 1H), 7.92 (d, J=7.9
Hz, 1H), 7.63 (t, J=8.4 Hz, 1H), 7.48 (s, br, 1H), 7.26 (t, J=6.5
Hz, 1H), 6.69 (s, 1H), 3.87 (s, 3H), 3.25 (sept, J=6.9 Hz, 1H),
2.94 (t, J=6.7 Hz, 2H), 2.75 (t, J=7.0 Hz, 2H), 2.17 (s, 5H), 1.31
(d, J=6.9 Hz, 6H); LC/MS 489.8 [M+H.sup.+].
Example 56: Preparation of
N2-(4-(1-amino-2-methylpropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N-
4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00091##
[0589]
2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-5-methoxy-2-methylphenyl)-2-methylpropanenitrile (100 mg,
0.194 mmol) was dissolved in tetrahydrofuran (2 mL), to which 1.0 M
BH.sub.3/THF (boran/tetrahydrofuran; 83.6 mg, 0.972 mmol) was added
at 0.degree. C., followed by stirring at room temperature for 12
hours. Methanol was added thereto to terminate the reaction, which
was distillated under reduced pressure. 1.5 N HCl (15 mL) was added
thereto, followed by extraction twice with ethylacetate. The water
layer was basified with sodium hydroxide aqueous solution, followed
by extraction twice with ethylacetate. The extracted organic layer
was dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
N2-(4-(1-amino-2-methylpropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N-
4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white
solid (45.0 mg, 0.087 mmol, yield: 45%).
[0590] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.51 (s, br, 1H),
8.57 (d, J=8.4 Hz, 1H), 8.16 (s, 1H), 7.99 (s, 1H), 7.93 (d, J=8.0
Hz, 1H), 7.63 (t, J=8.4 Hz, 1H), 7.46 (s, br, 1H), 7.26 (t, J=6.9
Hz, 1H), 6.87 (s, 1H), 3.88 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H),
2.96 (s, 2H), 2.34 (s, 3H), 1.39 (s, 6H), 1.31 (d, J=6.9 Hz, 6H),
1.26 (s, br, 2H); LC/MS 517.7 [M+H+.sup.].
Example 57: Preparation of
N2-(4-(2-aminopropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00092##
[0591] Step 1: Preparation of
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)propane-2-yl)-2,2,2-trifluoroacetamide
[0592]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine
(77.3 mg, 0.223 mmol) was dissolved in 0.08 M HCl.ethoxyethanol
(0.5 mL), to which the compound (54.0 mg, 0.186 mmol) prepared in
preparative example 22 was added, followed by stirring at
80.degree. C. for 12 hours. The reaction mixture was cooled to room
temperature, neutralized with sodium hydrogen carbonate aqueous
solution, and extracted twice with ethylacetate. The extracted
organic layer was dried over sodium sulfate and then filtered. The
solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by silica gel column
chromatography (eluent: ethylacetate/hexane, 2/3) to give the
target compound
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-5-methoxy-2-methylphenyl)propane-2-yl)-2,2,2-trifluoroacet-
amide as a white solid (83.0 mg, 0.138 mmol, yield: 74%).
[0593] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, br, 1H),
8.55 (d, J=8.4 Hz, 1H), 8.19 (s, 1H), 8.08 (s, 1H), 7.95 (d, J=7.9
Hz, 1H), 7.64 (t, J=8.5 Hz, 1H), 7.53 (s, br, 1H), 7.28 (t, J=8.5
Hz, 1H), 6.94 (s, 1H), 6.42 (s, br, 1H), 3.93 (s, 3H), 3.28 (sept,
J=6.9 Hz, 1H), 2.29 (s, 1H), 1.87 (s, 6H), 1.34 (d, J=6.9 Hz, 6H);
LC/MS 599.7 [M+H.sup.+].
Step 2: Preparation of
N2-(4-(2-aminopropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0594]
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-5-methoxy-2-methylphenyl)propane-2-yl)-2,2,2-trifluoroacetami-
de (73.0 mg, 0.121 mmol) prepared in step 1 was dissolved in
tetrahydrofuran (4.0 mL), methanol (2.0 mL) and water (1.0 mL), to
which lithium hydroxide hydrate (127 mg, 3.03 mmol) was added,
followed by stirring at 40.degree. C. for 24 hours. The reaction
mixture was distillated under reduced pressure, followed by
extraction twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/10) to give the target
compound
N2-(4-(2-aminopropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(iso-
propylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid (25.0
mg, 0.049 mmol, yield: 40%).
[0595] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.50 (s, br, 1H),
8.57 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 8.00 (s, 1H), 7.93 (d, J=7.9
Hz, 1H), 7.63 (t, J=7.3 Hz, 1H), 7.48 (s, br, 1H), 7.26 (t, J=6.9
Hz, 1H), 7.15 (s, 1H), 3.89 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H),
2.43 (s, 2H), 1.76 (s, br, 2H), 1.58 (s, 6H), 1.31 (d, J=6.9 Hz,
1H); LC/MS 504.0 [M+H.sup.+].
Example 58: Preparation of
5-chloro-N2-(4-(2-(dimethylamino)ethyl)-2-methoxy-5-methylphenyl)-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00093##
[0597]
N2-(4-(2-aminoethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isop-
ropylsulfonyl)phenyl)pyrimidine-2,4-diamine (25.0 mg, 0.051 mmol)
was dissolved in methanol (1.0 mL), to which acetic acid and
formalin (35%) (4.37 mg, 0.051 mmol) were added at 0.degree. C.,
followed by stirring at room temperature for 30 minutes.
Sodiumcyanoborohydride (4.80 mg, 0.076 mmol) was added thereto,
followed by stirring at room temperature for 30 minutes. Sodium
hydrogen carbonate aqueous solution was added thereto to terminate
the reaction, followed by extraction twice with ethylacetate. The
extracted organic layer was dried over sodium sulfate and then
filtered. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/9) to give the
target compound
5-chloro-N2-(4-(2-(dimethylamino)ethyl)-2-methoxy-5-methylphenyl-
)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white
solid (20.0 mg, 0.039 mmol, yield: 77%).
[0598] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, br, 1H),
8.58 (d, J=8.3 Hz, 1H), 8.18 (s, 1H), 8.05 (s, 1H), 7.95 (d, J=8.0
Hz, 1H), 7.66 (t, J=8.5 Hz, 1H), 7.51 (s, br, 1H), 7.29 (t, J=7.5
Hz, 1H), 6.73 (s, 1H), 3.90 (s, 3H), 3.28 (sept, J=6.9 Hz, 1H),
2.87-2.84 (m, 2H), 2.69-2.66 (m, 2H), 2.51 (s, 6H), 2.20 (s, 3H),
1.32 (d, J=6.9 Hz, 6H); LC/MS 518.0 [M+H.sup.+].
Example 59: Preparation of
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)-2-methylpropyl)formamide
##STR00094##
[0600]
N2-(4-(1-amino-2-methylpropane-2-yl)-2-methoxy-5-methylphenyl)-5-ch-
loro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (80.0
mg, 0.154 mmol) was dissolved in ethylformate (3 mL), followed by
reflux-stirring at 60.degree. C. for 4 hours. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)-2-methylpropyl)formamide as a
white solid (80.0 mg, 0.146 mmol, yield: 94%).
[0601] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, br,
0.7H), 9.51 (s, br, 0.2H), 8.56 (d, J=8.3 Hz, 1H), 8.16 (s, 1H),
8.11 (s, br, 1H), 8.04 (s, 1H), 7.93 (d, J=7.7 Hz, 1H), 7.63 (t,
J=8.3 Hz, 1H), 7.48 (s, br, 1H), 7.26 (t, J=8.3 Hz, 1H), 6.86 (s,
0.8H), 6.78 (s, 0.2H), 5.20 (s, br, 1H), 3.88 (s, 2H), 3.87 (s,
1H), 3.67 (d, J=5.9 Hz, 1.6H), 3.48 (d, J=6.6 Hz, 0.4H), 3.26
(sept, J=6.9 Hz, 1H), 2.36 (s, 2.3H), 2.34 (s, 0.7H), 1.44 (s, 6H),
1.31 (d, J=6.9 Hz, 6H); LC/MS 546.0 [M+H.sup.+].
Example 60: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-met-
hyl-1-(methylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine
##STR00095##
[0603]
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-5-methoxy-2-methylphenyl)-2-methylpropyl)formamide
(54.0 mg, 0.098 mmol) was dissolved in tetrahydrofuran (5.0 mL), to
which lithium aluminum hydride (37.5 mg, 0.988 mmol) was added,
followed by stirring at 60.degree. C. for 12 hours. Water and
sodium hydroxide aqueous solution were added thereto to terminate
the reaction. The reaction mixture was filtered, and the filtrate
was extracted twice with ethylacetate. The solvent was eliminated
by distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/9) to give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-met-
hyl-1-(methylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine as a
white solid (10.0 mg, 0.018 mmol, yield: 20%).
[0604] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.51 (s, br, 1H),
8.57 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 7.97 (s, 1H), 7.92 (d, J=7.9,
1H), 7.63 (t J=7.2, 1H), 7.45 (s, br, 1H), 7.26 (t, J=7.2 Hz, 1H),
6.90 (s, 1H), 3.87 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H), 2.85 (s,
2H), 2.39 (s, 3H), 2.34 (s, 3H), 1.45 (s, 6H), 1.31 (d, J=6.9 Hz,
6H), 1.25 (s, br, 1H); LC/MS 531.7 [M+H.sup.+].
Example 61: Preparation of
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)-
amino)-5-methoxy-2-methylphenyl)propane-2-yl)formamide
##STR00096##
[0606]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (280
mg, 0.809 mmol) was dissolved in 0.08 M HCl-ethoxyethanol (1 mL),
to which the compound (150 mg, 0.674 mmol) prepared in preparative
example 23 was added, followed by stirring at 80.degree. C. for 12
hours. The reaction mixture was cooled to room temperature,
neutralized with sodium hydrogen carbonate aqueous solution, and
extracted twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: ethylacetate/hexane, 2/3) to give the target compound
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimid-
ine-2-yl)amino)-5-methoxy-2-methylphenyl)propane-2-yl)formamide as
a white solid (197 mg, 0.371 mmol, yield: 55%).
[0607] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.52 (s, br,
0.6H), 9.49 (s, br, 0.3H), 8.53 (t, J=7.7 Hz, 1H), 8.18 (s, 0.6H),
8.16 (s, 0.4H), 8.13 (s, 0.4H), 8.08 (s, 0.6H), 8.03-8.01 (m,
0.7H), 7.96 (s, 0.3H), 7.93 (d, J=8.0 Hz, 1H), 7.63 (t, J=7.7 Hz,
1H), 7.53 (s, br, 0.6H), 7.50 (s, br, 0.4H), 7.29-7.28 (m, 0.5H),
7.24-7.23 (m, 0.5H), 6.93 (s, 0.4H), 6.92 (s, 0.6H), 6.05-6.01 (m,
0.6H), 5.63 (s, br, 0.4H), 3.90 (s, 1.9H), 3.89 (s, 1.1H), 3.26
(sept, J=6.9 Hz, 1H), 2.32 (s, 1H), 2.29 (s, 2H), 1.81 (s, 2H),
1.73 (s, 4H), 1.31 (d, J=6.9 Hz, 6H); LC/MS 532.0 [M+H.sup.+].
Example 62: Preparation of
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenethyl)formamide
##STR00097##
[0609]
N2-(4-(2-aminoethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isop-
ropylsulfonyl)phenyl)pyrimidine-2,4-diamine (250 mg, 0.510 mmol)
was dissolved in ethylformate (10 mL), followed by reflux-stirring
at 60 for 4 hours. The solvent was eliminated by distillation under
reduced pressure. Then, purification was performed by silica gel
column chromatography (eluent: methanol/dichloromethane, 1/9) to
give the target compound
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-5-methoxy-2-methylphenethyl)formamide as a white solid
(200 mg, 0.386 mmol, yield: 76%).
[0610] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.52 (s, br, 1H),
8.57 (d, J=8.4 Hz, 1H), 8.18 (s, 1H), 8.16 (s, 1H), 8.06 (s, 1H),
7.93 (d, J=6.5 Hz, 1H), 7.63 (t, J=8.4 Hz, 1H), 7.49 (s, br, 1H),
7.29 (t, J=9.9 Hz, 1H), 6.68 (s, 0.8H), 6.61 (s, 0.2H), 5.54 (s,
br, 1H), 3.87 (s, 3H), 3.53 (q, J=6.8 Hz, 1.7H), 3.44-0.342 (m,
0.4H), 3.26 (sept, J=6.9 Hz, 1H), 2.82 (t, J=7.2 Hz, 2H), 2.18 (s,
3H), 1.31 (d, J=6.9 Hz, 6H); LC/MS 517.7 [M+H.sup.4].
Example 63: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)ethyl)phenyl)pyrimidine-2,4-diamine
##STR00098##
[0612]
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-5-methoxy-2-methylphenethyl)formamide (180 mg, 0.347
mmol) was dissolved in tetrahydrofuran (15.0 mL), to which lithium
aluminum hydride (132 mg, 3.47 mmol) was added, followed by
stirring at 60.degree. C. for 12 hours. Water and sodium hydroxide
aqueous solution were added thereto to terminate the reaction. The
reaction mixture was filtered, and the filtrate was extracted twice
with ethylacetate. The solvent was eliminated by distillation under
reduced pressure. Then, purification was performed by silica gel
column chromatography (eluent: methanol/dichloromethane, 1/9) to
give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)ethyl)phenyl)pyrimidine-2,4-diamine as a white solid
(30.0 mg, 0.059 mmol, yield: 17%).
[0613] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.51 (s, br, 1H),
8.57 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 8.00 (s, 1H), 7.92 (d, J=7.9
Hz, 1H), 7.63 (t, J=8.4 Hz, 1H), 7.48 (s, br, 1H), 7.26 (t, J=7.3
Hz, 1H), 6.70 (s, 1H), 3.86 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H),
2.79 (s, 4H), 2.47 (s, 3H), 2.18 (s, 3H), 1.77 (s, br, 1H), 1.31
(d, J=6.9 Hz, 6H); LC/MS 504.0 [M+H.sup.+].
Example 64: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine
##STR00099##
[0615]
N-(2-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-5-methoxy-2-methylphenyl)propane-2-yl)formamide (170
mg, 0.319 mmol) was dissolved in tetrahydrofuran (15.0 mL), to
which lithium aluminum hydride (121 mg, 3.19 mmol) was added,
followed by stirring at 60.degree. C. for 12 hours. Water and
sodium hydroxide aqueous solution were added thereto to terminate
the reaction. The reaction mixture was filtered, and the filtrate
was extracted twice with ethylacetate. The solvent was eliminated
by distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/9) to give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-(2-(me-
thylamino)propane-2-yl)phenyl)pyrimidine-2,4-diamine as a yellow
solid (45.0 mg, 0.086 mmol, yield: 27%).
[0616] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.51 (s, br, 1H),
8.57 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.93 (d, J=7.9
Hz, 1H), 7.63 (t, J=8.3 Hz, 1H), 7.48 (s, br, 1H), 7.26 (t, J=6.2
Hz, 1H), 6.93 (s, 1H), 3.88 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H),
2.40 (s, 3H), 2.16 (s, 3H), 1.74 (s, br, 1H), 1.52 (s, 6H), 1.31
(d, J=6.9 Hz, 6H); LC/MS 520.0 [M+H.sup.+].
Example 65: Preparation of
5-chloro-N2-(4-(1-(dimethylamino)-2-methylpropane-2-yl)-2-methoxy-5-methy-
lphenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00100##
[0618]
N2-(4-(1-amino-2-methylpropane-2-yl)-2-methoxy-5-methylphenyl)-5-ch-
loro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0619] (40.0 mg, 0.077 mmol) and diisopropylethylamine (24.9 mg,
0.192 mmol) were dissolved in dimethylformamide (1.0 mL), to which
methyliodide (21.9 mg, 0.154 mmol) was added, followed by stirring
at 80.degree. C. for 10 minutes in a microwave reactor. The spot of
the starting material was disappeared, which was confirmed by TLC.
Water (10 ml) was added thereto to terminate the reaction, followed
by extraction twice with ethylacetate (15 ml). The organic layer
was washed with brine. The solvent was eliminated by distillation
under reduced pressure. Then, purification was performed by silica
gel column chromatography (eluent: methanol/dichloromethane, 1/9)
to give the target compound
5-chloro-N2-(4-(1-(dimethylamino)-2-methylpropane-2-yl)-2-methoxy-5-methy-
lphenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as
a yellow solid (20.0 mg, 0.036 mmol, yield: 47%).
[0620] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.49 (s, br, 1H),
8.57 (d, J=8.3 Hz, 1H), 8.15 (s, 1H), 7.95 (s, 1H), 7.92 (d, J=8.0
Hz, 1H), 7.63 (t, J=8.4 Hz, 1H), 7.46 (s, br, 1H), 7.26 (t, J=7.6
Hz, 1H), 6.94 (s, 1H), 3.88 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H),
2.60 (s, 2H), 2.36 (s, 3H), 2.11 (s, 6H), 1.44 (s, 6H), 1.31 (d,
J=6.9 Hz, 6H); LC/MS 546.6 [M+H.sup.4].
Example 66: Preparation of 5-chloro-N2-(4-(2-(dimethylamino)
propane-2-yl)-2-methoxy-5-methylphenyl)-N4-(2-(isopropylsulfonyl)phenyl)p-
yrimidine-2,4-diamine
##STR00101##
[0622]
N2-(4-(2-aminopropane-2-yl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(-
2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (10.0 mg, 0.019
mmol) and dichloroethylamine (6.41 mg, 0.049 mmol) were dissolved
in dimethylformamide (1.0 mL), to which methyliodide (5.63 mg,
0.039 mmol) was added, followed by stirring at 80.degree. C. for 10
minutes in a microwave reactor. The spot of the starting material
was disappeared, which was confirmed by TLC. Water (10 ml) was
added thereto to terminate the reaction, followed by extraction
twice with ethylacetate (15 ml). The organic layer was washed with
brine. The solvent was eliminated by distillation under reduced
pressure. Then, purification was performed by silica gel column
chromatography (eluent: methanol/dichloromethane, 1/9) to give the
target compound
5-chloro-N2-(4-(2-(dimethylamino)propane-2-yl)-2-methoxy-5-methylphenyl)--
N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as a yellow
solid (20.0 mg, 0.036 mmol, yield: 47%).
[0623] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.50 (s, br, 1H),
8.59 (d, J=8.3 Hz, 1H), 8.15 (s, 1H), 7.93-7.90 (m, 2H), 7.63 (t,
J=8.3 Hz, 1H), 7.46 (s, br, 1H), 7.24 (t, J=7.7 Hz, 1H), 6.91 (s,
1H), 3.86 (s, 3H), 3.26 (sept, J=6.9 Hz, 1H), 2.47 (s, 3H), 2.16
(s, 6H), 1.38 (s, 6H), 1.31 (d, J=6.9 Hz, 6H); LC/MS 532.1
[M+H.sup.+].
Example 67: Preparation of
N2-(2-(2-aminoethyl)-5-methoxybiphenyl-4-yl)-5-chloro-N4-(2-isopropylsulf-
onyl)phenyl)pyrimidine-2,4-diamine
##STR00102##
[0624] Step 1: Preparation of
N-(2-(4-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamin-
o)-5-methoxybiphenyl-2-yl)ethyl)-2,2,2-trifluoroacetamide
[0625]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (227
mg, 0.66 mmol) and the compound (185 mg, 0.55 mmol) prepared in
preparative example 24 were dissolved in 0.08 M HCl-ethoxyethanol
(1.6 mL), followed by stirring at 100.degree. C. overnight.
Ethoxyethanol was removed from the reaction mixture. The reaction
mixture was extracted with ethylacetate. The organic layer was
washed with brine, dried over magnesium sulfate, filtered, and
concentrated under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 4/1) to give the target compound
N-(2-(4-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-ylamin-
o)-5-methoxybiphenyl-2-yl)ethyl)-2,2,2-trifluoroacetamide as a
yellow solid (150 mg, 0.23 mmol, yield: 50%).
[0626] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.59 (s, 1H), 8.56
(d, J=8.4 Hz, 1H), 8.29 (s, 1H), 8.20 (s, 1H), 7.93 (dd, J=7.9, 1.4
Hz, 1H), 7.66 (t, J=8.4 Hz, 1H), 7.60 (s, 1H), 7.46-7.37 (m, 3H),
7.31-7.23 (m, 2H), 6.77 (s, 1H), 5.99 (s, br, 1H), 3.90 (s, 3H),
3.28-3.22 (m, 3H), 2.77 (t, J=6.9 Hz, 2H), 1.33 (d, J=6.9 Hz, 6H);
LC/MS 648.20 [M+H.sup.+].
Step 2: Preparation of
N2-(2-(2-aminoethyl)-5-methoxybiphenyl-4-yl)-5-chloro-N4-(2-isopropylsulf-
onyl)phenyl)pyrimidine-2,4-diamine
[0627]
N-(2-(4-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2--
ylamino)-5-methoxybiphenyl-2-yl)ethyl)-2,2,2-trifluoroacetamide
(100 mg, 0.15 mmol) prepared in step 1 was dissolved in
tetrahydrofuran (1 mL), to which water (0.5 mL) containing lithium
hydroxide dissolved therein was added, followed by stirring at room
temperature for 3 hours with methanol (0.5 mL). The reaction
mixture was extracted with ethylacetate. The organic layer was
washed with brine, dried over magnesium sulfate, filtered, and
concentrated under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
ethylacetate/hexane, 3/1) to give the target compound
N2-(2-(2-aminoethyl)-5-methoxybiphenyl-4-yl)-5-chloro-N4-(2-isopropylsulf-
onyl)phenyl)pyrimidine-2,4-diamine (30 mg, 0.05 mmol, yield:
35%).
[0628] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H), 8.58
(d, J=8.4 Hz, 1H), 8.21 (s, 1H), 8.17 (s, 1H), 7.90 (d, J=7.8 Hz,
1H), 7.67 (t, J=8.4 Hz, 1H), 7.50 (s, 1H), 7.40-7.25 (m, 5H), 6.76
(s, 1H), 3.87 (s, 3H), 3.30-3.21 (m, 1H), 2.82 (d, J=6.0 Hz, 2H),
2.73 (s, 2H), 1.30 (d, J=6.9 Hz, 6H); LC/MS 552.20 [M+.sup.H].
Example 68: Preparation of
N2-(4-(aminomethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine
##STR00103##
[0629] Step 1: Preparation of
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylbenzyl)-2,2,2-trifluoroacetamide
[0630] The compound (100 mg, 0.381 mmol) prepared in preparative
example 25 and
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (145
mg, 0.419 mmol) were dissolved in 0.08 M HCl.ethoxyethanol (1.0 mL)
at room temperature, followed by stirring at 80.degree. C. for 12
hours. The reaction mixture was added with sodium hydrogen
carbonate, followed by extraction twice with ethylacetate (15 ml).
The solvent was eliminated by distillation under reduced pressure.
Then, purification was performed by column chromatography (eluent:
ethylacetate/hexane, 3/7) to give the target compound
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylbenzyl)-2,2,2-trifluoroacetamide as a white
solid (180 mg, 0.314 mmol, yield: 82%).
[0631] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.54 (s, br, 1H),
8.53 (d, J=8.3 Hz, 1H), 8.18 (s, 1H), 8.14 (s, 1H), 7.93 (d, J=7.9
Hz, 1H), 7.64 (t, J=8.3 Hz, 1H), 7.55 (s, br, 1H), 7.27 (t, J=7.8
Hz, 1H), 6.76 (s, 1H), 6.29 (s, br, 1H), 4.48 (d, J=5.3 Hz, 2H),
3.89 (s, 3H), 3.25 (sept, J=6.9 Hz, 1H), 2.18 (s, 3H), 1.31 (d,
J=6.9 Hz, 6H); LC/MS 572.1 [M+H.sup.+].
Step 2: Preparation of
N2-(4-(aminomethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine
[0632] The compound (170 mg, 0.297 mmol) prepared in step 1 was
dissolved in tetrahydrofuran (4.0 mL), methanol (2.0 mL), water
(2.0 mL), and lithiumhydroxidemonohydrate (62.4 mg, 1.49 mmol) at
room temperature, followed by stirring for 12 hours.
Tetrahydrofuran and methanol were eliminated from the reaction
mixture under reduced pressure. Water (15 ml) was added thereto to
terminate the reaction, followed by extraction twice with
ethylacetate (35 ml). The solvent was eliminated by distillation
under reduced pressure. Then, purification was performed by column
chromatography (eluent: methanol/dichloromethane, 1/9) to give the
target compound
N2-(4-(aminomethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopropylsu-
lfonyl)phenyl)pyrimidine-2,4-diamine as a white solid (110 mg,
0.231 mmol, yield: 78%).
[0633] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, br, 1H),
8.59 (d, J=8.3 Hz, 1H), 8.18 (s, 1H), 8.05 (s, 1H), 7.93 (d, J=7.8
Hz, 1H), 7.66 (t, J=8.5 Hz, 1H), 7.54 (s, br, 1H), 7.28 (t, J=8.4
Hz, 1H), 6.92 (s, 1H), 3.92 (s, 3H), 3.85 (s, 2H), 3.28 (sept,
J=6.9 Hz, 1H), 2.21 (s, 3H), 1.68 (s, br, 2H), 1.32 (d, J=6.9 Hz,
6H); LC/MS 475.9 [M+H.sup.+].
Example 69: Preparation of
1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)-N,N,N-trimethylmethanealuminum
iodide
##STR00104##
[0635]
N2-(4-(aminomethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine (50.0 mg, 0.105 mmol)
was dissolved in dimethylformamide (1 mL), to which
diisopropylethylamine (33.9 mg, 0.262 mmol) and methyliodide (29.8
mg, 0.210 mmol) were added at room temperature, followed by
stirring at 80.degree. C. for 10 minutes in a microwave reactor.
Water was added thereto to terminate the reaction, followed by
extraction twice with ethylacetate. The extracted organic layer was
dried over sodium sulfate and then filtered. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylphenyl)-N,N,N-trimethylmethanealuminum iodide
as a white solid (20.0 mg, 0.030 mmol, yield: 29%).
[0636] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.58 (s, br, 1H),
8.52 (d, J=8.3 Hz, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 7.93 (d, J=8.0
Hz, 1H), 7.69-7.66 (m, 2H), 7.42 (s, br, 1H), 7.31 (t, J=7.7 Hz,
1H), 5.06 (s, 2H), 3.99 (s, 3H), 3.44 (s, 9H), 3.29 (sept, J=6.9
Hz, 1H), 2.37 (s, 3H), 1.34 (d, J=6.9 Hz, 6H); LC/MS 518.0
[M+I-].
Example 70: Preparation of
5-chloro-N2-(4-((dimethylamino)methyl)-2-methoxy-5-methylphenyl)-N4-(2-(i-
sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00105##
[0638]
N2-(4-(aminomethyl)-2-methoxy-5-methylphenyl)-5-chloro-N4-(2-(isopr-
opylsulfonyl)phenyl)pyrimidine-2,4-diamine (50.0 mg, 0.105 mmol)
was dissolved in methanol (21.0 mL), to which one drop of acetic
acid and formalin (35%) (19.8 mg, 0.051 mmol) were added at
0.degree. C., followed by stirring at room temperature for 30
minutes. Sodiumcyanoborohydride (9.90 mg, 0.157 mmol) was added
thereto, followed by stirring at room temperature for 30 minutes.
Sodium hydrogen carbonate aqueous solution was added thereto to
terminate the reaction, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/9) to give the target compound
5-chloro-N2-(4-((dimethylamino)methyl)-2-methoxy-5-methylphenyl)-N4-(2-(i-
sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid
(30.0 mg, 0.059 mmol, yield: 57%).
[0639] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.49 (s, br, 1H),
8.57 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 8.02 (s, 1H), 7.92 (d, J=7.9
Hz, 1H), 7.63 (t, J=8.3 Hz, 1H), 7.53 (s, br, 1H), 7.26 (t, J=8.5
Hz, 1H), 6.87 (s, 1H), 3.88 (s, 3H), 3.36 (s, 2H), 3.25 (sept,
J=6.9 Hz, 1H), 2.26 (s, 6H), 2.19 (s, 3H), 1.31 (d, J=6.9 Hz, 6H);
LC/MS 503.9 [M+H.sup.+].
Example 71: Preparation of
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylbenzyl) formamide
##STR00106##
[0641]
2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidine-4-amine (214
mg, 0.617 mmol) and the compound (100 mg, 0.514 mmol) prepared in
preparative example 26 were dissolved in 0.08 M HCl-ethoxyethanol
(1 mL), followed by stirring at 80.degree. C. for 12 hours. The
reaction mixture was cooled to room temperature, neutralized with
sodium hydrogen carbonate aqueous solution, and extracted twice
with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/9) to give the target compound
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-5-methoxy-2-methylbenzyl)formamide as a white solid (110 mg,
0.218 mmol, yield: 42%).
[0642] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.52 (s, br, 1H),
8.54 (d, J=8.3 Hz, 1H), 8.25 (s, 1H), 8.16 (s, 1H), 8.09 (s, 1H),
7.93 (d, J=7.9 Hz, 1H), 7.63 (t, J=8.3 Hz, 1H), 7.53 (s, br, 1H),
7.26 (t, J=7.8 Hz, 1H), 6.78 (s, 1H), 5.59 (s, br, 1H), 4.44 (d,
J=5.4 Hz, 2H), 3.88 (s, 3H), 3.25 (sept, J=6.9 Hz, 1H), 2.18 (s,
3H), 1.31 (d, J=6.9 Hz, 6H); LC/MS 503.6 [M+H.sup.+].
Example 72: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-((meth-
ylamino)methyl)phenyl)pyrimidine-2,4-diamine
##STR00107##
[0644]
N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2--
yl)amino)-5-methoxy-2-methylbenzyl)formamide (50.0 mg, 0.099 mmol)
was dissolved in tetrahydrofuran (15.0 mL), to which lithium
aluminum hydride (37.6 mg, 0.992 mmol) was added, followed by
stirring at 60 for 12 hours. Water and sodium hydroxide aqueous
solution were added thereto to terminate the reaction, and the
reaction mixture was filtered. The filtrate was extracted twice
with ethylacetate. The solvent was eliminated by distillation under
reduced pressure. Then, purification was performed by silica gel
column chromatography (eluent: methanol/dichloromethane, 1/9) to
give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-methyl-4-((meth-
ylamino)methyl)phenyl)pyrimidine-2,4-diamine as a white solid (8.00
mg, 0.016 mmol, yield: 17%).
[0645] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.50 (s, br, 1H),
8.56 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 8.04 (s, 1H), 7.92 (d, J=7.9
Hz, 1H), 7.64 (t, J=8.4 Hz, 1H), 7.52 (s, br, 1H), 7.26 (t, J=8.3
Hz, 1H), 6.91 (s, 1H), 3.88 (s, 3H), 3.72 (s, 2H), 3.25 (sept,
J=6.9 Hz, 1H), 2.51 (s, 3H), 2.19 (s, 3H), 2.02 (s, br, 1H), 1.31
(d, J=6.9 Hz, 6H); LC/MS 489.90 [M+H.sup.+].
Example 73: Preparation of
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperazine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine
##STR00108##
[0647] The compound (500 mg, 0.089 mmol) prepared in example 48 was
dissolved in tetrahydrofuran (5.0 mL), to which lithium aluminum
hydride (10 mg, 0.27 mmol) was added, followed by stirring at
60.degree. C. for 1 hour. Water and sodium hydroxide aqueous
solution were added thereto to terminate the reaction, and the
reaction mixture was filtered. The filtrate was extracted twice
with ethylacetate. The solvent was eliminated by distillation under
reduced pressure. Then, purification was performed by silica gel
column chromatography (eluent: methanol/dichloromethane, 1/9) to
give the target compound
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-5-(2-(piperazine--
1-yl)ethyl)phenyl)pyrimidine-2,4-diamine as a yellow solid (11 mg,
0.020 mmol, yield: 23%).
[0648] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, 1H), 8.58
(d, J=8.1 Hz, 1H), 8.18 (s, 1H), 8.14 (s, 1H), 7.92 (dd, J=7.9, 1.4
Hz, 1H), 7.63-7.69 (m, 1H), 7.55 (s, 1H), 7.22-7.28 (m, 1H), 6.81
(s, 1H), 3.88 (s, 3H), 3.26 (sept, J=6.8 Hz, 1H), 2.95-3.01 (m,
4H), 2.66-2.72 (m, 2H), 2.44-2.48 (m, 6H), 1.32 (d, J=6.8 Hz, 6H);
LC/MS 545.2 [M+H.sup.+].
Example 74: Preparation of
N2-(5-(2-aminoethyl)-2-ethoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00109##
[0649] Step 1: Preparation of
N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-hydroxy-2-(prop-1-ene-2-yl)phenethyl)-2,2,2-trifluoroacetamide
[0650]
1-(6-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-7-methoxy-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifl-
uoroethanone (500 mg, 0.770 mmol) was dissolved in dichloromethane
(20 mL), to which 1 M borontribromide.dichloromethane (3.85 mL,
3.85 mmol) was added at -78.degree. C., followed by stirring at
room temperature for 1 hour. Water was added thereto to terminate
the reaction, and the reaction mixture was filtered. The filtrate
was extracted twice with dichloromethane. The solvent was
eliminated by distillation under reduced pressure. Then,
purification was performed by silica gel column chromatography
(eluent: methanol/dichloromethane, 1/9) to give the target compound
N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-
-2-yl)amino)-4-hydroxy-2-(prop-1-ene-2-yl)phenethyl)-2,2,2-trifluoroacetam-
ide as a yellow solid (200 mg, 0.334 mmol, yield: 43%).
[0651] no NMR data; LC/MS 598.1 [M+H.sup.+].
Step 2: Preparation of
N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-ethoxy-2-(prop-1-ene-2-yl)phenethyl)-2,2,2-trifluoroacetamide
[0652] The compound (50.00 mg, 0.083 mmol) prepared in step 1 was
dissolved in dimethylformamide (1.0 mL), to which potassium
carbonate (23.1 mg, 0.167 mmol) and ethyliodide (14.34 mg, 0.092
mmol) were added, followed by stirring at 80.degree. C. for 30
minutes in a microwave reactor. Water was added thereto to
terminate the reaction, followed by extraction twice with
ethylacetate. The extracted organic layer was dried over sodium
sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/9) to give the target compound
N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-ethoxy-2-(prop-1-ene-2-yl)phenethyl)-2,2,2-trifluoroacetamide
as a white solid (25.0 mg, 0.036 mmol, yield: 48%).
[0653] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, br, 1H),
8.53 (d, J=8.3 Hz, 1H), 8.17 (s, 1H), 8.16 (s, 1H), 7.94 (d, J=7.9
Hz, 1H), 7.62 (t, J=7.0 Hz, 1H), 7.58 (s, br, 1H), 7.26 (t, J=7.3
Hz, 1H), 6.65 (s, 1H), 6.19 (s, br, 1H), 5.22 (s, 1H), 4.85 (s,
1H), 4.12 (q, J=6.9 Hz, 2H), 3.35-3.26 (m, 3H), 2.76 (t, J=6.9 Hz,
2H), 2.04 (s, 3H), 1.47 (t, J=6.9 Hz, 3H), 1.32 (d, J=6.9 Hz, 6H);
LC/MS 626.20 [M+H.sup.+].
Step 3: Preparation of
N2-(5-(2-aminoethyl)-2-ethoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0654] The compound (25.0 mg, 0.039 mmol) prepared in step 2 was
dissolved in tetrahydrofuran (1.0 mL), methanol (0.50 mL), and
water (0.50 mL), to which lithium hydroxide hydrate (10.05 mg,
0.239 mmol) was added, followed by stirring at 40.degree. C. for 12
hours. The reaction mixture was distillated under reduced pressure.
The reactant was diluted with water, followed by extraction twice
with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
N2-(5-(2-aminoethyl)-2-ethoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2-(-
isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid
(8.0 mg, 0.015 mmol, yield: 38%).
[0655] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.56 (s, br,
0.3H), 9.50 (s, br, 0.5H), 8.60 (d, J=8.3 Hz, 0.3H), 8.53 (d, J=8.3
Hz, 0.7H), 8.17 (s, 1H), 8.10 (s, 0.3H), 8.08 (s, 0.6H), 7.95-7.88
(m, 1H), 7.65 (t, J=7.3 Hz, 1H), 7.56 (s br, 0.6H), 7.53 (s, br,
0.3H), 7.30-7.20 (m, 1H), 6.64 (s, 1H), 5.18 (s, 1H), 4.84 (s, 1H),
4.10 (q, J=6.9 Hz, 2H), 3.31-3.22 (m, 1.5H), 2.89-2.83 (m, 0.6H),
2.67-2.64 (m, 2.7H), 2.03 (s, 3H), 1.45 (t, J=6.9 Hz, 3H), 1.32 (d,
J=6.9 Hz, 6H); LC/MS 529.90 [M+H.sup.+].
Example 75: Preparation of
N2-(5-(2-aminoethyl)-2-methoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2--
(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
##STR00110##
[0656] Step 1: Preparation of
N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxy-2-(prop-1-ene-2-yl)phenethyl)-2,2,2-trifluoroacetamide
[0657]
N-(5-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidine-2-yla-
mino)-4-hydroxy-2-(prop-1-ene-2-yl)phenethyl)-2,2,2-trifluoroacetamide
(50.00 mg, 0.083 mmol) was dissolved in dimethylformamide (1.0 mL),
to which potassium carbonate (23.1 mg, 0.167 mmol) and methyliodide
(13.05 mg, 0.092 mmol) were added, followed by stirring at
80.degree. C. for 30 minutes in a microwave reactor. Water was
added thereto to terminate the reaction, followed by extraction
twice with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/9) to give the target compound
N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidine-2-yl)ami-
no)-4-methoxy-2-(prop-1-ene-2-yl)phenethyl)-2,2,2-trifluoroacetamide
as a white solid (25.0 mg, 0.040 mmol, yield: 49%).
[0658] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.57 (s, br,
0.6H), 9.55 (s, br, 0.4H), 8.56-8.52 (m, 1H), 8.18-8.17 (m, 1.6H),
8.04 (s, 0.4H), 7.95-7.92 (m, 1H), 7.64 (t, J=7.2 Hz, 1H), 7.56 (s
br, 0.3H), 7.53 (s, br, 0.6H), 7.32-7.23 (m, 1H), 6.75 (s, 0.4H),
6.66 (s, 0.7H), 6.22 (s, br, 1H), 5.23 (s, 1H), 4.87 (s, 1H), 3.91
(s, 1H), 3.89 (s, 2H), 3.65-3.56 (m, 1H), 3.42-3.35 (m, 1.4H), 3.26
(sept, J=6.9 Hz, 1H), 2.81-2.79 (m, 1.4H), 2.72-2.69 (m, 0.7H),
2.05 (s, 1H), 1.83 (s, 2H), 1.32 (d, J=6.9 Hz, 6H); LC/MS 611.50
[M+H.sup.+].
Step 2: Preparation of
N2-(5-(2-aminoethyl)-2-methoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2--
(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
[0659] The compound (25.0 mg, 0.040 mmol) prepared in step 1 was
dissolved in tetrahydrofuran (1.0 mL), methanol (0.50 mL), and
water (0.50 mL), to which lithium hydroxide hydrate (10.0 mg, 0.245
mmol) was added, followed by stirring at 40.degree. C. for 12
hours. The reaction mixture was distillated under reduced pressure.
The reactant was diluted with water, followed by extraction twice
with ethylacetate. The extracted organic layer was dried over
sodium sulfate and then filtered. The solvent was eliminated by
distillation under reduced pressure. Then, purification was
performed by silica gel column chromatography (eluent:
methanol/dichloromethane, 1/10) to give the target compound
N2-(5-(2-aminoethyl)-2-methoxy-4-(prop-1-ene-2-yl)phenyl)-5-chloro-N4-(2--
(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine as a white solid
(8.0 mg, 0.015 mmol, yield: 38%).
[0660] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.53 (s, br, 1H),
8.56 (d, J=8.4 Hz, 1H), 8.19 (s, 1H), 8.12 (s, 1H), 7.95 (d, J=8.1
Hz, 1H), 7.68 (t, J=8.1 Hz, 1H), 7.54 (s, br, 1H), 7.32-7.27 (t,
J=7.8 Hz, 1H), 6.67 (s, 1H), 5.21 (s, 1H), 4.87 (s, 1H), 3.90 (s,
3H), 3.28 (sept, J=6.9 Hz, 1H), 2.73-2.67 (m, 4H), 2.07 (s, 3H),
1.34 (d, J=6.9 Hz, 6H); LC/MS 515.80 [M+H+].
TABLE-US-00001 TABLE 1 Example Compound Structure 1 ##STR00111## 2
##STR00112## 3 ##STR00113## 4 ##STR00114## 5 ##STR00115## 6
##STR00116## 7 ##STR00117## 8 ##STR00118## 9 ##STR00119## 10
##STR00120## 11 ##STR00121## 12 ##STR00122## 13 ##STR00123## 14
##STR00124## 15 ##STR00125## 16 ##STR00126## 17 ##STR00127## 18
##STR00128## 19 ##STR00129## 20 ##STR00130## 21 ##STR00131## 22
##STR00132## 23 ##STR00133## 24 ##STR00134## 25 ##STR00135## 26
##STR00136## 27 ##STR00137## 28 ##STR00138## 29 ##STR00139## 30
##STR00140## 31 ##STR00141## 32 ##STR00142## 33 ##STR00143## 34
##STR00144## 35 ##STR00145## 36 ##STR00146## 37 ##STR00147## 38
##STR00148## 39 ##STR00149## 40 ##STR00150## 41 ##STR00151## 42
##STR00152## 43 ##STR00153## 44 ##STR00154## 45 ##STR00155## 46
##STR00156## 47 ##STR00157## 48 ##STR00158## 49 ##STR00159## 50
##STR00160## 51 ##STR00161## 52 ##STR00162## 53 ##STR00163## 54
##STR00164## 55 ##STR00165## 56 ##STR00166## 57 ##STR00167## 58
##STR00168## 59 ##STR00169## 60 ##STR00170## 61 ##STR00171## 62
##STR00172## 63 ##STR00173## 64 ##STR00174## 65 ##STR00175## 66
##STR00176## 67 ##STR00177## 68 ##STR00178## 69 ##STR00179## 70
##STR00180## 71 ##STR00181## 72 ##STR00182## 73 ##STR00183## 74
##STR00184## 75 ##STR00185##
Experimental Example 1: Inhibition of ALK WT Anaplastic Lymphoma
Kinase Activity
[0661] The following experiment was performed in order to measure
the activity of the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention to inhibit
anaplastic lymphoma kinase (ALK) activity at enzyme level.
[0662] To measure the activity to inhibit ALK, each of the
compounds prepared in examples listed in table 2 (2 .mu.l) was
loaded in a 384 well plate. Then, each of the compounds was mixed
with anaplastic lymphoma kinase (ALK) enzyme (1 .mu.l) and biotin
conjugated peptide substrate (2 .mu.l), followed by culture for 15
minutes. ATP solution (5 .mu.l) was added thereto, followed by
kinase reaction at room temperature for 30 minutes. Streptavidin
conjugated XL 665 (5 .mu.l) dissolved in ethylenediaminetetraacetic
acid solution and europium (Eu.sup.3+) conjugated
anti-phosphotyrosine antibody (5 .mu.l) were added to the reaction
solution to terminate the reaction. Upon completion of the
reaction, one hour culture was performed, followed by analysis
using homogeneous time-resolved fluorescence (HTRF, Cisbio).
OD.sub.615/665 was measured with Wallac Envision 2103. IC.sub.50 of
each compound was determined by using prism software (Version 5.01,
Graphpad). The results are shown in table 2.
TABLE-US-00002 TABLE 2 ALK WT Example (IC.sub.50 .mu.M) 1 2.8 2
0.43 3 0.012 4 0.00044 5 0.15 6 0.16 7 0.01 8 0.01 9 0.0037 10
0.004 11 0.004 12 0.02 13 0.00084 14 0.0019 15 0.0026 16 0.01 17
0.04 18 0.3 19 0.03 20 0.01 21 0.001 22 0.01 23 0.01 24 0.00088 25
0.04 26 0.0035 27 0.0038 28 0.097 29 0.002 30 0.05 31 0.01 32 0.03
33 0.42 34 0.17 35 0.03 36 0.21 37 0.74 38 2.1 39 0.04 40 0.2 41
0.0031 42 0.01 43 0.19 44 0.0095 45 0.026 46 0.19 47 0.012 48
0.0042 49 0.034 50 0.27 51 0.0034 52 0.0048 53 0.021 54 0.2 55
0.0027 56 0.0049 57 0.0015 58 0.0014 59 0.0078 60 0.0015 61 0.0021
62 0.004 63 0.0015 64 0.0012 65 0.0022 66 0.0028 67 -- 68 0.001932
69 0.002001 70 0.003371 71 0.00472 72 0.001735 73 0.001 74 -- 75
--
[0663] In Table 2 above, - indicates that the experiment was not
performed.
[0664] As shown in table 2, the compounds of the present invention
displayed excellent anaplastic lymphoma kinase (ALK WT) inhibition
activity. Particularly, the compounds of examples 4, 7-11, 13-16,
20-24, 26-27, 29, 31, 41-42, 44, 48, 51-52, 55-56, and 68-73
exhibited excellent anaplastic lymphoma kinase (ALK WT) inhibition
activity at the concentration of 0.01 .mu.M or less.
[0665] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
significantly inhibit the ALK activity, so that it can be
effectively used as a pharmaceutical composition for the prevention
or treatment of such cancers as non-small cell lung cancer,
neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomysarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
Experimental Example 2: Inhibition of ALK L1196M Anaplastic
Lymphoma Kinase Activity
[0666] To measure the activity of the
N2-(2-methoxyphenyl)pyrimidine derivative represented by formula 1
of the present invention to inhibit anaplastic lymphoma kinase
(ALK) activity at enzyme level, the following experiment was
performed by the same manner as described in experimental example 1
except that ALK L1196M protein was used instead of ALK WT protein.
The results are shown in table 3.
TABLE-US-00003 TABLE 3 ALK L1196M Example (IC.sub.50 .mu.M) 1 3.88
2 1.19 3 0.021 4 0.00085 5 0.1 6 10 7 0.05 8 0.1 9 0.01 10 0.05 11
0.04 12 0.32 13 0.01 14 0.01 15 0.02 16 0.06 17 0.78 18 2.2 19 0.24
20 0.06 21 0.01 22 0.03 23 0.18 24 0.01 25 0.23 26 0.02 27 0.02 28
0.66 29 0.014 30 1 31 0.06 32 0.11 33 -- 34 -- 35 -- 36 -- 37 -- 38
-- 39 -- 40 -- 41 -- 42 -- 43 -- 44 0.045 45 -- 46 -- 47 -- 48 --
49 -- 50 -- 51 -- 52 -- 53 0.036 54 0.57 55 0.0017 56 0.0034 57
0.0016 58 0.0013 59 0.0061 60 0.0017 61 0.0025 62 0.0044 63 0.0019
64 0.0014 65 0.0036 66 0.0015 67 -- 68 0.0021 69 0.002 70 0.0021 71
0.0028 72 0.0022 73 -- 74 -- 75 --
[0667] In Table 3 above, - indicates that the experiment was not
performed.
[0668] As shown in table 3, the compounds of the present invention
displayed excellent anaplastic lymphoma kinase (ALK L1196M)
inhibition activity. Particularly, the compounds of examples 4, 9,
13-14, 21, 24, 55-66, and 68-72 exhibited excellent anaplastic
lymphoma kinase (ALK L1196M) inhibition activity at the
concentration of 0.01 .mu.M or less.
[0669] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
significantly inhibit the ALK activity, so that it can be
effectively used as a pharmaceutical composition for the prevention
or treatment of such cancers as non-small cell lung cancer,
neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomysarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
Experimental Example 3: Inhibition of ALK IR Anaplastic Lymphoma
Kinase Activity
[0670] To measure the activity of the
N2-(2-methoxyphenyl)pyrimidine derivative represented by formula 1
of the present invention to inhibit anaplastic lymphoma kinase
(ALK) activity at enzyme level, the following experiment was
performed by the same manner as described in experimental example 1
except that IR (Insulin Receptor) protein was used instead of ALK
WT protein. The results are shown in table 4.
TABLE-US-00004 TABLE 4 IR Example (IC.sub.50 .mu.M) 1 >10 2 1.82
3 0.043 4 0.0023 5 4.7 6 1.1 7 0.05 8 0.1 9 0.02 10 0.03 11 0.02 12
0.18 13 0.01 14 0.01 15 0.02 16 0.05 17 0.63 18 1.7 19 0.11 20 0.02
21 0.01 22 0.03 23 0.12 24 0.01 25 0.08 26 0.01 27 0.01 28 0.38 29
0.02 30 0.14 31 0.09 32 0.07 33 -- 34 -- 35 -- 36 -- 37 -- 38 -- 39
-- 40 -- 41 0.0021 42 -- 43 -- 44 0.057 45 -- 46 -- 47 -- 48 -- 49
-- 50 -- 51 -- 52 -- 53 0.12 54 0.55 55 0.0018 56 0.0032 57 0.0026
58 0.0023 59 0.018 60 0.0039 61 0.0061 62 0.017 63 0.0035 64 0.0019
65 0.0026 66 0.006 67 -- 68 0.0057 69 0.0035 70 0.0048 71 0.006 72
0.0038 73 -- 74 -- 75 --
[0671] In Table 4 above, - indicates that the experiment was not
performed.
[0672] As shown in table 4, the compounds of the present invention
displayed excellent anaplastic lymphoma kinase (IR) inhibition
activity. Particularly, the compounds of examples 4, 13-14, 21, 24,
26-27, 41, 55-58, 60-61, 63-66, and 68-72 exhibited excellent
anaplastic lymphoma kinase (IR) inhibition activity at the
concentration of 0.01 .mu.M or less.
[0673] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
significantly inhibit the ALK activity, so that it can be
effectively used as a pharmaceutical composition for the prevention
or treatment of such cancers as non-small cell lung cancer,
neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomysarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
Experimental Example 4: Evaluation of Cytotoxicity of ALK Inhibitor
in the Non-Small Cell Lung Cancer Cell Line H3122
[0674] The following experiment was performed to evaluate the
cytotoxicity of the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention in the non-small
cell lung cancer cell line H3122.
[0675] Particularly, 4,000 H3122 cells containing ALK enzyme were
distributed in each well of a 96 well plate together with 100 .mu.l
of DMEM (Dulbecco's Modified Eagle's Medium). One day later, the
compound of the present invention was added to each well at
different concentrations of 10 M, 2 M, 0.4 M, 0.08 M, 0.0016 M, and
0.00032 M. DMSO (dimethylsulfoxide) was added to the well that was
not loaded with the compound by the same amount as the compound.
Three days after the addition of the compound, DMEM was eliminated.
10% TCA (trichloroacetic acid) was added to fix the cells. The
wells were washed with running water three times and the live cells
were stained with SRB solution (1 sulphorodamine B). Then, OD was
measured to calculate the population of the live cells. IC.sub.50
of the experimental compound used in the experiment above was
calculated by using prism software (Version 5.01, Graphpad). When
the activity of H3122 containing ALK enzyme was reduced under 50%,
it was considered that the compound demonstrated the inhibition
effect. GI.sub.50 values of the compound are shown in Table 5
below. GI.sub.50 of the experimental compound used in the
experiment above was calculated by using prism software (Version
5.01, Graphpad). The results are shown in Table 5.
TABLE-US-00005 TABLE 5 cytotoxicity H3122 Example (GI.sub.50 .mu.M)
1 3.06 2 2.63 3 0.77 4 0.08 5 10 6 10 7 0.79 8 1.9 9 0.22 10 1.2 11
1.4 12 4.7 13 0.99 14 0.05 15 1.1 16 0.41 17 0.88 18 3.6 19 1.1 20
0.31 21 0.06 22 0.27 23 1.4 24 0.09 25 1.3 26 0.14 27 0.42 28 0.82
29 0.1 30 0.48 31 0.7 32 0.71 33 10 34 2.2 35 1.6 36 10 37 10 38 10
39 0.93 40 0.33 41 0.19 42 0.15 43 >10 44 1 45 10 46 10 47 0.69
48 0.58 49 10 50 10 51 1.1 52 0.096 53 0.074 54 0.25 55 0.06 56
0.053 57 0.012 58 0.013 59 0.063 60 0.041 61 0.052 62 0.068 63 0.02
64 0.029 65 0.026 66 0.035 67 0.23 68 0.11 69 1.7 70 0.037 71 0.028
72 0.025 73 0.16 74 0.77 75 0.23
[0676] As shown in Table 5, the compounds of the examples of the
present invention showed cytotoxic effect on H3122 cells, the
non-small-cell lung cancer cells containing ALK enzyme. In
particular, the compounds of examples 4, 14, 21, 24, 52-53, 55-66,
and 70-72 demonstrated excellent cytotoxic effect on H3122 cells
containing ALK enzyme at the concentration of 0.1 .mu.M or
less.
[0677] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
have cytotoxic effect on H3122 cells, the non-small-cell lung
cancer cells, containing ALK enzyme, so that it can be effectively
used as a pharmaceutical composition for the prevention or
treatment of such cancers as non-small cell lung cancer,
neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomysarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
Experimental Example 5: Evaluation of Cytotoxicity of ALK Inhibitor
in the Non-Small Cell Lung Cancer Cell Line H2228
[0678] To evaluate the cytotoxicity of the
N2-(2-methoxyphenyl)pyrimidine derivative represented by formula 1
of the present invention in the non-small cell lung cancer cell
line H2228, the following experiment was performed by the same
manner as described in experimental example 4 except that the
non-small cell lung cancer cell line H2228 was used instead of the
non-small cell lung cancer cell line H3122. The results are shown
in Table 6.
TABLE-US-00006 TABLE 6 Cytotoxicity H2228 Example (GI.sub.50 .mu.M)
1 2.1 2 3.77 3 1.21 4 0.11 5 7.8 6 10 7 0.8 8 0.88 9 0.23 10 1.8 11
1.4 12 1.1 13 0.87 14 0.09 15 0.78 16 0.52 17 2.3 18 4.9 19 10 20
0.42 21 0.08 22 0.46 23 2.5 24 0.66 25 1.5 26 0.42 27 0.51 28 0.98
29 0.14 30 0.76 31 0.51 32 0.64 33 10 34 2.3 35 1.6 36 10 37 10 38
10 39 0.87 40 -- 41 -- 42 -- 43 -- 44 -- 45 -- 46 -- 47 -- 48 -- 49
-- 50 -- 51 -- 52 -- 53 -- 54 -- 55 -- 56 -- 57 -- 58 -- 59 -- 60
-- 61 -- 62 -- 63 -- 64 -- 65 -- 66 -- 67 -- 68 -- 69 -- 70 -- 71
-- 72 -- 73 -- 74 -- 75 --
[0679] In Table 6 above, - indicates that the experiment was not
performed.
[0680] As shown in Table 6, the compounds of the examples of the
present invention showed cytotoxic effect on H2228 cells, the
non-small-cell lung cancer cells containing ALK enzyme. In
particular, the compounds of examples 4, 7-9, 13-16, 20-22, 24,
26-32, and 39 demonstrated excellent cytotoxic effect on H2228
cells containing ALK enzyme at the concentration of 1.0 .mu.M or
less.
[0681] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
have cytotoxic effect on H2228 cells, the non-small-cell lung
cancer cells containing ALK enzyme, so that it can be effectively
used as a pharmaceutical composition for the prevention or
treatment of such cancers as non-small cell lung cancer,
neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomysarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
Experimental Example 6: Evaluation of Cytotoxicity of ALK Inhibitor
in Ba/F3 EML4-ALK L1196M Cells
[0682] To evaluate the cytotoxicity of the
N2-(2-methoxyphenyl)pyrimidine derivative represented by formula 1
of the present invention in Ba/F3 EML4-ALK L1196M cells, the
following experiment was performed.
[0683] Particularly, the experiment was performed by the same
manner as described in experimental example 4 except that Ba/F3
EML4-ALK L1196M, the cell line prepared by introducing the EML4
(Echiinoderm Microtubule-Associated Protein-like 4)-ALK mutant form
L1196M in the rodent IL-3-dependent pro-B lymphoma cell line Ba/F3
was used instead of the non-small cell lung cancer cell line H3122.
The results are shown in Table 7.
TABLE-US-00007 TABLE 7 BaF3 EML4 ALK Example L1196M .mu.M 1 1.46 2
2.8 3 0.18 4 0.09 5 2 6 2.1 7 0.78 8 0.97 9 0.32 10 0.73 11 0.78 12
0.97 13 0.73 14 0.08 15 0.68 16 0.8 17 0.88 18 1.9 19 1.1 20 0.41
21 0.09 22 0.28 23 1.9 24 0.24 25 1.7 26 0.23 27 0.64 28 0.8 29
0.12 30 0.32 31 1.2 32 1.8 33 10 34 10 35 5 36 10 37 10 38 10 39
1.8 40 1.5 41 0.49 42 0.56 43 >10 44 >10 45 10 46 10 47 1.8
48 1.3 49 10 50 10 51 1.6 52 0.49 53 0.19 54 0.44 55 0.3 56 0.096
57 0.055 58 0.035 59 0.099 60 0.068 61 0.081 62 0.26 63 0.058 64
0.066 65 0.066 66 0.091 67 0.39 68 0.039 69 >10 70 0.066 71
0.062 72 0.054 73 0.32 74 1.60 75 0.39
[0684] As shown in Table 7, the compounds of the examples of the
present invention showed cytotoxic effect on EML4-ALK L1196M. In
particular, the compounds of examples 56-61, 63-66, 68, and 70-72
demonstrated excellent cytotoxic effect on Ba/F3 EML4-ALK L1196M at
the concentration of 0.01 .mu.M or less.
[0685] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
have cytotoxic effect on Ba/F3 EML4-ALK L1196M, so that it can be
effectively used as a pharmaceutical composition for the prevention
or treatment of such cancers as non-small cell lung cancer,
neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomysarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
Experimental Example 7: Evaluation of Cytotoxicity of ALK Inhibitor
in Ba/F3 EML4-ALK WT Cells
[0686] To evaluate the cytotoxicity of the
N2-(2-methoxyphenyl)pyrimidine derivative represented by formula 1
of the present invention in Ba/F3 EML4-ALK WT cells, the following
experiment was performed.
[0687] Particularly, the experiment was performed by the same
manner as described in experimental example 4 except that Ba/F3
EML4-ALK WT, the cell line prepared by introducing the EML4
(Echiinoderm Microtubule-Associated Protein-like 4)-ALK in the
rodent IL-3-dependent pro-B lymphoma cell line Ba/F3 was used
instead of the non-small cell lung cancer cell line H3122. The
results are shown in Table 8.
TABLE-US-00008 TABLE 8 Ba/F3 EML-ALK WT Example (IC.sub.50 .mu.M) 1
0.56 2 0.7 3 0.17 4 0.04 5 2 6 1.6 7 0.71 8 0.53 9 0.24 10 0.36 11
0.37 12 1.5 13 0.06 14 0.02 15 0.13 16 0.34 17 0.33 18 1 19 0.52 20
0.14 21 0.03 22 0.16 23 1.8 24 0.31 25 1.3 26 0.09 27 0.39 28 -- 29
-- 30 0.3 31 -- 32 -- 33 -- 34 -- 35 -- 36 -- 37 -- 38 -- 39 -- 40
0.38 41 0.17 42 0.13 43 >10 44 2.1 45 3 46 10 47 0.52 48 1.5 49
2.5 50 10 51 0.33 52 0.13 53 0.061 54 0.25 55 0.068 56 0.036 57
0.012 58 0.01 59 0.038 60 0.019 61 0.024 62 0.06 63 0.013 64 0.015
65 0.014 66 0.02 67 0.11 68 0.12 69 >10 70 0.021 71 0.015 72
0.015 73 0.097 74 0.36 75 0.11
[0688] In Table 8 above, - indicates that the experiment was not
performed.
[0689] As shown in Table 8, the compounds of the examples of the
present invention showed cytotoxic effect on Ba/F3 EML4-ALK WT. In
particular, the compounds of examples 4, 13-14, 21, 26, 53, 55-66,
and 70-73 demonstrated excellent cytotoxic effect on Ba/F3 EML4-ALK
WT at the concentration of 0.1 .mu.M or less.
[0690] Therefore, the N2-(2-methoxyphenyl)pyrimidine derivative
represented by formula 1 of the present invention was confirmed to
have cytotoxic effect on Ba/F3 EML4-ALK WT, so that it can be
effectively used as a pharmaceutical composition for the prevention
or treatment of such cancers as non-small cell lung cancer,
neuroblastoma, inflammatory myeloid fibroblastic tumor,
rhabdomysarcoma, myofibroblastoma, breast cancer, stomach cancer,
lung cancer, and melanoma.
Experimental Example 8: In Vivo Xenograft Evaluation for H3122
Induced Lung Cancer
[0691] <8-1> Experiment Preparation
[0692] The nude mice (BALB/c nu/nu, female) used in this experiment
were purchased from Charles River Japan, Inc. and raised and tested
under SPF (Specific Pathogen Free) control. The human non-small
cell lung cancer cell line H3122 maintained by Korea Research
Institute of Chemical Technology was used in this experiment.
[0693] <8-2> Experiment Method
[0694] The female nude mice adapted to the laboratory were
implanted with cancer. Particularly, H3122 cells grown to the
appropriate size for passage were cut into 3.times.3.times.3
mm.sup.3, which was transplanted (s.c.) under the right side of the
nude mouse. When the size of the implanted cancer reached about 200
mm.sup.3, administration of the compound of example 58 was started;
this was the first day (day 1). For the control, 20% PEG 400+3%
Tween 80 in DDW was orally administered. For the experimental group
(7 mice/group), the compound was dissolved in the same solvent of
the control, which was orally administered 14 times in total
(q.d..times.14). The size of the cancer was measured every 2-3 days
after the administration using a caliper and the diameters (long
diameter (a), short diameter (b)) of the cancer were measured. The
size of the cancer (volume, V) was calculated according to
mathematical formula 1.
Volume (mm.sup.3)=a.times.b.sup.2/2 Mathematical Formula 1
[0695] (In the mathematical formula 1,
[0696] a represents the horizontal length of the cancer; and
[0697] b represents the vertical short length of the cancer).
[0698] The results are shown in FIG. 1.
[0699] FIG. 1 is a graph showing the results of observing the size
of cancer in the control group, the LDK378-treated group, and the
group treated with the compound of example 58 over the time.
[0700] As shown in FIG. 1, the cancer size was significantly
increased in the control group not treated with LDK378 or the
compound of the invention. In the meantime, when the compound of
example 58 of the present invention was treated, the effect of
inhibiting cancer size was excellent, similar to LDK378.
Manufacturing Example 1: Preparation of Powders
TABLE-US-00009 [0701] Compound of formula 1 2 g Lactose 1 g
[0702] Powders were prepared by mixing all the above components,
which were filled in airtight packs according to the conventional
method for preparing powders.
Manufacturing Example 2: Preparation of Tablets
TABLE-US-00010 [0703] Compound of formula 1 100 g Corn starch 100 g
Lactose 100 g Magnesium stearate 2 mg
[0704] Tablets were prepared by mixing all the above components by
the conventional method for preparing tablets.
Manufacturing Example 3: Preparation of Capsules
TABLE-US-00011 [0705] Compound of formula 1 100 g Corn starch 100 g
Lactose 100 g Magnesium stearate 2 mg
[0706] Capsules were prepared by mixing all the above components,
which were filled in gelatin capsules according to the conventional
method for preparing capsules.
Manufacturing Example 4: Preparation of Injectable Solution
TABLE-US-00012 [0707] Compound of formula 1 500 g Mannitol 180 g
Na.sub.2HPO.sub.4.cndot.2H.sub.2O 26 g Distilled water 2974 mg
[0708] Injectable solutions were prepared by mixing all the above
components according to the conventional method for preparing
injectable solutions.
Manufacturing Example 5: Preparation of Health Functional Food
TABLE-US-00013 [0709] Compound of formula 1 500 g Vitamin complex
proper amount Vitamin A acetate 70 mg Vitamin E 1.0 mg Vitamin B1
0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 mg
Vitamin C 10 mg Biotin 10 mg Nicotinic acid amide 1.7 mg Folic acid
50 mg Calcium pantothenate 0.5 mg Minerals proper amount Ferrous
sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg
Potassium phosphate monobasic 15 mg Potassium phosphate dibasic 55
mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium
chloride 24.8 mg
[0710] Vitamins and minerals were mixed according to the preferable
composition rate for health food. However, the composition rate can
be adjusted. The constituents were mixed according to the
conventional method for preparing health food and then the
composition for health food was prepared according to the
conventional method.
Manufacturing Example 6: Preparation of Health Beverages
TABLE-US-00014 [0711] Compound of formula 1 500 g Citric acid 1000
mg Oligosaccharide 100 mg Maesil (Prunus mume) Extract 2 mg Taurine
1 mg Purified water 900 ml
[0712] The above constituents were mixed according to the
conventional method for preparing health beverages. The mixture was
heated at 85 for 1 hour with stirring and then filtered. The
filtrate was loaded in 2 liter sterilized containers, which were
sealed and sterilized again, stored in a refrigerator until they
would be used for the preparation of a composition for health
beverages.
[0713] The constituents appropriate for favorite beverages were
mixed according to the preferred mixing ratio but the composition
ratio can be adjusted according to regional and national
preferences, etc.
INDUSTRIAL APPLICABILITY
[0714] The N2-(2-methoxyphenyl)pyrimidine derivative, the optical
isomer thereof, or the pharmaceutically acceptable salt thereof of
the present invention is very effective in suppressing anaplastic
lymphoma kinase (ALK) activity and as a result it can improve the
effectiveness of treatment on cancer cells having anaplastic
lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK,
so that it can be effectively used as a pharmaceutical composition
for preventing or treating cancer.
[0715] Those skilled in the art will appreciate that the
conceptions and specific embodiments disclosed in the foregoing
description may be readily utilized as a basis for modifying or
designing other embodiments for carrying out the same purposes of
the present invention. Those skilled in the art will also
appreciate that such equivalent embodiments do not depart from the
spirit and scope of the invention as set forth in the appended
Claims.
* * * * *